var title_f4_28_4544="Esophageal adenocarcinoma EUS CPC";
var content_f4_28_4544=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F69981&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F69981&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Esophageal adenocarcinoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 288px; height: 269px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAENASADASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5dlkfzX+dup703zH/AL7fnSSn94/1NNzQA/zH/vt+dHmP/fb86Z9KQ+9AD/Mf++350eY/99vzplSwwTT58mKSQjrsUtj8qAE8x/77fnR5j/32/OpBZXbKrLbTlW6ERnB/So3hmjfZJE6P6MpBoAPMf++350eY/wDfb86akbyZ8tWYgZO0ZwPWpVtLlwhS3mYP90hCd309aAI/Mf8Avt+dL5j/AN9vzpfs83I8mTg7T8p4Pp9aJree3OJ4ZIif76Ff50AJ5j9nb86PMf8Avt+dJDFJM22GN5G9EBJ/Sni1uPLMvkTeWOrbDj86AG+Y/wDfb86PMf8Avt+dOFvMWZRDJuQZYbTlR6miSCaNQ0kUiqRkFlIBHrQA3zH/AL7fnR5j/wB9vzqT7LcmPf8AZpth4DeWcfnSNa3I3g28wKcsNh+X6+lADPMk/vtj60eY46O350zaeTjgdTU62V2yhltpyp6ERkg0AR+Y56u350eY/wDfb86VoZRvzE42fe+U/L9fSl+zzZUeTJlhuHyHkev0oAb5j/32/OjzH/vt+dNYFThgQfenxQyyKxjidwvUqpOKAE8x/wC+350eY/8Afb86fLbTw486CWPPTehGfzpwsbsgEWtwQeh8tuf0oAiErj+NvzpTK5/jb86c9pcRozSW8yqvUshAFQ0ASCV/77fnSmVx/G351FRQBKJXP8bfnRvfP32/Oo6M+9AEnmP/AH2/OjzH/vt+dR5NGTQBJ5j/AN9vzp8Uj+Ynzt1HeoOafFnzUz6igCOX/Wv/ALxpmK6rw9pROoWupalapLpdxLLHtBHJUEngcjHaqvi5NPjfTzpMRS3a3B3N96Q5OWb3oAwOlJSg8Gp4Y1yPMBPtQBXr0T4PjUDPrH9nrrjJ5C+aNIl8uTG7+I/3OufaubsbRJ7mKNo02t32DpXbxaTpltE8sunKyqu7BjGB9TQBseMrvXtPOlXmn3Hiu0sxPGon+1lbDB7RBeQevf1rDm1Gx1BGn1qbVrzW2W6EU7XCtHtB/j3AsfwNc7cT6bucxWcO1jhAUHFRrZWzZBSFARgll7+lAFbwOL83mof2aZ9/2GXzPJJB2Y5zjtXpOk3txYeH7S/1C48T6fZJa4jaC7QREcDNocfIfX15rzh7OCInyokdAcHcv3j6CtOytbN8iWzhDqPu7AcfnQB3mlmyutVtsazdpJc7p1sSjSS3ZH3JmlHy+Z6HFY/jbw74p1m3nRNM8WXRilEgXVnM8yLg5IIAwufasq10aw8xlkhjc4yAVFKmj2qOPtNpbZY/Ku3HFAGH8OI9aHiG4j8P/bE1IW0qgWrFXHHqOa9Imgu7rRNPWP8A4SVdP3f6XLFNnTlYH5y8Y+8wPJ55Nc+dLswwCadau+M7RCuAP8antdEsp3Utp0CRg/N+5oAL0X08Ec/hXWLnVr2QFr+8WN4S9upxiQMclB3zwanu5NQg0XU/+EkFw+nT7FsftJLIIT1aHPAUHB+XFXLnQdN2KYtOsQg7mEVkCx053Maafak55xCvHvkigDo9ej1eGz01tPXxPc2KeWu+C7A09+P4Rj/WehJ61Uu4tWKapG7eK0YRZuHluEaWIY6Xvy/OnpmsK807TAwR7OzQ452RYH8qZZW+nQgr9itQM9ZLYSZ/McUAcx4QvYLCHVXureK7hIjBjbofn4I/GvWtY/4SOe40mfRk8WrG5QgwXBFhnaeERcYbPvXKyaXYXMe9LCy29yiKv6DpVW40yyV1CWdorNwEKA5/E0AV70akF1wXv2vzFjg/tbLHlt/PmepxjrWpaLqcLS3PiHW7jSLXCrp1w8TzHyWP3YwpyEI444rKm0yxjcForUY+9GU6/jVaS308Fg1tCoHQBFJH/wBagBPiV4Z1K0vW1SPT7kaIURIrvyyIm44wf6VJ4HGsmwtToDzrarcZ1Ly22ptyNvmdiPTPeqpsLR28yGK1AHZu/wCFMe2hT5ltbY9iNuRQB3Xib7Wlw0Gur4iitbieJYZNenErRtuzujOBhfpVfQda1y71a2sBqmv3UaG6EcGn3rCXg4Hl5JAPpx0rg9kYk2fZrZSecsFxj6GtTwhozeKtetNCtLCI3t1LsjaKMYA6liR0AGST7UAd9eabrt74L8RSzf8ACUk6bE0txDql+vlFWbCiVWwXkxkjHp9AfBK9x+Lmo6fp2j2vgXwe6PoWlSF72aPrf3fRpDjqB0A/oBXkBiinGyBMSr2FAGdRmtIW2dxKqjoOQwyKalo2eQu0nrkYFAGfS8VptCih12KQOhIwc1XmjRHUcAN1BH3aAKmKBW5pdnHs1LzAjGO1Z0BGecjke9dz8C/hpYfEWXVU1HUbuy+yKhXyEVt2fXNAHlWafF/rU+or3f4u/BPSfA/g2bWbHWL+6mjkRBHNGgU5PtXg0bEyr/vCgC7JqVyq+VHKyBJHcMvBJbgkn6VUlnkmVFkdmWNdqAn7o9BVy608x6ZHf/abZhLM8fkK+ZVx3K9gexrOzQBYs4TNMBjIHJreNvGyRJGgjkB5OP51zaOUOQSPpWnY3rI24scDsecmgDqYLq30sK8qlyTgYHJFPuvFb30JtWjeOA8H/aHpXM3l59uIeQ4wcAZ7VMrRhMyq8i5woB6n0oAsloIpl+zBWzwARwv/ANerPyDBn8svngR9RWX5jwXBlwh4yqcfJU1lFIg8+5kCofmxnmgDSnl2ReWkoaQjPTcV/wAKm0uAiVEaYNxu6d/c0WSSTwyOERGYZwTk1csre2gfEQLy9PMyTz6Ad/rQB1Gk2HnGSUJG8e0YyhJB9a0horqd8sSbc9c8/niquh/arSBplZhkgfMMA/n1rori8ja3Wbd5jAYAJPJ+lAFK9tNJtbb/AElWVSOAgLMx+tYthcHYfIhKQ5IAcfMP61Q1m9YXQ8zO8t8uTnH4Ve05fNvIVeckMMlCNq0AbAt9tkTDFvJHLhs/pWFc/JaSB94YDhFOD9eldckBERiM8Yj/ANk4B9h61lTxXL7mGUVeOn+NAHHuktwI/KjcleN0hz+nWni0YDEhdZW6PkrT55pDOVhhlZz1xjP6VY0+2ld8sowT8yt1B9x1oAfbQwyTRhlZ2jHJ5x/9eor2aCGchNro3VWHzKfatyctEQDFGi4AyuTn9azLq2h84O8ckgPTbGRzQBm3EEUirOHXIHJ2c/jWXJFAx83zYSwP8K9fb1rpPLjgiZkV+eznB/MGq7WEcsSzbl3dAowaAOd+zJNFIY0KSluQTlRWfK6pJ5XlqCOGxxn8q6eeACRlcGNAPlf0P+FYkNlslkMkyLtJJLZ6e1AFC6W3iSOOVypPQYyR/wDWr1CXzPhH4Ckhj+Xx74ig3PtGH02yPQeqyP8AmPYrky/DrQbDSdNuPiD4khM1hpzbdPs2PF9dfwgf7KkZP074IrzTxFq9/wCKdTv9X1JpG1O4kMkjZ4Poo9ABgAdgKAMSG7S3hJkU+Y3ZRgg/WgLaSsZYgyynnJPf+hqs8hkIWQmNxwcDIP1q1p8ErytEVQDHODgkexoAVlCujTRyZI6qOR/jVyaMx2sc5hBRjh/6GtSyt1QRxzBzGRyWGR+BqPVbYRuI4mIiA7cg0AYF84EZ3qeeEB5GPT61nuoBQyH5SODWzcywG1kVRmROSOo/KsW4dZIwyqyr270AaeiSHytUQnI+xuQevpXuf7HjbbjxH/uR/wAzXiXhmSzXSdbSW1Z7xrVjFOJioQZGQUx82fqMV7P+yI2258Q/9c4/5mgD0P8Aabct8K7sf9PEf86+NIv9an1FfYf7SrZ+F13/ANd4/wCdfHkX+tT6igC9d6nLLpkenNFAIYZnlVwmHJPYt3HtWdWxeyWB0C3jjhUaiLhzJKGJLJ2BHQc1j0ALUkILNhep7ntTYlDPgnA71bi8tSvDOT2oAjEqhyoAIIxnFXrVCDtkDgHoWP8ASmyQIJFc54OWOO/pSxXEktzh22E5A56CgB8ZwTIULfwr1OPertrNHIyxkN8x4+XJJ/wo0mIy3JQqvlsPXrWzbWkIybj5sEgLHx/+ugC/b28iRxhYUKMcsX5J9wK6Wzs2EZf5yOgxxisrw9ayajOYo98cY+VAeCBXdwWcmlW6iZuBztYZB9/egBl9YyWumRMhBbGSoO41x19fSRsYoBMHA6gitzX9ZbysHCx9FROp+tczE5d3kmG0D7qsetAD98UgEjRq0hGMyE8GtLQin2hExulzy8jfKPoKzreSGcODKCByCx7+1QWUVy2peaDiIdWkYhR9AaAPUoreyaYSRSkso5IwMn/CszUraB5WYCVh32qev1NW9IEV3aoEUu3QlMfMau6tp6xiBQJNrcFm4C0AcJeQeTvcIdg/hXCt+dV7G6ni/cww7wWy2MED8e1beqaYI3LETFmOEJ5BHr1rMhsrh2PlELGOAhx8x9zQBcm8tgHu4o0xwHDYI/KqMzlizwzSSY5+U1tLYzx6WzssbMv3lGNy/QVXMLyWPlRwFUPJMuOfoR0oAwZZkUHzIzlv4lk3H8RTbO3jEZcSKVHOVJBz/u96NQtJoJ4iqgID97fk/wD16sXsj2Uas7t5R5HO4Y+mKAK4vXdmEoIcDCnGM1d8GeHbvxd4jjtmdbbTYUNxf3bpsSCFfvNk8Z7D39s06PwtrN6dPeHTJZItVGbJiMCUgkYDE4B4PB5xz0rufHGl6h4W8Fjwp4ctjK8hWXXL1SMSyH7sCkkEquRnA/8AZhQBwHxR8aJ4h1SKy0i3EXhzTE8iwtgCPkHWQ/7TYz+XfJPASrHKfMhbyjjlQSCK6afwrrtheCOTTjHcNEZFVZFIKjqTg8Vm3NtMVMt1GViQgMXA4yMgAigDEitrmQtIDwp/1ka/0rT0i1+0kpgsyHIdeB7GtWHQp5LRr3TIWngVlTf5nAJ6DGc06xuntMST2pSFyUII5DDg4+lADTZuh8wuTxyEOBWdqUoiTEyRykfdGMZH1HeulTTZr2V4LeGVpCQoGQDuIyM8964rX7bUEvUs2gdZpCVVOCDjrigDIl/elzAnlDPc8g0WemPcq+CVOenY1teHPBviLxJFcTaPpVzdrbf64xAEA++SKjywiMLkwSxnGPQjtQBBp1kbaLVSnzR/ZH5PUdODXrv7Jj7LnxBn/nnH/OvPrfStSm8Pavq/2YiyW3eKSXevLZHbOf0ru/2VH23Ov84/dp/OgD0H9o993wyuh/03j/nXyHF/rU+or60/aJfPw1ugP+e8f86+S4v9an1FAE01tcAPI0Moj3EbipA6+tRJDK6MyRuyryxVcgfWu/8AEGua3cQ32m399fW1tNdi0+xXErBIADksydN3qcZ61r+E7K/0fSdVXTZ5bu2t7iSC+W2JERjKcSSjoV9M96APLbaJnfBGF6kkdq6PQtKW5vEmYDyYxuYVf8Q6TqD6lo32vTnsY7mzQRAR7VKjuPWrb4tJFsrP7o+aRz3x2oAoeIrfyrbeNsZY5VAK577E0Wxnw0j89cYrV1a6meRZHwSxO0noKzpmbz0Z2LAjlivp6UAbGiwSQyMzqWUjCgnr6mu107TY2RmYLJxlR021xdnfXckcIhiCkHliMAAVtWOsQwys6yL5uOWXv+FAHoWgR2+lyC4u+ML8pC4Bql4m8SLeOqwSFYwMAv1JrlLvWbmaRXaX5gMFXHUen0qrPi4cmeRIXHKAEFVNAGtJLvDB543ZAM7hwDWZqVzIpRUAkfvJiqtvdPLGUkPKnBAOA/vite2tfOgjnYMVXooPB+vrQBNa2avFCCeh5YDgt6VaazbcJHVDEozgDYPrSWsl21zGksaMp+6qjAH412MGkNJYsJcsHGdqdfpQBN4FEcgeOCUHPJBP3frXZy2rTWxAJkRepBGfwzXKaPb7JoWeDZGgwqhcZ+prcGo5u/s0scYi27k+fH54oAzNR0mOWYcux6gOwJFULayW6uhG8PKnHAGfyrsBe6WU3y3NtuU4IVqiN3pn7wW1zaeaf70mCD+NAFOfRZBbhVQuS2GUDmm3OjpFbeXCgjYj5gy7iKc+uWkCSWt5fNvzuEifd+gxUGo6w1tGGtr2K4jxkwyREk/jQByt3ouZGZDGyccuDz+VY+r2cx3RxsoA+XYvIBrqT4wtxdQxy2Ultk4Lx9PxFaEkdouo2WoXMkLWhlRn8g5LKGBIwe+KAPoXQLS28PeDtMt714YIbC0jWSSQhVQqgDMSenOa+cfGuoeGrbxHjRFgmt1YtHe3U7t5TE5YK27DKcnlsnmqXxl8Zav4puUiLzW+lRv8kMWduezN/eP8q88vI57iBbSVmMY6Oy459DmgDpr2Tw9b3srXsWnrHNIhjGhXxZmIOSZDIGx9Biq/i6Szv7gHSZk2KdpQsP3hI+8OB9Kw7HS3gmAeEtgctnt71KfJnE0LZ3JyjMMEfjQBLpMsVraOZLm2iuIrmMskh2SEA/eUDqB61n+NtStJ7G1uLSTdcLJI08WMck8MCOuetU9UupLXbI6IzqMAsedv9RXOyb5rrC8ITuAByhHofSgD0ez1nQG0+8kuriaR7i3VXS2cRyOQBwrMCAR9KbrFlYalqmjalp2r6Zb2tsgUw3d4vn++QFAP14rh5rWCK3Y5UKw+6DyKbaBY7VuTJA33RjoaAPon4DWkWmWvigHU9NuklXcDa3IkVeDxnjmvm7WZNt/PNyyeYwyPTJ60zz5RIQwUlhg47fWoHinj+aRgytwSOn4igCxoyebp2rzI33bV1IPXGRivT/2XG23Wu/8AXNP51wFnZRxaZq8sTAMbNgyA9Oldx+zG+281v/rmn8zQB3v7QT5+HF0P+m0f86+VIv8AWp9RX1J8e2DfDq6/67R/zr5bi/1qfUUAeg/2tBe29/aWdnpcsSXKCIQ2CRXBUuMyCbaGAzxjPGRWXe2lpDdeJrdrGWO6jYeSskvmGL5uRuB+ZjnGaytT8T63fWs9leapdzWkkxmeJ5CVZ8/eI9ar6bruqaZa3dtp9/c28F2u24SNyBKPRvWgDtr7QrnwxpukPeaXd2s8iuXlmiKecTyACew46VR88s7sjb3PDAdM1yUN5ctEYTNIyAHarMSFJ7itizvEt7NUJXPdj3NADGke7mZGX92h+92ApkskTExRnCICfXJp8cq+XskZY43z908n1NRzNGskZiTaudpB6kUAWbKWRrdlj3M2Nq8cD1NTRx/vERmAKjkhf85qtG7xuRCoC9wK3tPs98E0sg/ej5ssc4FAFG/mFsEJ2qTwjH5j+NO+zNeG3D7vMPKsuADUFyy3EoYBFjztCkZz71oNbyRzRHls/wAMfbPagB4thDFiU7ph90rkkfWtrSJHkVeGUY7UljagwMjoyuBj15ra0vTltbUrcHEp5VQ3BoAu2NsYpFuBiYD+A+v413ugRx3YLhSABgDGAD/jWDolsl5Em5T8n8Hcn/Cuxt7GC3syXfyww5C85+lAEs6QQ27y3cqmIDoK4fV5Pt91m1iEEIHP95h6k9AKveKPEMGnQhWX94OEQ9D7n0rzq41a51W4M07ssa8A42qffAHNAHSTXdhZgiCNbgg4ZF+fJ9z0FULrWYWfdFp0bBflxJIQB9ADTotHmvLMblmlUEMCwEaU7+wpFDNi0YnqskgOKAM0380reYqqiqcYbAANQz60lqCnlxxSODulidnH1x2rSTTUCMqx2nHGEbH6Gs3U9KCTKzW7KPVgDuHsaAIdOl1C7kIWX7UD0CKMgfQ1cs9Rm0h5DNbGRM4KSKf09DVG2ihs5lnt2kSQHKuecfl0puvaxcXgjNy0ZOdu7G0g+9AHUyazp8ixm9sL2ESj+BtxI9eakms/tsKyWbO9uoyCy9R6EVS8E4mWKOZjcRKSTuH3R/h9K9Bjs3jQmAxiBhn6UAcBeK4ZQqoQBhsdRXK+IbsQRqiffHBOQCBXX67MqSSxRDaueGzjn2rkdU05pYlln2NJ0whBOKAOSkV7gN5nmfKRs3c5rbsYoDbh+POCkEA5DgeoqGeJIY4dhIfPzK3Gf8KiiffcsY4goP8AED+fFAFe58lUBiiJYnIDDpU0QmitlDqNp52jpirRj5NwgJRMKVB61diKC1JAAYNkb+hoAy7W3ie4KKnLe3NZmoRvYTyRyZkQqVI7/Wt/VjFA8Eyfum4LKvP5Guf1y4N1Okyk5A5HfHrQBa0W6thpWtRNa+ZO9m2ycysDEBjI2jg5967j9mp9t9rQzjMafzNecaMxA1ZQ2Va0fI/Ku/8A2cm26hrH/XJP50Ad78c23fD275/5ap/OvmKL/Wp9RX0t8bGz4AvB/wBNE/nXzTF/rU+ooA7jU/Ar6beyS3x1BtHji82S+t7Qumf7qkkKT+IrnfFNjpun6isOkXN3cQmNWY3UKxOrH+EhWYfrXQ3vi2eDXDFqtncvaQxi3msRdlVYqeucEDp6Gua8RXmn3+ovcaVZXNnC/LJcXIuGLeu4IvHtigDMVivQ1LJJIU2v0FQg4INSLG8hz685NAEqyRiIqFyxPX0FW0umEmwYCjGSRnFZyAE4zz2q7ExitnVsBzyOOtAGrbybnZoXV2YghscCt+dtlhKVfcTwSnQmuV0lsOfNAxj5QB3q9LczuViUoIATkDrQBs6PBHc2ruYguBhcHnPvWzpunzRHzJZGDY+Vf4ce9ZGk3sSWXlIQUHJaupsLXzoEuCzlV5ZSe1AFmyhG5WiVppCwyQMcV1OlaC9xbmSYMGboWPQVyE+vRQyAKqhc4TPB9+laul+LdSvJ/LghGyMbVYD5VHrQB6H4f0+PSbR5ppsDpuIxn2rK8UeJfs0ZESRlmGY8t09zVa51aaaxLYSSRRzk8GvOtXu9+ptk5nk9TlU9h60APxdahf8AmS/Nk5JY5J/oK1rq90/RbcyPtklIOCMHH4VWSUadavlXe6K889q5+18Lan4jmaedcQA5LM2yNfck8UAZerePdSnlmSCXbGRtABJH1wOK5w6tqbSM63s65HzYBr0xPDvhfTV2X+qrLIOsVlF5nP8AvHikH/CHq21bDW2A/i2oKAPPdP1rWxL/AKPeSOx4w6bq7Gw8SanZRq2p2onT7rAKQMeuAevvWxb6Z4WnlV7PUrqymByFuoRj8xXcjw5b6jpoKS2ruB/rYW4b60AcbA+m61Ep01jFcrkmEk8/nXMalY3DmQbCCv3lPc+vtWvrmi/2DP8AbraYKVOSQeOO2Kv6ffWfiSxJ8lLe+X5SUbiQUAQ+D9UazmXy5Qsy9R13D3Fel2+rzXESlYAytkSKpHT1FeSahGllcAxkAjgAjABrrdCvB5Cm3IDnlwxOPx9BQBPrMUTTRyR5aMkqwbjbXKXqLHM0TLJ0/hPGPWu51yzaeyjKHbID823gHNcpqSNbyFXKsvseSfTNAHIXKB8ou1XQk5zyw9ealt9Klt54S29Un6PjIzWnPalijyIGLH5Rjn35qTUroRwokUzJ5fPPUelAFVlhily2fmOzgfK3v7VVukAD/dzyPLbpVqS+jEau4A39RjODWdfXccsOZEUP/C3qRQBRuPKyEaTIYAqOwI7Vh6ncqpVVYDbxjFXryMiJ5CwyecjsfesG+zhXQDa4/HNAG/4d0e8fSdU1SMW5s1t5EfNzGHB46Rlt5+oGK6/9nt9uo6t/1yX+ded+HRhr4kdbSTB/Ku/+AJxqGq/9cl/nQB3Xxlfd4DvB/tp/OvnCL/Wp9RX0P8YGz4Gux/tp/OvniL/Wp9RQBf8AEV3Hfazc3EG7y3bjcMHpWbT5f9a/1NMoAVQOcmtFITLZqVUrg4HvVWxi865Va7mPw7O2ijykIRDk/LzmgDgwNk3c4PapJSZJPnyAB0FOuYJFumBRx82BgUrJIJSyjGD3oAnWRljG4nAU4HuamDIwjBDeaRjd0yKbKqeVE0ZKnBBJ9fatHw9pdxqt/HFDneBgcZx70Aa1jGqsjRxMApAdefz962dT1M2ZEVurMCMNg9KzmvltbaTLAyhim7pyOK577T57HzpWyCfmLY3UAdbZxpetCtwTGp4GAGyfTNdnYlbG0aO28oSbfnUc4X0+teZ6TfC3AwziInJ5zXX6dqTyohITccbV5OR70AdReLBBoss0w8tFGMKe56c1wOmvDdag5U7UHcgg1t+JL95ljRlGEByF+7VXwJp2+W4vLw7bS3y7A9GPYUAbvkQ2dsL7WS8kZ5gs0GC/ufaqF7dX2s7TqUn2ayH+rtIuFA+nep7mVrqeS9vV4H3Vz+Qra0XToobVdV1oMBJ/qoB95/Yeg96AMuw0lpMLZ2n0+XJNaf8AwjWtNylmxH/XKs/xF8Q4tOUwxTC2UdILU4P/AAJuprjW+JJMu4QTkdcmVjQB2F/pNxb8X1hgeuzbWdapd6Zc/aNDuXjZesLHg+2O9WPDnxLW5ZYWuWAbgxXJ3qfz6V099ptrrFq93pYEFzGNzwA5/FfUUAc7qQHiqylmtC0GqwAma1zw/qVz/KvM9Ju5dF15Fm3rhsg54PNeguZobhb22/d31s2Tj+Mf1qj4/wBKt7+2tdas4wEn+ZkH8DjqKANHxPCl9p0V4iKplGWxzhqPAcyh2AlUMDhl6/nUnhmU6hoM1u8Y+RQVJ5rP8NK8WqTxwABCcFW4xQB6dIRe2NzbsymZRw68ce1chqYiEKRbWeVeBIBjn+tdfZJGqNh8YALAiuc1WCO2v3iILxPyuW4FAGNLEfIVvmfy1JLJzXIa1cLcM6g7d4+Vh2rsYZYopvKG1YmyDk4xmuJ1aF3lmUKNqv8AKMdqAK1tdlWCZ/dcA7hzSXsrKg3xYwxBA9PWmWK26zb5XYbXGR1BrY1ryZLCSWNDtQ4Ld6AOTv5/PtJckqAPlyOtYM8zykbuMDAFa1203yjy8qoO09sGsy5haMnecn1HQigC94cP72+z/wA+kn9K7z4Ettv9UP8A0yX+dcd4ZuYYrTVYHsYJZpbRylw7OHhxj7oDBTn3BrrPggcX2pH/AKZr/OgDtPi2+7wVdf76fzrwCL/Wp9RXu/xVfPg26H+2n868Ii/1qfUUAEv+tf6mmU+X/Wv9TTKAOi8D26XGsbZV3KFzj8a98s4LePRLaOVdrS72GR1wOK8c+D9n9t8SvECAfKznGe9et+KbrDW9laEieGFhlelAHnMBsibppyrMhKj2rl7y08wXE8GWI+Y1bvgNjxgHzWJLd8HPeqE16LW1by2zKwIOKAMm0JMse85RDkelb+meJrjTvNktBDG5XAOCPyrmFYY+9znpTZAUYqaALt9fCZcLncW3EnuaqwuDIC5wc8E9BUWOPpSCgDXgnVY4zK4HUg+tdj4SuJmdnILRjJyTntXDTIv9nRsWUsG7dvrXS+EpmeGSJSQwQ4285oA68f6RtkBM2DnOQCDW9dBrDQrG2jB33shd/p2rjfDd4qXzQOGcnjax27a7zxFDIY9JlSMrGkOfXBoAXRrBb7WoraRcQRDzHz3ArA+Jfid4FkeE4kf93Co/gQeldX4TB36jLvOBAcEjGD7V5Z4sAufGmmW8hzEXX8eaAMsxWWgW0V3rMH2/V7hfMjtnPyRA9Gf1+lVj451f7saWEUXaNbSPaB6cjP61n+L5pJ/El+0p5WUoB6AcAVjUAdnaz6b4pb7PNbRabrDf6maD5YpW9GXsfpXUfDfxBd2eomwvGK3Vs2F3dfcV5RBI0U0ciHDowYH3Fd/fN5Xj+ymQYeeKOR8epHNAHpvi60S31GC+txiC4AbA9+orO0+AT6RrOmNzsHnx+3rW/wCIl3+F7Bj95SQPzrI0g7fEEqHgPaNn34oAxvBCbJLpTlE2kYJ68das6VEBrkhT5EkGSAOv4UeF4hHJdzMdoCHtkVf0C2ElxdSKu9VQkseoPagDeCu1uHijAYYyvOaytbsJpUWT5RxgA/eFdBFJtto1YssgXoSBisnWPNWZ7gPlcfKpXj8DQBx0oWeSRirYj+U+pI7msu8aSSfy52xG3TbwMdq10lmAumVceYOPl+Zfeua1JpmdxykvHzDndn2oAoymJY5EbDYfhlPJHvWqsezT51Uny5Oc56AVzl7FdhcKqgLgM23G40+OS5w0c4kEezA2nuaAK88qJIyxkiLoS3fms29mQSsFBYbduPQ+tWWXFw6kFiBt25xj8Kz7iKWNmiKHOe55oAvaAPlvj3NpIP5V1/wXbbeaj/1zX+dYHh7Rrk6TqeotNZLCltIpha6jE56ciLO4j3AxW18H223mof7i/wA6AOt+J758I3P++v8AOvEYv9an1FezfEps+E7gf7a/zrxmL/Wp9RQAS/61/qaZT5f9a/1NMoA9L+A7Mnii6Kbc/Zz97pXTeI7+aye6uTtLtlcDsa4f4TTJDrlyZHKgwkA++a2PHsoKKVIxK2XXqSRQBzN5dqEabrLICGK1zbuW2ZJPtmtLXWVPIWJdi7c4rNikCyA8YIwQKAIjyx5/OrF+u2VeBjaKgJxJk4OD2qe/YPOGXOCooAq0pB60fSnFflDZ60AX7C3863lGCcDdx2rW8H/8fLR7TubI3EcVW8NOSJEBAA6nGevt3q9DbHTdTikOArvkY4VhmgDfNq1pfQyvGF6Dk4FeqxwJqPhy2kQ/PDlTz/IVx11bx3On749uU+YKPQ+v/wBauk+H18nlyWFw24PynOBuHpQBa8Jyp9ta3lJ2yqUHXvxXmXxNsJrDU4L+JCHt5MNjtg16HqsS2WoM8TnJbKgDn3HtV7WdOh8S6fvVFa4Mf7yHu49R7igDwjxdp/20DXtNUyWVyAZtvPkydw3pXK4r0S40HW/DV3JPocjPCfvxlc8ejKapNrErP+/8J6Y8/dvIK5P0HFAGH4W0STVLsTSgxafAd887DCqBzjPqfSuq8PBvEPjOXUI0ItoyFj47DgCovsPiHxKI4bsJZaevSKNBHGB9BXqfhTQbPwzpYu7ldkacxq3DSt2P0oAteKWEdtp2ng/OqBnHoTzWJprBtS1W6/gtrfywfc1Hqd/JPLNfSgmWQ/u071fstOe20yCw4F3dN9oucn7o7A0AU7VRYaJPKzfNKflz2Fa/hSxSLRWuGGx53zxzn/61YmqltQ1eDTrfAgGBnPauoGyCZYtwKQ/Jk44PtQBFeS+XBMI1+ZiADu4H1qO8ulm09RJHjZyWB6VX1IbZ/Md85P3jgZ+tSRTxCNFYDy3y26TH6UAcrqVw0LTpHGrhlByO4rnZ2QXiTO+0kZY5rb1h28+U7+ASQFHGK5aeRZ5fKI8uQ5OeQMf1oAi1GdVmVoclGYllPPfg1FIP9LILAJtBG3pmkZ38wR5Urk7WxyRUU0fl3BALLjqRgA/jQBXmeEStHNvVgNw4zms1Ss9zI07EgL970NakgDs0m4h8EEt0IrCLnLJEd+eCcUAaej/O2osW3EWkgU+3Fb/wnbbd3/8AuL/Oud0OJovt5Pe0kB/St34XNtur3/cX+dAHT/EV8+F5x/tr/OvIov8AWp9RXq3j993hqYf7a/zrymL/AFqfUUAEv+tf6mmU+X/Wv9TTKAOr+Hcix6w+4bspjH41o+MlVdZkUMwWIZU9qzfh4QusSMQThOw96m8U3nmSzyJ8xLFST2oA5e8uXuZAznoMCoSxJHtSda3bXwjrtzdQ20GnStNLD9pRCyjMf97k4/DrQBhsxY5PWhm3EZ7DFdIngTxM6WrrpM2LptkOWUFj9M8fjVXUfCut6d9s+26fLF9j2/aMlT5e7pnBoAxKntjyAQu3vmoVPPJIFSKQkmN3y56gc0AX9NlNjfjeB5bYVuc8etdrJbi9tcoRI6DKuW4/OuFZo85Tbu7NnoPcVr6JqMn2do3J2jpjrQB2PhbWHjYQSxoSnBDNjj096sQXzWmrF4ZAsQbcvUlR6e1cLaXLx3fmFXOD1PBP/wBeuqtzb3Ceapcyg/MpY5X6UAepsBrunJPDj7Wg3H/aHrWJFcySzqkExhuoT2PGak8J6jts1V2bbn7xGCv1NXr+Oz1Bna8j2SKf+PmA4P4jvQAp1tJcLrmnCWQcefCSr/iRQLrw23zA3w9ty8fmKrWkJcbIry2nUYCyA4f/AIEp/pU8mlX5bdGtrIvY7sE/gaAAazYW5H9lacZZu0lwS+PoOlZmoXU11MbjVZt7jpEDnHpV1tMviD9pvLW1jBwcMMj3pYYdE0nEsrtfXOOCRxn6UAVtI0555V1C9tyApzDE46nsfpSalqL75LexffcztiV8Hn2HsKsXk+o6rCTbr9ngP4Mfp60tna2Wj27PdPvuX6KTyPx7UAWNF0+LSbBpLpQ9zIOp9e1UbxpoJcOsjJnop4zSW12phee42rGegJyQPaqkupKynyQ2SCN2Puj1NAEOp36NMkMilWUZLn+Kqwu0lMLAKzRcAyDpzVKcLETcyFZUAxgdc+tMhhWbGQyrjcfMOSRQAmqTiZ5CzbSOoHeufmlUMGcgADAU9DVuW5iS2ljkjZVYkq2etZt2AqrIFEjAYXzGx+VAFTZJPOsit+6B3YIzgjpUd1OXl2XMgJDZXAyCaehVbdnkDhC2AobHNZ9wybEOWR8k5z2oAkmncwiOCN8qeS2MGqcmImZkcHI5KjGfwour2VVaP5cHgHpiqMpAwwcnNAHQeHLlI9O1eBrW2leW1crO6sZIyMfdOcDPfINXfho225vD/sD+dYfh7JGoAk8WkmB+Va/w7OLi7/3R/OgDofHUm7w7MP8AaX+deYxf61PqK9G8atnQJf8AeX+decxf61PqKACX/Wv9TTKfL/rX+pplAHWfDk41eYdAYiCfSofFnyKihlB3EMoq58LmB12WNgGEkRXBqDxxA6XDNs+QORuoA5uxKLfW5lwIxIpbPTGea9Knl8O6zptzY6NdfYZ2uvOd9WvI9rAcnYyoMA9gc15fSqwAIIz6e1AHo3ifXtIvmeKytrCKdWh8y9V5C9wgPIILFRgjsBxUFpqHh2O2kW7a7e8aS4MbwTIsIBHHmKVJbPsRXn+fSlII4NACGjtRSUAPUA9TipYJmik4OfxqAE9O1PABX5clvTFAGv8AJJtck7jxjOCDXR6M8kdvuYbkB7HkCuasseSWMmJM9MdB71qW7NEFkikZNvdun0PegD0DTZowyvDKYiPU/LWxPK00aB3j8xhyN39elcvoEqS28zlwp+pKj061ctdZeOUpeiN0Hy5XAz6UAaTae3ljMzxqOCgGefWprXTQ5xHcux6kKSCP6Vdt7uYwNIkq7TgcqM/TNZF5dToWbzX3KSNqkEfX6UAdFb6HCu5p7hQwX5lJx/8AXpqf2Xp7q53St6YBGaxtPuZ7pCxtJrmQciQ/IM+vrVW8t715S1w7tJ6ZHHsMUAaV/rrz3LxiRIlYcKmOR/SuZur6e7fasmUQ8bv4h7Vdg05IRi7MmzrgsQRn1ojjthMBCVjiXliOBn8aAJNPspY4il1ulLrkLvwagvJXwLaPbuHJfdnb7VLNI8SmSycsoPzzydSPQVRVWBldsMX5z0wPegCwGkj01EURybn5XjP4mpFBdxbKFyx5dOce2aqKIYhGWkDtjC4fA+tXFdEeIkiQN821OFH1PrQAzVbC3toHWSVWRlxwM1w1/HLPJEqhRDGCQ3Uk+4rq9avfPBLoEj6BV7fQVQj04LbpPl85JVW9KAOeublmhSEBcw/O7P19hisNma5mbDFxnOMY/wD1V02oWo81ndC0jcZPArJvLVIJHeF8hQOCeDQBm3AwymYjZ6Ac1UdgxJGRjoKuOS5Ej7SoOBmqb8/MABnsKAOl8N6Wz6Nqepfb9PULbyJ9ma4AuG9wnUineAm23F1/uj+dZ+gJgagT1+xyfh0q14KbbPc/7o/nQBueL33aJKP9pf51wMX+tT6iu38UvnR5B/tCuIi/1qfUUAEv+tf6mmU+X/Wv9TTKAOv+GkLSa1I6HBjj3Z/Guh8eWEi+crRk+cu8AdjWV8I7Oa71q7+zBjJHBuwvcZrvvEVtdT6eVnjG9Adh7kehoA8HIIJB4IoHBrQ1qyNpcnnKvz9DWdQAp60oB/CkpRjHfNACHGeM496SnelIetABRSUo5oAt2cgVl6Ag8nPJrXtnNw/ljAK/U5/CsizdoXUhM+uRXSaHbJNOfnCcggkcD2oA2rVpfJNukI8vAGVP3qsxPHLN5bsLeVMDHGCaLyxuba187ALHj5RnPpVVYo5QomVvOHTaT19zQB01lcyRA+a77OmSoCn3zUV7cpc3a/IXwMDH/wBbrWGmoz2iyxTeUUXoqkkfhirmlaoZSFuEfIHATk/X2oA6WzBEg8+Vwi8ZUHb9DRqN2STJZsgeIdXOCPcVm/2nbiPBmZnYZ2hslfwFZTanvkkRBK7kD/Vrg/8AAgaALt1cyylRIfmfG5sZ/P1pxhtyhWUA4+YbV4b8arhvkzIGQ+rnaB+Heq5kcssbEcdD6/XHagC1OTIsShlZBypLHg+1NlDQyMrlDuGSQSQD71EyeVM0qTR7zgMSxx+XrS3NzDE+Q29QRkjsfSgBj+dLbrlDgc4bANIPM2FSwibbnYhBb8ajLy75JbqSNgOVO0/LTbCKa9jkMhfLcmTB5HpQBdsrKe7twzdOo3DtUd9EsMG2Z3LdNwOB9K0IZkgtv3ZzIFwfRRVMyPc27ykBUHKs/wDnvQBz9yVeZYjJtVhtBPaqWp20KJlMHacFj/KtNH+zpJNcIryE5QEfKvuTWVqd3Iy+dJhUYbVXHLH1xQBzswDBBgksc/T2FMa3MaM0vy9hVyNJAJdgO9h94jpT7C3lvplWVf3EfLFe5oAl8Pwt5epSkHH2STH6U/wi22a4/wB0fzrpdPiNloeuosVsYp7ViHeIGRcY+63b3rlPDLbZZv8AdFAGv4kctpUg9xXIRf61PqK6bXXzpzj3FczF/rU+ooAJf9a/1NMp8v8ArX+pplAHqn7PNyLbxbdsRndbEY9ea931jRrbXoRND+6uo8jb2Psa+dfgzdLa+ILpm+80BC/XNe76VrhUrO+0O3ySRk4oA8f8ZeEhHPIpjdGySO9eZajYy2UxSTBHYivr7VbOz1uBVUqtwvKHpuFeO+M/BxjmZ5Ic8kMB1I9RQB4xS1qaxpMtjO4WN/JHKse4rOETnBCnkZFADcDsaSlKt02nj2pF75oADjHFPiRmOVUtijnaCFIHf0NXdPt/OGVGB3JIAFAGzoGnpc7PNOxWOGR2IB+hrrF0WKEL9lldgDl/lPy+1ZXhUCzudskodQP9WeVxXoVpYQ7N8jPGj/dcHC49BQByEVtcTuUiu3JVuYyCdtaUmmTT2LSWk9vIQMECTBBrR1G3gsbaV4d0/pgbcfiOtc7NetCiPbwxMxba5Byc/TtQBiXK3Ongqy7yG55Bx+NamlWnnuJCBJEwz0/Q807XL+OWNQhXeRghSpP+NZVhJJEA/wBpZZAcZUcgfzoA6qKGOElJYUVT0bcfyqvNPFYs+2BM/wB4YH45NQxXl3KjKZNykZKryT9eKytQlza7hLMsm7Bzg5HofSgCT7bHNM6+YBuGcMdxNPa9aCSInD8fKOQPxrJYbWDyFWIGA7nge1T2b4gdt0e4/wDLQYwvsBQBr2zT38u+V1EIPJKAAfSrl0sKhIrYpK+d21j+prDsbu4SNldkl3N1XnA9qvRrtZZmZ15wAq5//XQBckgvJNrOyIjcCMjnHrirFok/kTBHMS87vp/So4Lthc+fLHIIlHyoVGWPqT2qjeX0t27Knyxjlo1H6UAWJrsLEqwkGID5uhLGk1PUXezFvEDnAy3A/WsmQSxlWMSrv4AAPApkrs6eX5RZgc4z1+tAEdxdQou2ZvMKjIHbP9aymLXsTSucgtgewqxJaXNxKyhFCpw7dMewqePTfITDMGcjKJ/doAy5VMwKybkDEKipxkVt2EKR2yW0K4/iO3/PWqNpbSLIfN65PXr9a1rMrFkw49Cew9vc0ASz7v7Kv1dSpS0f5c/TrXF6C22SU+1d8Yl/4R7V5TqFgJzbvvtWZ/PI4xgbduP+BV55pBxJJ9KANLWHBsWHuKwIv9an1Fa+ptm0Ye4rIi/1qfUUAEv+tf6mmU+X/Wv9TTKAOj8DztbasZVQuVXoDjvXq1pqDSyiUEkr3Pceh968n8FOE1KTJwCmPrXf2MxW4JR96HjjrQB3+kam0MYaVvkDjr/DW5cyW99Mbe8hVvMHBJ4PuDXCRTNDall+c56DkYrRs9QWNwLkum5cRyKcqp9xQBQ8R+DLhLh/sqtNBnO1ucD0NcwPCISdhJCVXtgcCvT49VktrEvcyeYgHLr95fqO4rnx4gtrot5jq5U/LIOMezCgDhrvwZCx80wTCH+9jIqFNC023+aSMoo4LDkj610V14mmtZbgQXEYJ5Cocg/UGuO1d59QuWljMSSsuJFRsBh6gUAYviS3ijnMdq6lByAMfMPas6zeRsrGSq9yQPyzTb7zY5irKylenNLbSoxXzMe4wcGgDe0ZiX271SRDkD7ufb0rsI7vU2t3eGMNEFxhXwPyFcRZTBWc+YyqOQrYYEe2Oa15NSP2Xa37tSOT/gf8aAL0l5Ibcop2y9+D/Sq6GaOKRvNVnI+bB3Z/CsuKQbA0RDnPVgVP6Ugvora6aO5j2PJ1ZGzn60AJJIpjLKpAPykxjD0tjdXMJOQkaHqHTf8ArUkc0UNyfJlYKFyQGyakhmglmUpIYHPTePv0AXYZVSEzQPIZMZLbflH4VYdbm4tl81ElLDghD+dQ21z9hulDlAWHZOR74qa+v/NmCxNLIBwxRc7f8KAKr2UkcYR4wkT8hsFifwNSWlnAhIMSkDnkha0LYRyqBIHRCMAs33qkj0q1kut7vumOCC756dOBQBTeAxyK1ssKAj7qDJP44rd0eGA2bSsWe4P8LHaE/HrWlpukXM9vMsio7nkyE4CD0GafB4YezgMsED+YTlmyD+JoA5i7Vo5SCS8jn+Ht+ZrP2tHMDHKYpnODnHI9/wDCuxtdDvNRvJIofMAH3pQBn6Z6Ctaw8LadppLX0vnXJ+6iLyPxoA4W30+5uneTDBQeXc4zUE+kgSK3zOwPzHdwPaut8QWbvJFb6dExZjghTnb9TWTqkEGl2ItvtCSTscPt+Y59BigDEjVIpXeQDHQR/wD1qopHJPMzwBIs8GRjnH0rQiAb5IVz/eZup/wpkiIAzySg9sKeAKAK6iGNjGpZ0UfM/wDePc1k+YXvCbZm27vlAPQdyas6g58pyzFEP3UX7xFYivKDhXWMEYIz0oA2be6jm/tZYsMRaOGfPXpXL6e213PfFdHpSxLZal5Yx/oknzHqx4rl7Y4Y/SgC5eyFoCPeqEX+tT6ip7h8x496gi/1qfUUAEv+tf6mmV1HxC02LS9bW2hWJcRKzeUwZSx5OCOCPeuXoA2PC8bSaiQgBO08E4zXcWkttblY5XaOQnG4jofQ1wGiNGt2fNyARgEHBBrq5JTBGXkLyKRw55z7H3oA7CBLlLhikgw4BFNuL5opwbhEYdHTOMiuZg1cx20QeVtyH92xPI/2T61Dqt8b9FcshdecDrQB0uqaygij+y3IC9MN95PYj0rm7m7nBkMUiszclOorCmKl2ZpSzYznGCPr7VDBcmA4ZpFDHllwwFAFue5eJtxEbo47jDLWTc3koO0NlO3/AOupLuUyny3cP/ddf61QmheM8qQB7YoAWSXzTlgQ3sakimSPHyEMOjA1DEozuf7vfinHyiWxuHpzQBqeeg2ytbs5HR06flTp7l5gm6PDdFYnn6VlE7SAC2O/PWpoppAACcqOVJbpQBqCWSOHYLhUfuvU/lTRcFlzIsLsvGQ2Dj6Vno6NJ5hlAb0cA1WkdjKXyM57UAawuUWY7pSisMZB5HtzVu0dZpMTRW7xjowba2P61hxvsUbgxB+h5qeO42yJvJX0+UKMUAdHHNAsuYD5YXr5gJB/GtC2u/tTqiLEE/idQEP/ANeuXklS4uIi8uV745q9JMkAQQ7Y4wckgkE/WgDrTHMcMbYyKowuXzn8BVqJHeMYWO1KDJYLgn865my8SeV+7LsV7KFLE/jWlDftNOk8oXyB1VG5H1JoA2rDUH2yKu4MP4pScH3rRi8RvL5dtcJM0Y/hTChvw61kahqKXSQpp8JSMcl92M/jVW6Viqsbld4/gU9PxoA7a71mUGOO0ZoYwMbEwoHuTWZPdoJGlF1vIHO3kg/WuVivIrdWV5AZzysYYnP1pkF5c3uI4WiiJ+9gUAbc+s3EVl5cIEDyNgF/mkcf0rPEMas8j8TuOpPJ+g7CoJmEDJFGFaRusmRn8PSsmWfZcS+QGlkJwZGbv/hQBaUW1t50R3EHlyW5Y/0FY80peM4BjXPAQZNWpIIxGryzKZG5Jx1PsPT3NQS3ETuLW324AyzdyaAKd6xjVOQSe5OWJ+lUR+5Y4jBk6gN61ckNtayFmczTD8voKopOzuzSKu9uijsPU0AbGiX80dhq9t+4dZ7RtztArMMY4RyMr+HWuTRtua39KdnfUM4wLOTCjsOK56gB7NkYoi/1qfUUynxf61PqKANy98W6/caW+kz6tdyabnH2dnymB7VgVcktcyv8/wDEe1N+y/7f6UAbPhXXdP0mG7h1XRhqkM+0hftLQFCO+VBzW2vjDwyqFB4Qm2H+E6xKR/6DXF/Zf9v9KPsv+3+lAHXHxP4VMew+D5imc4OsSnH/AI7TrjxV4VnOT4MdO/yatIMf+O1x/wBl/wBv9KPsv+3+lAHVnxF4TJBPg+ckd/7Yk/8Aiamj8V+Fo7Wa3XwdL5c2N+dXkJOOn8Fcd9l/2/0o+y/7f6UAdT/b/hHH/ImS5HQ/2vJn/wBAobxB4SfG7wdOfrrEn/xFct9l/wBv9KPsv+3+lAHVS+IfCMkhb/hC3TP8KatIB/6DUf8AbnhD/oTZv/BvJ/8AEVzP2X/b/Sj7L/t/pQB1sPibwpDDNEng2TZMAGzq0h6HPHyVCNd8IA5/4QyX/wAG8n/xFcx9l/2/0o+y/wC3+lAHTnXfCBP/ACJko/7i8n/xFPk8Q+EZDk+C3UYAwurSAfX7tcr9l/2/0o+y/wC3+lAHT/274R/6E2b/AMG8n/xFWIPFXheGOVE8HylZU2Nu1aQ8f981yH2X/b/Sj7L/ALf6UAdQuv8AhJTlfB0yn21eT/4inDxH4VyC3hCdiOm7WJOP/Ha5X7L/ALf6UfZf9v8ASgDsx4v8MCVZE8GsjBdvy6rIAfc/L1pU8Y+HELEeEZTu67tWkP8A7LXF/Zf9v9KPsv8At/pQB3dp470C18zyfCUg3oYznVpDgH0+Xiqz+LfDMhBfwjcHHrrMuD/47XG/Zf8Ab/Sj7L/t/pQB2o8ZeGxnHg+QZ4P/ABNpP/iamk8deHXRVHg5kVV24TVZFB9z8vJrhPsv+3+lH2X/AG/0oA7ceNfDgUqPCEgB6gatJz/47Utp488PWjOYvB7fOpQhtUkIAPp8tcH9l/2/0o+y/wC3+lAHZS+LvDMpJfwhKSRjJ1eTgf8AfNQp4l8KoMJ4PmA9tXl/+Jrk/sv+3+lH2X/b/SgDrZvE3hSXZu8GOGUY3Lq0gLfX5eaZ/wAJF4TwQPB0wz1xq8n/AMTXK/Zf9v8ASj7L/t/pQB0N/r+hGxuI9H8OPYXcyeWZ21B5gFPUbSoH41ylWvsv+3+lH2X/AG/0oAq0+L/Wp9RU/wBl/wBv9KdHa4lT5/4h2oA//9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Endoscopic ultrasound view of the distal esophageal mass revealed extension of the lesion beyond the muscularis propia layer (arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Douglas Pleskow, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_28_4544=[""].join("\n");
var outline_f4_28_4544=null;
var title_f4_28_4545="Single knee chest PI";
var content_f4_28_4545=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F56440&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F56440&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 543px\">",
"   <div class=\"ttl\">",
"    Single knee to chest exercise",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 523px; height: 295px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The single knee to chest exercise is well tolerated during the early phase of a back rehabilitation program. Stretching of the low back muscles and fascia is obtained with this mobilizing procedure. The subject pulls one knee toward chest and holds it 5 to 10 seconds; 6 to 10 repetitions are performed twice daily.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_28_4545=[""].join("\n");
var outline_f4_28_4545=null;
var title_f4_28_4546="Patient information: Retinitis pigmentosa (The Basics)";
var content_f4_28_4546=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/83035\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?28/27/29105\">",
"         Parts of the eye",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?5/62/6114\">",
"         Patient information: Cataracts (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?36/16/37121\">",
"         Patient information: What are clinical trials? (The Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Retinitis pigmentosa (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/retinitis-pigmentosa-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H12130435\">",
"      <span class=\"h1\">",
"       What is retinitis pigmentosa?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Retinitis pigmentosa (called &ldquo;RP&rdquo; here) is the medical term for a group of eye disorders that cause vision loss. RP mostly damages the back of the eye, called the &ldquo;retina.&rdquo; This part of the eye contains the cells that react to light (",
"      <a class=\"graphic graphic_figure graphicRef70420 \" href=\"UTD.htm?28/27/29105\">",
"       figure 1",
"      </a>",
"      ).",
"     </p>",
"     <p>",
"      RP is caused by 1 or more abnormal genes. It usually runs in families. There are many different types of RP. Some people with RP have other health problems, but some just have RP.",
"     </p>",
"     <p>",
"      Over time, RP causes vision loss. It especially affects &ldquo;peripheral&rdquo; vision. Peripheral vision is how a person sees to the side. By age 40, most people with RP have very little peripheral vision. But they can often see straight ahead, see some details, and tell light from dark. Very few people with RP lose all their vision. &nbsp;",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H12130450\">",
"      <span class=\"h1\">",
"       What are the symptoms of retinitis pigmentosa?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The symptoms of some forms of RP start in childhood. With other forms, people do not notice symptoms until later in life.",
"     </p>",
"     <p>",
"      RP symptoms can include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Night blindness &ndash; This is the first symptom of RP. People with night blindness have more trouble seeing in dim light than they used to. The eyes might also take longer to adjust to dim light.",
"       </li>",
"       <li>",
"        Loss of peripheral vision",
"       </li>",
"       <li>",
"        Loss of sharp, clear vision &ndash; People with RP might not see small details or faraway objects as well as they used to.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H12130465\">",
"      <span class=\"h1\">",
"       Is there a test for retinitis pigmentosa?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. During an eye exam, a doctor might find changes that make him or her suspect RP. This is more likely if RP runs in the family.",
"     </p>",
"     <p>",
"      There are many tests for RP, but you might not need them all. The main tests include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Dark adaptometry &ndash; This test can tell doctors how much the RP has damaged the retina. After seeing a bright light, a person sits in a dark room for 30 minutes. Then the doctor shines dim lights to test how well the person sees. &nbsp;",
"       </li>",
"       <li>",
"        Electroretinography, also called &ldquo;ERG&rdquo; &ndash; This test measures electrical signals from the cells in the retina that react to light. During this test, a doctor gives medicine to make the eye numb. Then he or she puts a tiny wire under the lower eyelid. The wire picks up electrical signals from the retina. If RP has damaged the retina, the signals are not normal. An ERG test can find RP early. Sometimes, it can find RP before a person has any symptoms. &nbsp;",
"       </li>",
"       <li>",
"        Blood tests &ndash; These can show changes in the genes that usually cause RP. The changes can be a sign of RP. &nbsp;",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Doctors can also measure peripheral vision and color vision. If you have RP, you will have regular eye checkups and tests. &nbsp;",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H12130480\">",
"      <span class=\"h1\">",
"       How is retinitis pigmentosa treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Three rare forms of RP are treated with diet changes or vitamins. Your doctor will tell you if you have 1 of these forms.",
"     </p>",
"     <p>",
"      Right now, there is no cure for the most common forms of RP. Eating foods with a lot of omega 3 fatty acid, such as fish, might help. But doctors do not recommend vitamins or diet changes for most people with RP.",
"     </p>",
"     <p>",
"      Doctors can treat some of the problems that people with RP get. These problems and treatments include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Swelling of the macula (the center of the retina) &ndash; The swelling can make straight-ahead vision blurry. Medicines such as",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?6/25/6549?source=see_link\">",
"         acetazolamide",
"        </a>",
"        (brand names: Diamox, Sequels) or",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?25/25/26004?source=see_link\">",
"         dorzolamide",
"        </a>",
"        drops (sample brand name: Trusopt) can help with swelling.",
"       </li>",
"       <li>",
"        Cataracts &ndash; Cataracts is a condition that makes the lens of the eye cloudy. The cloudy lens can make straight-ahead vision blurry. If cataracts get bad enough, an eye doctor can take out the cloudy lens and put a clear one in its place.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      These treatments do not help peripheral vision or slow down RP.",
"     </p>",
"     <p>",
"      Doctors are studying treatments that might help people with RP in the future. For example, it is possible that someday doctors can replace a damaged gene that causes RP. This treatment is called &ldquo;gene therapy.&rdquo; Scientists are also studying how to put cells from a healthy retina into a damaged one, and how to create an artificial retina.",
"     </p>",
"     <p>",
"      A clinical trial is a research study that tests a new treatment or medicine. If you are interested in trying new RP treatments, ask your doctor or nurse about clinical trials for RP.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H12130495\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?36/16/37121?source=see_link\">",
"       Patient information: What are clinical trials? (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?5/62/6114?source=see_link\">",
"       Patient information: Cataracts (The Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?4/28/4546?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 83035 Version 2.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-125.39.66.147-B9BF6B98CC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_28_4546=[""].join("\n");
var outline_f4_28_4546=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12130435\">",
"      What is retinitis pigmentosa?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12130450\">",
"      What are the symptoms of retinitis pigmentosa?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12130465\">",
"      Is there a test for retinitis pigmentosa?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12130480\">",
"      How is retinitis pigmentosa treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12130495\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/83035\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?28/27/29105\">",
"      Parts of the eye",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?5/62/6114?source=related_link\">",
"      Patient information: Cataracts (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?36/16/37121?source=related_link\">",
"      Patient information: What are clinical trials? (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_28_4547="ECG atrial tachycardia with AV block";
var content_f4_28_4547=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F56931&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F56931&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 542px\">",
"   <div class=\"ttl\">",
"    ECG of atrial tachycardia with block",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 522px; height: 311px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The continous lead II ECG tracing initially shows a regular tachycardia at a rate of 160; the QRS complex is wide with a terminal S wave compatible with a right bundle branch block. There is gradual slowing of the rate with the development of AV nodal block; ultimately a series of nonconducted P waves (arrows) are seen and there is one escape ventricular premature beat (*). After a second ventricular premature beat (+), sinus rhythm is restored.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission by Samuel Levy, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_28_4547=[""].join("\n");
var outline_f4_28_4547=null;
var title_f4_28_4548="Pilocarpine (ophthalmic): Drug information";
var content_f4_28_4548=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Pilocarpine (ophthalmic): Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?18/3/18484?source=see_link\">",
"    see \"Pilocarpine (ophthalmic): Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?24/40/25219?source=see_link\">",
"    see \"Pilocarpine (ophthalmic): Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F9505057\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Isopto&reg; Carpine;",
"     </li>",
"     <li>",
"      Pilopine HS&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F9505058\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Diocarpine;",
"     </li>",
"     <li>",
"      Isopto&reg; Carpine;",
"     </li>",
"     <li>",
"      Pilopine HS&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F9509748\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Ophthalmic Agent, Antiglaucoma;",
"     </li>",
"     <li>",
"      Ophthalmic Agent, Miotic",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F9505229\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Glaucoma:",
"     </b>",
"     Ophthalmic:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Solution:",
"     </i>",
"     Instill 1-2 drops up to 6 times/day; adjust the concentration and frequency as required to control elevated intraocular pressure.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Gel:",
"     </i>",
"     Instill 0.5&rdquo; ribbon into lower conjunctival sac once daily at bedtime.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      To counteract the mydriatic effects of sympathomimetic agents (unlabeled use):",
"     </b>",
"     Ophthalmic:",
"     <i>",
"      Solution:",
"     </i>",
"     Instill 1 drop of a 1% solution in the affected eye.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F9505230\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F9505257\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gel, ophthalmic, as hydrochloride:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Pilopine HS&reg;: 4% (4 g) [contains benzalkonium chloride]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, ophthalmic, as hydrochloride [drops]: 1% (15 mL); 2% (15 mL); 4% (15 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Isopto&reg; Carpine: 1% (15 mL); 2% (15 mL); 4% (15 mL) [contains benzalkonium chloride]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F9505060\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Excludes gel",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F9505233\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;display:inline\">",
"     If both solution and gel are used, the solution should be applied first, then the gel at least 5 minutes later. Following administration of the solution, finger pressure should be applied on the lacrimal sac for 1-2 minutes.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F9505061\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;display:inline\">",
"     Management of chronic simple glaucoma, chronic and acute angle-closure glaucoma",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F9505063\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Counter effects of cycloplegics",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F9505047\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Isopto&reg; Carpine may be confused with Isopto&reg; Carbachol",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F9505080\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Hypertension, tachycardia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Diarrhea, nausea, salivation, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Burning, ciliary spasm, conjunctival vascular congestion, corneal granularity (gel 10%), lacrimation, lens opacity, myopia, retinal detachment, supraorbital or temporal headache, visual acuity decreased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Bronchial spasm, pulmonary edema",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Diaphoresis",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F9505071\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to pilocarpine or any component of the formulation; acute inflammatory disease of the anterior chamber of the eye",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F9505072\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Visual changes: May cause decreased visual acuity, especially at night or with reduced lighting.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F9505084\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP2A6 (weak), CYP2E1 (weak), CYP3A4 (weak)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F9505087\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetylcholinesterase Inhibitors: May enhance the adverse/toxic effect of Cholinergic Agonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-Blockers: May enhance the adverse/toxic effect of Cholinergic Agonists. Of particular concern are the potential for cardiac conduction abnormalities and bronchoconstriction. Management: Administer these agents in combination with caution, and monitor for conduction disturbances.  Avoid methacholine with any beta blocker due to the potential for additive bronchoconstriction.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.  Management: Limit the maximum adult dose of lomitapide to 30 mg daily when used in combination with any weak CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F9505069\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F9887312\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have not been conducted.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F9505070\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F9505259\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Gel",
"     </b>",
"     (Pilopine HS Ophthalmic)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     4% (4 g): $109.50",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Isopto Carpine Ophthalmic)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1% (15 mL): $89.28",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2% (15 mL): $91.32",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     4% (15 mL): $95.70",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Pilocarpine HCl Ophthalmic)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1% (15 mL): $44.70",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2% (15 mL): $47.07",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     4% (15 mL): $49.37",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F9505236\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Intraocular pressure, funduscopic exam, visual field testing",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F10962002\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Asthenopin (PH);",
"     </li>",
"     <li>",
"      Isopto Carpina (AR, BR, CO, PE, PY, UY, VE);",
"     </li>",
"     <li>",
"      Isopto Carpine (AE, AU, BE, BF, BH, BJ, CI, CY, EE, EG, ET, FI, GH, GM, GN, GR, HK, HN, IE, IQ, IR, JO, KE, KW, LB, LR, LY, MA, ML, MR, MU, MW, NE, NG, NL, NO, OM, PH, PL, QA, SA, SC, SD, SG, SL, SN, SY, TH, TN, TW, TZ, UG, YE, ZM, ZW);",
"     </li>",
"     <li>",
"      Isopto Pilocarpina (CN);",
"     </li>",
"     <li>",
"      Isopto Pilocarpine (FR);",
"     </li>",
"     <li>",
"      Liocarpina (IT);",
"     </li>",
"     <li>",
"      Locarp (IN);",
"     </li>",
"     <li>",
"      Medicarpine (PK);",
"     </li>",
"     <li>",
"      Miokar (ID);",
"     </li>",
"     <li>",
"      O.P.D. (TW);",
"     </li>",
"     <li>",
"      Ocu-Carpine (KP);",
"     </li>",
"     <li>",
"      Ocusert Pilo-20 (GB);",
"     </li>",
"     <li>",
"      Ocusert Pilo-40 (GB);",
"     </li>",
"     <li>",
"      Ocusert Pilocarpine (GB);",
"     </li>",
"     <li>",
"      Oftan-Pilocarpin (FI);",
"     </li>",
"     <li>",
"      P.V. Carpine Liquifilm Ophthalimic Solution (AU, NZ);",
"     </li>",
"     <li>",
"      Pil Ofteno (GT, SV);",
"     </li>",
"     <li>",
"      Pilo (BE, FR, NO);",
"     </li>",
"     <li>",
"      Pilocar (VE);",
"     </li>",
"     <li>",
"      Pilocarpol (DE);",
"     </li>",
"     <li>",
"      Pilogel (GB, IE, TW);",
"     </li>",
"     <li>",
"      Pilogel HS (CN, CZ, SG);",
"     </li>",
"     <li>",
"      Pilokarpin (DK);",
"     </li>",
"     <li>",
"      Pilomann (DE);",
"     </li>",
"     <li>",
"      Pilomin (BG);",
"     </li>",
"     <li>",
"      Pilopine-HS (AE, BF, BH, BJ, CI, CY, EG, ET, GH, GM, GN, IQ, IR, JO, KE, KW, LB, LR, LY, MA, ML, MR, MU, MW, NE, NG, OM, QA, SA, SC, SD, SL, SN, SY, TN, TZ, UG, YE, ZM, ZW);",
"     </li>",
"     <li>",
"      Pilopos (CZ);",
"     </li>",
"     <li>",
"      Pilopt Eye Drops (AU, NZ);",
"     </li>",
"     <li>",
"      Pilotonina (IT);",
"     </li>",
"     <li>",
"      Sno Pilo (IE);",
"     </li>",
"     <li>",
"      Spersacarpin (DE);",
"     </li>",
"     <li>",
"      Spersacarpine (CH, MY, PK, SE, TW);",
"     </li>",
"     <li>",
"      Zhenrui (CL)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F9505100\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Directly stimulates cholinergic receptors in the eye causing miosis (by contraction of the iris sphincter), loss of accommodation (by constriction of ciliary muscle), and lowering of intraocular pressure (with decreased resistance to aqueous humor outflow)",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F9505104\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Miosis: 10-30 minutes; Intraocular pressure reduction: 1 hour",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: Miosis: 4-8 hours; Intraocular pressure reduction: 4-12 hours",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9903 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-115.25.216.6-3A7D25EF8E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_28_4548=[""].join("\n");
var outline_f4_28_4548=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9505057\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9505058\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9509748\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9505229\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9505230\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9505257\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9505060\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9505233\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9505061\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9505063\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9505047\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9505080\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9505071\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9505072\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9505084\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9505087\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9505069\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9887312\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9505070\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9505259\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9505236\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10962002\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9505100\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9505104\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9903\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9903|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?18/3/18484?source=related_link\">",
"      Pilocarpine (ophthalmic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?24/40/25219?source=related_link\">",
"      Pilocarpine (ophthalmic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?32/55/33652?source=related_link\">",
"      Pilocarpine (systemic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?27/52/28484?source=related_link\">",
"      Pilocarpine (systemic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/44/7876?source=related_link\">",
"      Pilocarpine (systemic): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_28_4549="Pizotifen: Patient drug information";
var content_f4_28_4549=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Pizotifen: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/15/40181?source=see_link\">",
"     see \"Pizotifen: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F210801\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Sandomigran DS&reg;;",
"     </li>",
"     <li>",
"      Sandomigran&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F13154787\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10016045\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691455",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop headaches.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10016044\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702751",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to pizotifen or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703162",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a bowel block.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701342",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are using this drug to stop you from getting migraine headaches.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703859",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have taken certain drugs used for low mood (depression) like isocarboxazid, phenelzine, or tranylcypromine or drugs used for Parkinson's disease like selegiline or rasagiline in the last 14 days. Taking this drug within 14 days of those drugs can cause very bad high blood pressure. Talk with your doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10016049\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697179",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have been taking this drug for many weeks, talk with your doctor before stopping. You may want to slowly stop this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697225",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have glaucoma, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697334",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have prostate disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696611",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, mixed drinks, or other drugs and natural products that slow your actions.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696900",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take St John's wort with this drug. This drug may not work as well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10016050\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698060",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling lightheaded, sleepy, having blurred eyesight, or a change in thinking clearly. Avoid driving and doing other tasks or actions that call for you to be alert or have clear eyesight until you see how this drug affects you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698364",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swelling.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698392",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Weight gain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698027",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dry mouth. Good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help. See a dentist often.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698249",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Muscle pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698255",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Muscle weakness.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10016052\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699057",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Big change in balance.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698619",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in strength on 1 side is greater than the other, trouble speaking or thinking, change in balance, or blurred eyesight.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699031",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698988",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Numbness or tingling in your hands or feet.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699086",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sudden change in eyesight, eye pain, or irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699062",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A big weight gain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10016047\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698544",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a diary of your headaches.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10016048\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10016053\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10016054\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12046 Version 31.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-189.41.181.191-AA596B28AF-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_28_4549=[""].join("\n");
var outline_f4_28_4549=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F210801\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13154787\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016045\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016044\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016049\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016050\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016052\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016047\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016048\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016053\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016054\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?39/15/40181?source=related_link\">",
"      Pizotifen: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_28_4550="Skin biopsy subacute SLE I";
var content_f4_28_4550=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F51438&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F51438&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Subacute cutaneous lupus erythematosus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 238px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Light micrograph demonstrating a vaculopathic interface dermatitis without conspicuous follicular plugging. The infiltrate is largely confined to the superficial half of the dermis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Cynthia Magro, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_28_4550=[""].join("\n");
var outline_f4_28_4550=null;
var title_f4_28_4551="Varicella virus vaccine: Drug information";
var content_f4_28_4551=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Varicella virus vaccine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?10/40/10881?source=see_link\">",
"    see \"Varicella virus vaccine: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?12/5/12374?source=see_link\">",
"    see \"Varicella virus vaccine: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F233527\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Varivax&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F233528\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Varilrix&reg;;",
"     </li>",
"     <li>",
"      Varivax&reg; III",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F233542\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Vaccine, Live (Viral)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F233531\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Varicella immunization:",
"     </b>",
"     SubQ:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       U.S. labeling:",
"      </i>",
"     </b>",
"     Two doses of 0.5 mL separated by 4 weeks.",
"     <b>",
"      Note:",
"     </b>",
"     The ACIP recommends that all children and adults who received only 1 dose of vaccine receive a second dose (CDC, 2007).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Canadian labeling:",
"      </i>",
"     </b>",
"     Two single doses 0.5 mL separated by 4-8 weeks;",
"     <b>",
"      Note:",
"     </b>",
"     The NACI recommends that adolescents (&ge;13 years of age) and adults (&lt;50 years of age) who received only 1 dose of vaccine receive a second dose (NACI, 2012).",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F233537\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?12/5/12374?source=see_link\">",
"      see \"Varicella virus vaccine: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Varicella immunization:",
"     </b>",
"     SubQ:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       U.S. labeling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children &ge;12 months: 0.5 mL; a second dose may be administered &ge;3 months later",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     The ACIP recommends the routine childhood vaccination be 2 doses, with the first dose administered at 12-15 months of age. School age children should receive the second dose at 4-6 years of age, but it may be administered earlier provided &ge;3 months have elapsed after the first dose. All children and adolescents who received only 1 dose of vaccine should receive a second dose (CDC, 2007). If the second dose was administered &ge;4 weeks after the first dose, it may be considered as valid (CDC, 2013).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adolescents &ge;13 years: Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Canadian labeling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children &ge;12 months:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Varilrix&reg;: Two doses of 0.5 mL separated by &ge;6 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Varivax&reg; III: 0.5 mL as a single dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Alternative recommendations (NACI, 2012):",
"     </i>",
"     Two doses of 0.5 mL with first dose administered at 12-15 months of age. Separate doses by &ge;3 months; however, if rapid protection is necessary, may administer second dose after &ge;6 weeks.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adolescents &ge;13 years: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F3062225\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F233511\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution [preservative free]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Varivax&reg;: 1350 PFU [contains bovine serum, gelatin, neomycin (may have trace amounts), sucrose 25 mg/vial; supplied with diluent]",
"    </p>",
"   </div>",
"   <div class=\"block foccan drugH1Div\" id=\"F5951009\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: Canada",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Injection, powder for reconstitution [preservative free]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Varivax&reg; III: 1350 plaque-forming units (PFU) [contains gelatin and trace amounts of neomycin; packaged with diluent]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Injection, powder for reconstitution:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Valrilix&reg;: 10",
"     <sup>",
"      3.3",
"     </sup>",
"     plaque-forming units (PFU) [contains albumin and gelatin; packaged with diluent]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F233498\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F233514\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     For SubQ injection only; inject in the outer aspect of upper arm. Administer immediately following reconstitution.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Simultaneous administration of vaccines helps ensure the patients will be fully vaccinated by the appropriate age. Simultaneous administration of vaccines is defined as administering &gt;1 vaccine on the same day at different anatomic sites. The use of licensed combination vaccines is generally preferred over separate injections of the equivalent components. Separate vaccines should not be combined in the same syringe unless indicated by product specific labeling. Separate needles and syringes should be used for each injection. The ACIP prefers each dose of a specific vaccine in a series come from the same manufacturer when possible. Adolescents and adults should be vaccinated while seated or lying down. In general, preterm infants should be vaccinated at the same chronological age as full-term infants (CDC, 2011).",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-top:2em;text-align:justify;\">",
"     Antipyretics have not been shown to prevent febrile seizures. Antipyretics may be used to treat fever or discomfort following vaccination (CDC, 2011). One study reported that routine prophylactic administration of acetaminophen to prevent fever prior to vaccination decreased the immune response of some vaccines; the clinical significance of this reduction in immune response has not been established (Prymula, 2009).",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F233512\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Immunization against varicella in children &ge;12 months of age and adults",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     The ACIP recommends vaccination for all children, adolescents, and adults who do not have evidence of immunity. Vaccination is especially important for:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     &bull; Healthcare personnel",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     &bull; Persons with close contact to those at high risk for severe disease",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     &bull; Persons living or working in environments where transmission is likely (teachers, child-care workers, residents and staff of institutional settings)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     &bull; Persons in environments where transmission has been reported",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     &bull; Nonpregnant women of childbearing age",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     &bull; Adolescents and adults in households with children",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     &bull; International travelers",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     Postexposure prophylaxis: Vaccination within 3 days (possibly 5 days) after exposure to rash is effective in preventing illness or modifying severity of disease (CDC, 2007).",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F233548\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Varicella virus vaccine has been given in error (instead of the indicated varicella immune globulin) to pregnant women exposed to varicella.",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Other safety concerns:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Both varicella vaccine and zoster vaccine are live, attenuated strains of varicella-zoster virus. Their indications, dosing, and composition are distinct. Varicella is indicated in children to prevent chickenpox, while zoster vaccine is indicated in older individuals to prevent reactivation of the virus which causes shingles. Zoster vaccine is",
"       <b>",
"        not",
"       </b>",
"       a substitute for varicella vaccine and should not be used in children.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F233540\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      All serious adverse reactions must be reported to the U.S. Department of Health and Human Services (DHHS) Vaccine Adverse Event Reporting System (VAERS) 1-800-822-7967 or online at",
"      <a href=\"https://vaers.hhs.gov/esub/index\" target=\"_blank\">",
"       https://vaers.hhs.gov/esub/index",
"      </a>",
"      .",
"     </b>",
"     In Canada, adverse reactions may be reported to local provincial/territorial health agencies or to the Vaccine Safety Section at Public Health Agency of Canada (1-866-844-0018).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Fever (10% to 15%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Local: Injection site reaction (19% to 33%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Chills, fatigue, headache, irritability, malaise, nervousness, sleep disturbance",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Generalized varicella-like rash (1% to 6%), contact rash, dermatitis, diaper rash, dry skin, eczema, heat rash, itching, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, appetite decreased, cold/canker sore, constipation, diarrhea, nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Lymphadenopathy",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Local: Varicella-like rash at the injection site (1% to 3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthralgia, myalgia, stiff neck",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Otic: Otitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Cough, lower/upper respiratory illness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Allergic reactions, teething",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Anaphylaxis, anaphylactic shock, angioneurotic edema, aplastic anemia, aseptic meningitis, ataxia, Bell's palsy, cerebellar ataxia (acute), cerebrovascular accident, disseminated varicella infection, encephalitis, erythema multiforme, febrile seizure, Guillain-Barr&eacute; syndrome, hemiparesis (acute), Henoch-Sch&ouml;nlein purpura, hepatitis, herpes zoster, nonfebrile seizure, pneumonitis, Stevens-Johnson syndrome, thrombocytopenia (including idiopathic thrombocytopenia purpura), transverse myelitis, varicella (vaccine strain)",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F233517\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     U.S. labeling: Severe allergic or anaphylactic reaction to the vaccine or any component of the formulation; immunosuppressed or immunodeficient individuals including individuals with leukemia, lymphomas, or other malignant neoplasms affecting the bone marrow or lymphatic systems; persons with AIDs or other clinical manifestations of HIV; those receiving immunosuppressive therapy (including immunosuppressive doses of corticosteroids); primary and acquired immunodeficiency states; active, untreated tuberculosis; current febrile illness (per manufacturer labeling); pregnancy",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Canadian labeling: Additional contraindications (not in U.S. labeling): Varivax&reg; III: Family history of congenital or hereditary immunodeficiency (unless immune competence of vaccine recipient is demonstrated); Varilrix&reg;: Primary or acquired immunodeficiency with a total lymphocyte count &lt;1200/mm",
"     <sup>",
"      3",
"     </sup>",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F233502\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anaphylactoid/hypersensitivity reactions: Immediate treatment (including epinephrine 1:1000) for anaphylactoid and/or hypersensitivity reactions should be available during vaccine use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Syncope: Syncope has been reported with use of injectable vaccines and may be accompanied by transient visual disturbances, weakness, or tonic-clonic movements. Procedures should be in place to avoid injuries from falling and to restore cerebral perfusion if syncope occurs (CDC, 2008).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Acute illness: May administer to patients with mild acute illness with or without low grade fever (CDC, 2007).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; HIV: Although the manufacturer contraindicates administration to persons with HIV, guidelines for use are available. Children with HIV infection with age-specific CD4+ T-lymphocyte percentages &ge;15% may receive live attenuated varicella vaccine. Vaccination may be considered for adolescents and adults with CD4+ T-lymphocyte counts &ge;200 cells/microliter (CDC, 2007).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Antibody-containing products: Varicella vaccine and antibody-containing products (eg,  immune globulin, blood products) should",
"     <b>",
"      not",
"     </b>",
"     be administered simultaneously.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Salicylates: Avoid salicylates for 6 weeks after vaccination; varicella may increase the risk of Reye's syndrome.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Vaccines:  In order to maximize vaccination rates, the ACIP recommends simultaneous administration of all age-appropriate vaccines (live or inactivated) for which a person is eligible at a single clinic visit, unless contraindications exist. The use of combination vaccines is generally preferred over separate injections, taking into consideration provider assessment, patient preference, and adverse events (CDC, 2011).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Albumin: Products may contain albumin.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Gelatin: Products may contain gelatin. Use is contraindicated in patients with a history of anaphylactic/anaphylactoid reaction to gelatin.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Neomycin: Products may contain neomycin. Use is contraindicated in patients with history of anaphylactic/anaphylactoid reactions to neomycin. Contact dermatitis due to neomycin is not a contraindication to the vaccine.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Appropriate use: Varilrix&reg; (Canadian availability; not available in U.S.): Approved for use in high-risk patients (eg, acute leukemia, chronic disease, organ transplantation) if complete remission &ge;12 months (acute leukemia), lymphocyte count &ge;1200/mm",
"     <sup>",
"      3",
"     </sup>",
"     and evidence of immune competence can be demonstrated prior to vaccination. Canadian National Advisory Committee on Immunization (NACI) suggests that Varivax&reg; III may also be used for select groups (NACI, 2012). Consult product labeling and/or NACI for specific recommendations regarding appropriate use in high risk patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Congenital or hereditary immunodeficiency: Defer use in patients with a family history of congenital or hereditary immunodeficiency until immune competence in the vaccine recipient is demonstrated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Effective immunity: Vaccination may not result in effective immunity in all patients. Response depends upon multiple factors (eg, type of vaccine, age of patient) and may be improved by administering the vaccine at the recommended dose, route, and interval. Vaccines may not be effective if administered during periods of altered immune competence (CDC, 2011).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Transmission of virus: Vaccinated individuals should not have close association with susceptible high-risk individuals (newborns, pregnant women, immunocompromised persons) for 6 weeks following vaccination.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13300208\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F233505\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     5-ASA Derivatives: May enhance the adverse/toxic effect of Varicella Virus-Containing Vaccines. The primary concern is the potential development of Reye's Syndrome, a condition that has been associated with the use of salicylates in children with varicella infections.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AzaTHIOprine: May enhance the adverse/toxic effect of Vaccines (Live).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Belimumab: May enhance the adverse/toxic effect of Vaccines (Live).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): May enhance the adverse/toxic effect of Vaccines (Live).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fingolimod: May enhance the adverse/toxic effect of Vaccines (Live). Vaccinial infections may develop. Fingolimod may diminish the therapeutic effect of Vaccines (Live).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hydroxychloroquine: May enhance the adverse/toxic effect of Vaccines (Live).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Immune Globulins: May diminish the therapeutic effect of Vaccines (Live). Management: Live organism vaccination should be withheld for up to 6 months following immune globulin administration.  Live vaccine given immediately prior to immune globulin may require repeat vaccination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Immunosuppressants: May enhance the adverse/toxic effect of Vaccines (Live). Vaccinial infections may develop. Immunosuppressants may diminish the therapeutic effect of Vaccines (Live). Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.",
"     <b>",
"      Exceptions:",
"     </b>",
"     AzaTHIOprine; Beclomethasone (Oral Inhalation); Betamethasone; Budesonide (Systemic, Oral Inhalation); Corticotropin; Cortisone; Cytarabine (Liposomal); Dexamethasone (Systemic); Fludrocortisone; Fluticasone (Oral Inhalation); Hydrocortisone (Systemic); Hydroxychloroquine; Leflunomide; Mercaptopurine; Methotrexate; MethylPREDNISolone; PrednisoLONE (Systemic); PredniSONE; Triamcinolone (Systemic).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Leflunomide: May enhance the adverse/toxic effect of Vaccines (Live).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mercaptopurine: May enhance the adverse/toxic effect of Vaccines (Live).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrexate: May enhance the adverse/toxic effect of Vaccines (Live).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: May enhance the adverse/toxic effect of Varicella Virus-Containing Vaccines. Reye's Syndrome may develop.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Smallpox Vaccine: May enhance the adverse/toxic effect of Varicella Virus Vaccine. It may be difficult to determine which vaccine caused skin lesions or other adverse effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tuberculin Tests: Vaccines (Live) may diminish the diagnostic effect of Tuberculin Tests.  Management: If a parenteral live vaccine has been recently administered, a scheduled PPD skin test should not be administered for at least 4-6 weeks following the administration of the vaccine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F233519\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Varivax&reg; should not be administered to pregnant females and pregnancy should be avoided for 3 months (per manufacturer labeling; 1 month per ACIP) following vaccination.  Varicella disease during the 1st or 2nd trimesters may result in congenital varicella syndrome. The onset of maternal varicella infection from 5 days prior to 2 days after delivery may cause varicella infection in the newborn. All women should be assessed for immunity during a prenatal visit; those without evidence of immunity should be vaccinated upon completion or termination of pregnancy (CDC, 2007).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     A pregnancy registry has been established for pregnant women exposed to varicella virus vaccine (800-986-8999).",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F233533\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F12705146\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Following immunization, varicella virus was not detected in the milk samples of 12 breast-feeding women and none of the breast-fed infants seroconverted. Immunization should not be delayed due to breast-feeding (CDC, 2007). The manufacturer recommends that caution be exercised when administering varicella virus vaccine to nursing women. Breast-feeding infants should be vaccinated according to the recommended schedules (CDC, 2011).",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16324073\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Injection",
"     </b>",
"     (Varivax Subcutaneous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1350 pfu/0.5 mL (1): $113.81",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F233509\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Rash, fever; monitor for syncope for 15 minutes following administration. If seizure-like activity associated with syncope occurs, maintain patient in supine or Trendelenburg position to reestablish adequate cerebral perfusion.",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F233520\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Okavax (HK, SG, TW);",
"     </li>",
"     <li>",
"      Suduvax (KP);",
"     </li>",
"     <li>",
"      V-Z Vax (PH);",
"     </li>",
"     <li>",
"      Vaccin Varilrix (FR);",
"     </li>",
"     <li>",
"      Varicela Biken (EC);",
"     </li>",
"     <li>",
"      Varilrix (AR, AU, BB, BE, BM, BR, BS, BZ, CH, CN, CO, CR, CZ, DK, DO, EE, ES, FI, GB, GT, GY, HK, HN, ID, IL, IN, JM, KP, MX, NI, NL, NO, PA, PE, PH, PY, SE, SR, SV, TH, TT, TW, UY);",
"     </li>",
"     <li>",
"      Varipox (IN);",
"     </li>",
"     <li>",
"      Varivax (DE, ES, FR, GB, HK, IE, PH)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F233501\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     As a live, attenuated vaccine, varicella virus vaccine offers active immunity to disease caused by the varicella-zoster virus",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F233516\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Seroconversion: ~4-6 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: Antibody titers detectable at 10 years postvaccination",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Bernstein HH, Rothstein EP, Watson BM, et al, &ldquo;Clinical Survey of Natural Varicella Compared With Breakthrough Varicella After Immunization With Live Attenuated Oka/Merck Varicella Vaccine,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 1993, 92(6):833-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/28/4551/abstract-text/8233746/pubmed\" id=\"8233746\" target=\"_blank\">",
"        8233746",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), \"Advisory Committee on Immunization Practices (ACIP) Recommended Immunization Schedule for Persons Aged 0 Through 18 Years - United States, 2013,\"",
"      <i>",
"       MMWR Surveill Summ",
"      </i>",
"      , 2013, 62(1):2-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/28/4551/abstract-text/23364302/pubmed\" id=\"23364302\" target=\"_blank\">",
"        23364302",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), &ldquo;Prevention of Varicella: Recommendations of the Advisory Committee on Immunization Practices (ACIP),&rdquo;",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2007, 56(RR-4):1-40. Available at",
"      <a href=\"file://www.cdc.gov/mmwr/preview/mmwrhtml/rr5604a1.htm\" target=\"_blank\">",
"       file://www.cdc.gov/mmwr/preview/mmwrhtml/rr5604a1.htm",
"      </a>",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/28/4551/abstract-text/17585291/pubmed\" id=\"17585291\" target=\"_blank\">",
"        17585291",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), &ldquo;Recommendations of the Advisory Committee on Immunization Practices (ACIP): General Recommendations on Immunization,&rdquo;",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2011, 60(2):1-64.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/28/4551/abstract-text/21293327/pubmed\" id=\"21293327\" target=\"_blank\">",
"        21293327",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), &ldquo;Simultaneous Administration of Varicella Vaccine and Other Recommended Childhood Vaccines - United States, 1995-1999,&rdquo;",
"      <i>",
"       MMWR",
"      </i>",
"      , 2001, 50(47):1058-61.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/28/4551/abstract-text/11808928/pubmed\" id=\"11808928\" target=\"_blank\">",
"        11808928",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC),&ldquo;Syncope After Vaccination -- United States, January 2005-July 2007,&rdquo;",
"      <i>",
"       MMWR Morb Mortal Wkly Rep",
"      </i>",
"      , 2008, 57(17):457-60.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/28/4551/abstract-text/18451756/pubmed\" id=\"18451756\" target=\"_blank\">",
"        18451756",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chaves SS, Gargiullo P, Zhang JX, et al, &ldquo;Loss of Vaccine-Induced Immunity to Varicella Over Time,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2007, 356(11):1121-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/28/4551/abstract-text/17360990/pubmed\" id=\"17360990\" target=\"_blank\">",
"        17360990",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kuter BJ, Weibel RE, Guess HA, et al, &ldquo;Oka/Merck Varicella Vaccine in Healthy Children: Final Report of a 2-Year Efficacy Study and 7-Year Follow-up Studies,&rdquo;",
"      <i>",
"       Vaccine",
"      </i>",
"      , 1991, 9(9):643-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/28/4551/abstract-text/1659052/pubmed\" id=\"1659052\" target=\"_blank\">",
"        1659052",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Advisory Committee on Immunization (NACI), \"Active Vaccines: Varicella Vaccine,&rdquo; from Public Health Agency of Canada,  Ottawa, ONT: Minister of Public Works and Government Services Canada. Available at file://www.phac-aspc.gc.ca/publicat/cig-gci/p04-vari-eng.php; last accessed January 23, 2013.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Prymula R, Siegrist CA, Chlibek R, et al, &ldquo;Effect of Prophylactic Paracetamol Administration at Time of Vaccination on Febrile Reactions and Antibody Responses in Children: Two Open-Label, Randomised Controlled Trials,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 2009, 374(9698):1339-50.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/28/4551/abstract-text/19837254/pubmed\" id=\"19837254\" target=\"_blank\">",
"        19837254",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Steering Committee on Quality Improvement and Management, Subcommittee on Febrile Seizures American Academy of Pediatrics, &ldquo;Febrile seizures: Clinical Practice Guideline for the Long-Term Management of the Child With Simple Febrile Seizures,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2008,  121(6):1281-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/28/4551/abstract-text/18519501/pubmed\" id=\"18519501\" target=\"_blank\">",
"        18519501",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10038 Version 39.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-61.234.146.186-869C284B9E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_28_4551=[""].join("\n");
var outline_f4_28_4551=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233527\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233528\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233542\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233531\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233537\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3062225\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233511\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5951009\">",
"      Dosage Forms: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233498\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233514\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233512\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233548\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233540\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233517\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233502\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13300208\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233505\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233519\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233533\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12705146\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16324073\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233509\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233520\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233501\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233516\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10038\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10038|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?10/40/10881?source=related_link\">",
"      Varicella virus vaccine: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?12/5/12374?source=related_link\">",
"      Varicella virus vaccine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_28_4552="Safety and societal issues related to dementia";
var content_f4_28_4552=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Safety and societal issues related to dementia",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/28/4552/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/28/4552/contributors\">",
"     Daniel Press, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/28/4552/contributors\">",
"     Michael Alexander, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/28/4552/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/28/4552/contributors\">",
"     Steven T DeKosky, MD, FAAN",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/28/4552/contributors\">",
"     Kenneth E Schmader, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/28/4552/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/28/4552/contributors\">",
"     April F Eichler, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?4/28/4552/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 30, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H18644508\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with dementia have a decreased ability to make decisions. Safety issues are therefore important aspects of the care of patients with dementia. Different safety concerns arise in a relatively predictable manner as dementia progresses. Addressing these issues proactively can prevent serious incidents.",
"   </p>",
"   <p>",
"    This topic review will discuss the recognition and management of safety and societal issues related to dementia. The management of neuropsychiatric symptoms of dementia is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/48/27402?source=see_link\">",
"     \"Treatment of behavioral symptoms related to dementia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The pharmacologic treatment of memory and behavioral problems related to dementia is also discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/4/33865?source=see_link\">",
"     \"Treatment of dementia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DRIVING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Often the first safety issue to be confronted is driving. Discussions of driving cessation are challenging. Surrendering a license often represents a severe loss of independence. Patients are generally unaware of their deficits (particularly their deficits in judgment) and are not accurate assessors of their driving ability. With early diagnosis, many patients with mild dementia will still be able to drive safely for a period of time, but all will eventually progress to the point where it is no longer safe to drive.",
"   </p>",
"   <p>",
"    In one survey, individuals with Alzheimer disease (AD) in the first year after diagnosis had a similar rate of crashes as registered drivers of all ages (0.068 and 0.067 per year, respectively), although higher than age-matched controls (0.037) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/28/4552/abstract/1\">",
"     1",
"    </a>",
"    ]. The risk of crashes rose in the following years, to 0.159 by year four. Other studies have been inconsistent in associating a higher rate of crashes with dementia [",
"    <a class=\"abstract\" href=\"UTD.htm?4/28/4552/abstract/2\">",
"     2",
"    </a>",
"    ]. One problem is that statistics of motor vehicle accidents may under-represent the risk since older patients substantially reduce their driving [",
"    <a class=\"abstract\" href=\"UTD.htm?4/28/4552/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, studies of driving evaluations consistently demonstrate worse performance in patients with dementia compared with age-matched controls [",
"    <a class=\"abstract\" href=\"UTD.htm?4/28/4552/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. Impaired driving safety is associated with the degree of cognitive impairment as measured by neuropsychological test performance, in particular, measures of overall cognition as well as more specific measures of visual perception and motor function [",
"    <a class=\"abstract\" href=\"UTD.htm?4/28/4552/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. As an example, in one prospective cohort study, older individuals who took more than 147 seconds to complete the Trails B test and those who took more than 352 ms on Useful Field of View subtest 2 were more than twice as likely to be involved in an at-fault motor vehicle accident [",
"    <a class=\"abstract\" href=\"UTD.htm?4/28/4552/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A systematic review of studies that evaluated predictors of driving capacity in persons with dementia found that the Clinical Dementia Rating (CDR) scale (",
"    <a class=\"graphic graphic_table graphicRef53706 \" href=\"UTD.htm?0/0/2\">",
"     table 1",
"    </a>",
"    ) had the best evidence of utility in evaluating driving safety [",
"    <a class=\"abstract\" href=\"UTD.htm?4/28/4552/abstract/6\">",
"     6",
"    </a>",
"    ]. Drivers with a CDR = 0 are in general safe to drive; patients with a CDR = 2 are considered unsafe to drive. Patients with a CDR of 0.5 or 1 have a higher risk of unsafe driving compared to those with a CDR = 0, but a substantial proportion (41 to 85 percent) will be judged to be safe drivers by an on-road driving evaluation.",
"   </p>",
"   <p>",
"    Other predictors of unsafe driving have been identified [",
"    <a class=\"abstract\" href=\"UTD.htm?4/28/4552/abstract/6\">",
"     6",
"    </a>",
"    ]. It is important to note that these are more helpful in identifying drivers at risk; their absence does not identify a safe driver. Predictors of unsafe driving include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Recent (one to five years) history of motor vehicle accident or citation",
"     </li>",
"     <li>",
"      Self-restricted driving",
"     </li>",
"     <li>",
"      Aggressive or impulsive behaviors",
"     </li>",
"     <li>",
"      Caregiver's assessment of marginal or unsafe driving",
"     </li>",
"     <li>",
"      Mini-mental state examination (MMSE) score of 24 or less",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    An American Academy of Neurology practice parameter suggests an algorithm for evaluating driving safety in patients with dementia based upon the clinical dementia rating (CDR) (",
"    <a class=\"graphic graphic_table graphicRef53706 \" href=\"UTD.htm?0/0/2\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?4/28/4552/abstract/6\">",
"     6",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with a CDR = 2 are at high risk for unsafe driving. Patients and families should be counselled to stop driving and interventions should be made pursuant to state guidelines.",
"     </li>",
"     <li>",
"      Patients with a CDR = 0.5 or 1 are at intermediate risk for unsafe driving. Considering this along with the other risk factors noted above, patients and families should be encouraged to develop alternative sources of transportation, to consider voluntary surrender of driving privileges, limiting driving to daylight hours, and to consider referral for a professional driving evaluation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Mandatory reporting of a moderate or severe dementia is required in some states in the US (eg, California, Pennsylvania) as well as certain provinces in Canada and Australia [",
"    <a class=\"abstract\" href=\"UTD.htm?4/28/4552/abstract/7\">",
"     7",
"    </a>",
"    ]. Although a number of driving safety tests have been suggested, no guidelines have been broadly implemented [",
"    <a class=\"abstract\" href=\"UTD.htm?4/28/4552/abstract/8-10\">",
"     8-10",
"    </a>",
"    ]. Local programs may exist to evaluate these patients with neuropsychological and roadside tests. In the absence of these programs, the department of motor vehicles will often perform roadside testing, but patients must be informed that even if they pass they will need to be retested at regular intervals as their disease progresses. Families must be warned about potential liability for accidents. They may need to take possession of car keys, or even the cars, and restrict all driving.",
"   </p>",
"   <p>",
"    Impaired cognition is only one factor limiting driving in older persons. Medications, sleep disorders, along with visual and motor impairments should also be considered in assessing driving safety [",
"    <a class=\"abstract\" href=\"UTD.htm?4/28/4552/abstract/6\">",
"     6",
"    </a>",
"    ]. This topic is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/19/3385?source=see_link\">",
"     \"Approach to the evaluation of older drivers\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18644325\">",
"    <span class=\"h1\">",
"     FINANCIAL CAPACITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Financial capacity has been defined as the &ldquo;ability to independently manage one&rsquo;s financial affairs in a manner consistent with personal self-interest&rdquo; [",
"    <a class=\"abstract\" href=\"UTD.htm?4/28/4552/abstract/11\">",
"     11",
"    </a>",
"    ]. Impaired financial capacity can be the presenting clinical deficit in a patient with early dementia and can have serious consequences with the potential for financial mismanagement and vulnerability to scams and exploitation.",
"   </p>",
"   <p>",
"    Because impaired financial capacity can occur early in the course of dementia and is inevitable in all patients, it should be addressed relatively early after diagnosis with the patient and family [",
"    <a class=\"abstract\" href=\"UTD.htm?4/28/4552/abstract/12-15\">",
"     12-15",
"    </a>",
"    ]. Recommendations include execution of a durable power of attorney which can take effect immediately or in the future after impaired capacity has been demonstrated. Other practical interventions can include online banking, direct deposit, automatic bill-pay, joint bank accounts, over-draft protections, and the use of living trusts [",
"    <a class=\"abstract\" href=\"UTD.htm?4/28/4552/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    While certain neuropsychological tests can help assess financial capacity (eg, Financial Capacity Instrument) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/28/4552/abstract/14\">",
"     14",
"    </a>",
"    ], none of these instruments are well validated against financial outcomes or are likely to be, and none substitute for oversight from a trusted caregiver. When the latter is not available, a court-appointed conservator or guardian may need to be appointed.",
"   </p>",
"   <p>",
"    Patients and family can be referred to the Alzheimer&rsquo;s Association:",
"    <span class=\"nowrap\">",
"     file://www.alz.org",
"    </span>",
"    or 1-800-272-3900 for referrals regarding financial or legal planning. Other resources include the American Association of Retired persons (AARP) Money Management Program:",
"    <span class=\"nowrap\">",
"     file://www.aarpmmp.org",
"    </span>",
"    or 1-888-687-2277 (English) and 1-877-627-3350 (Spanish) and the National Council on Aging Benefits Check Up service:",
"    <span class=\"nowrap\">",
"     www.benefitscheckup.org/",
"    </span>",
"    or 1-202-479-1200.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     COOKING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Another daily activity that can generate concern early in the disease is cooking. Distractibility, forgetfulness, or difficulty following directions could lead to injuries, burns, or fires. We recommend early use of microwave ovens, particularly if the patient is unfamiliar with their use and may require instruction. Learning to use a new device will be easier early in the disease process.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     WANDERING AND BECOMING LOST",
"    </span>",
"    &nbsp;&mdash;&nbsp;Safety problems center around personal mobility in later stages of dementia. Distractibility and restlessness may lead to wandering. Signs on doors may reorient patients, and alarms may control movement. Regular supervised exercise can also lessen restlessness and the drive to wander. However, memory loss with spatial impairment can cause a wandering patient to get lost [",
"    <a class=\"abstract\" href=\"UTD.htm?4/28/4552/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The issue of wandering and becoming lost, with the attendant potential for physical harm or death, is one of the concerns that often leads families and caregivers to place demented patients in nursing homes. Little research is available on the risk of becoming lost. However, a review of this issue that analyzed data from several available studies [",
"    <a class=\"abstract\" href=\"UTD.htm?4/28/4552/abstract/17-20\">",
"     17-20",
"    </a>",
"    ] produced the following observations [",
"    <a class=\"abstract\" href=\"UTD.htm?4/28/4552/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Who is at risk",
"    </span>",
"    &nbsp;&mdash;&nbsp;All persons with dementia are at risk of becoming lost [",
"    <a class=\"abstract\" href=\"UTD.htm?4/28/4552/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The risk may be higher for demented men than for women.",
"     </li>",
"     <li>",
"      Individuals residing in professional care settings are at risk as well as those at home.",
"     </li>",
"     <li>",
"      Wandering is only a risk factor; individuals who had never wandered have become lost.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Situations involving risk",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of becoming lost is increased when demented persons are unattended, even in their own residences [",
"    <a class=\"abstract\" href=\"UTD.htm?4/28/4552/abstract/21\">",
"     21",
"    </a>",
"    ]. However, about 65 percent of people with dementia are in the presence of a caregiver at the time they become lost. Becoming lost appears to be a highly unpredictable event and can occur even when individuals with dementia are in their own homes or are engaged in activities they had routinely performed many times in the past without incident.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Risk of death",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most individuals who are found alive remain out in the open in populated areas of the community [",
"    <a class=\"abstract\" href=\"UTD.htm?4/28/4552/abstract/21\">",
"     21",
"    </a>",
"    ]. The risk of death is increased if the demented person ends up secluded in natural or sparsely populated areas [",
"    <a class=\"abstract\" href=\"UTD.htm?4/28/4552/abstract/19\">",
"     19",
"    </a>",
"    ]. About 91 percent of persons with dementia who died were found in natural areas such as woods, fields, ditches, bodies of water (nearly 22 percent drowned), or abandoned vehicles. The risk of death also appears to be associated with the hottest and coldest times of the year.",
"   </p>",
"   <p>",
"    The time it took to search for and locate a missing person with dementia also correlated with the risk of death, as most individuals found alive were located within 24 hours, and all were found within four days.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Factors impeding the search",
"    </span>",
"    &nbsp;&mdash;&nbsp;Locating a person with dementia who becomes lost can be difficult, and this problem is compounded by several factors related to the increased likelihood of abnormal behavior [",
"    <a class=\"abstract\" href=\"UTD.htm?4/28/4552/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      People with dementia often behave in an unpredictable manner when lost.",
"     </li>",
"     <li>",
"      The accuracy of the search is usually not enhanced by predictions from families and caregivers.",
"     </li>",
"     <li>",
"      The lost persons rarely call for help or respond to searcher's calls.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Effective search strategies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Search strategies should not be based on the individual characteristics of the missing person, since the unpredictable and abnormal behavior is likely to negate any prior individual patterns [",
"    <a class=\"abstract\" href=\"UTD.htm?4/28/4552/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Caregivers should report the person missing immediately to local authorities (and to Safe Return if registered).",
"     </li>",
"     <li>",
"      An intensive search should begin immediately, so that the individual has less time to find a secluded hiding place and has reduced exposure to the elements.",
"     </li>",
"     <li>",
"      Searches should continue through the night, as individuals often continue to wander.",
"     </li>",
"     <li>",
"      The initial 6 to 12 hours of the search should cover a five mile radius around the location where the lost person was last seen, concentrating on open, populated areas, including the inside of easily accessible buildings.",
"     </li>",
"     <li>",
"      If initial search efforts fail, the subsequent efforts should be devoted to an intensive foot search of natural and sparsely populated areas beginning within a one mile radius of the last known location and extending from there.",
"     </li>",
"     <li>",
"      If the person with dementia traveled by automobile, initial search efforts should focus on locating the vehicle.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Prevention",
"    </span>",
"    &nbsp;&mdash;&nbsp;Caregivers, both formal and informal, must be informed that all persons with dementia are at risk of becoming lost, even if the individual has never wandered or exhibited \"risky\" behavior in the past [",
"    <a class=\"abstract\" href=\"UTD.htm?4/28/4552/abstract/21\">",
"     21",
"    </a>",
"    ]. Since the risk is highest when persons with dementia are left unattended, every effort should be made to ensure continuous supervision. Community resources, adult day care and respite care facilities, and caregiver support groups may be utilized, if available, to reduce the burden on families and caregivers.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Safe Return",
"    </span>",
"    &nbsp;&mdash;&nbsp;Registration with Safe Return or similar programs is critical, as persons with dementia often cannot remember their address, phone number, or possibly even their name. Identification information can facilitate return if a patient is lost. The Alzheimer's Association administers the nationwide \"Safe Return\" program with identification bracelet, necklace, or clothing tags and 24-hour assistance. More information is available online at",
"    <a class=\"external\" href=\"file://www.alz.org/Services/SafeReturn.asp\">",
"     www.alz.org/Services/SafeReturn.asp",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     FALLS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Falls are a major safety problem in some dementing illnesses, even early in the disease. The possibility of a parkinsonian syndrome should be considered if patients fall early in the course of illness; progressive supranuclear palsy, in particular, often presents with rigidity, poor postural reflexes, and frequent unprotected falls, in addition to the characteristic vertical gaze deficits.",
"   </p>",
"   <p>",
"    Falls eventually become a problem in all dementias. In one study of 1608 Swedish persons above the age of 75, the risk of hip fracture was twice as high when the score on the Mini-Mental State Examination was suggestive of cognitive impairment (score 18 to 23) compared with those who had no impairment [",
"    <a class=\"abstract\" href=\"UTD.htm?4/28/4552/abstract/22\">",
"     22",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/25/28057?source=see_link&amp;anchor=H8#H8\">",
"     \"Evaluation of cognitive impairment and dementia\", section on 'Mini-Mental State Examination'",
"    </a>",
"    .) Patients who fall require careful evaluation to determine the etiology, with special attention to the possibility of a myelopathy (from cervical spondylosis or vitamin B12 deficiency), a peripheral neuropathy, or visual impairment. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/4/22602?source=see_link\">",
"     \"Falls in older persons: Risk factors and patient evaluation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     AGGRESSIVE BEHAVIOR",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to the patient's safety, occasionally aggressive and even assaultive behavior can endanger a caregiver. The caregiver is often too embarrassed to mention this, if the practitioner does not specifically ask. In one case series, more than one-third of caregivers reported either psychological or physical abuse from the patient over the prior three months [",
"    <a class=\"abstract\" href=\"UTD.htm?4/28/4552/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Caregivers can also become so frustrated with the constant vigilance required for care of the demented patient that they may verbally or physically abuse the patient. In either case, health care practitioners are mandated reporters and should notify elderly protection services.",
"   </p>",
"   <p>",
"    The management of aggression in patients with dementia is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/48/27402?source=see_link\">",
"     \"Treatment of behavioral symptoms related to dementia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     LIVING ALONE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Living alone presents additional risks for people with cognitive impairment and dementia, as self neglect, disorientation, and poor judgment may go unrecognized and unreported until there is a major problem or crisis [",
"    <a class=\"abstract\" href=\"UTD.htm?4/28/4552/abstract/24\">",
"     24",
"    </a>",
"    ]. However, few data exist regarding this population. The lack of data is exacerbated by the symptoms of cognitive impairment, which may cause this population to become disconnected from family, friends, and the healthcare system [",
"    <a class=\"abstract\" href=\"UTD.htm?4/28/4552/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Identifying risk factors for harm in patients with dementia who live alone is an important goal. This problem was addressed by a prospective cohort study of 139 patients aged 65 or older with cognitive impairments who lived alone and were followed for 18 months [",
"    <a class=\"abstract\" href=\"UTD.htm?4/28/4552/abstract/25\">",
"     25",
"    </a>",
"    ]. Harm was defined as an episode of physical injury to self or others, or property loss or damage due to self neglect or disorientation, resulting in need for emergency services. Four variables were significantly predictive of harm:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Self perception of fewer social resources",
"     </li>",
"     <li>",
"      Poorer performance on the Mini Mental State Examination (MMSE)",
"     </li>",
"     <li>",
"      Presence of chronic obstructive pulmonary disease",
"     </li>",
"     <li>",
"      Presence of cerebrovascular disease",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Over the course of 18 months, 30 (22 percent) of the participants had an incident of harm; the most frequent was failure to eat and drink in nine cases. Only one incident of smoke damage and no incidents of wandering occurred, perhaps due to the small population size and relatively short period of follow-up. Further studies with larger sample sizes are needed to confirm the results of this investigation and to provide physicians with reliable predictors of harm for patients with cognitive impairments who live alone.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     VOTING",
"    </span>",
"    &nbsp;&mdash;&nbsp;The issue of voting by people with cognitive impairment or dementia presents multiple problems related to the integrity of the electoral process, individual autonomy, and voter rights [",
"    <a class=\"abstract\" href=\"UTD.htm?4/28/4552/abstract/26\">",
"     26",
"    </a>",
"    ]. This issue is likely to grow in magnitude, as both voting rates and dementia prevalence are highest in the elderly.",
"   </p>",
"   <p>",
"    While the few data that exist suggest that voting rates decline among people with advanced dementia, many continue to vote. As an example, in a study that surveyed 100 outpatients with dementia after the November 2000 US presidential election, 60 percent of respondents voted [",
"    <a class=\"abstract\" href=\"UTD.htm?4/28/4552/abstract/27\">",
"     27",
"    </a>",
"    ]. Increasing severity of dementia was associated with reduced knowledge about the election and reduced voting participation by patients and caregivers. Voting rates for those with mild, moderate, and severe dementia were 77 versus 37 versus 18 percent, respectively.",
"   </p>",
"   <p>",
"    In the United States, mental incapacity or incompetence is recognized as a valid reason for disenfranchisement of individuals with cognitive impairment or dementia at both the federal and state level [",
"    <a class=\"abstract\" href=\"UTD.htm?4/28/4552/abstract/26\">",
"     26",
"    </a>",
"    ]. However, there is currently no uniform regulation or standard used to define mental incapacity or incompetence in regard to voting.",
"   </p>",
"   <p>",
"    One proposed standard defines the capacity to vote as having the ability to understand the nature and effect of voting and the capacity to choose among the candidates and questions on the ballot. Uniform state laws incorporating this test of competence have been advocated as a constitutionally appropriate model [",
"    <a class=\"abstract\" href=\"UTD.htm?4/28/4552/abstract/26\">",
"     26",
"    </a>",
"    ]. Critics of a uniform standard have voiced concern over any approach that might rely on a test of competency. Some suggest an alternate approach, which would address the issue of voting competence during legal hearings that determine guardianship because of mental incapacity.",
"   </p>",
"   <p>",
"    Individuals may retain the capacity to vote in the early stages of dementia but may require assistance from caregivers [",
"    <a class=\"abstract\" href=\"UTD.htm?4/28/4552/abstract/26\">",
"     26",
"    </a>",
"    ]. The practical effect of the need for assistance is that caregivers may end up serving a screening role in deciding competence and providing access to voting. Similar to the situation with legal standards, there is no single reliable instrument available to physicians or caregivers to assess the capacity to vote.",
"   </p>",
"   <p>",
"    Current voting practice in the United States includes provisions such as secret balloting designed to reduce the risk of coercion. However, these provisions may be an impediment to caregiver assistance with voting. On the other hand, use of methods such as absentee ballots permits maximal assistance but raise concerns of voting fraud. As an example, some argue that it is not appropriate for family or other caregivers to vote by proxy on behalf of the person with dementia, even if they have legal authority to make decisions by proxy for other medical and legal matters [",
"    <a class=\"abstract\" href=\"UTD.htm?4/28/4552/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Further study is needed to develop standardized methods that can provide guidance in assessing the capacity to vote. Permissible forms of assistance that do not encourage abuse are also needed.",
"   </p>",
"   <p>",
"    More information about voting by people with dementia is available online at the University of Pennsylvania Alzheimer's Disease Center (",
"    <a class=\"external\" href=\"file://www.uphs.upenn.edu/adc/pdf/Fall2004.pdf\">",
"     file://www.uphs.upenn.edu/adc/pdf/Fall2004.pdf",
"    </a>",
"    ). Additional information is available online from the Bazelon Center for Mental Health Law (",
"    <a class=\"external\" href=\"file://www.bazelon.org/issues/voting/index.htm\">",
"     www.bazelon.org/issues/voting/index.htm",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1136087\">",
"    <span class=\"h1\">",
"     END OF LIFE ISSUES",
"    </span>",
"    &nbsp;&mdash;&nbsp;While palliative and hospice care can benefit patients with severe dementia at the end of their lives, it is probably under-used [",
"    <a class=\"abstract\" href=\"UTD.htm?4/28/4552/abstract/28-30\">",
"     28-30",
"    </a>",
"    ]. One barrier is that rates of decline and predictors of mortality are not well understood in patients with severe dementia [",
"    <a class=\"abstract\" href=\"UTD.htm?4/28/4552/abstract/31,32\">",
"     31,32",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/23/20855?source=see_link\">",
"     \"Palliative care: Issues specific to geriatric patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Medicare hospice eligibility requires an estimated survival of less than six months, which in the setting of dementia is defined by the following criteria [",
"    <a class=\"abstract\" href=\"UTD.htm?4/28/4552/abstract/33\">",
"     33",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Stage 7c on the Functional Assessment Staging scale (FAST) (in this stage, the patient is incontinent, dependent in all activities of daily living, nonambulatory, with speech limited to less than five words) [",
"      <a class=\"abstract\" href=\"UTD.htm?4/28/4552/abstract/34\">",
"       34",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The occurrence of one of the following six medical conditions in the prior year:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Aspiration pneumonia",
"     </li>",
"     <li>",
"      Pyelonephritis or other upper urinary tract infection",
"     </li>",
"     <li>",
"      Septicemia",
"     </li>",
"     <li>",
"      Multiple decubitus ulcers, stage 3 or higher",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/20/34120?source=see_link&amp;anchor=H4#H4\">",
"       \"Pressure ulcers: Epidemiology, pathogenesis, clinical manifestations, and staging\", section on 'Staging'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Recurrent fever after antibiotics",
"     </li>",
"     <li>",
"      Poor nutritional status defined as insufficient oral intake to sustain life (energy &lt;1000",
"      <span class=\"nowrap\">",
"       kCal/day,",
"      </span>",
"      fluids &lt;1",
"      <span class=\"nowrap\">",
"       L/day,",
"      </span>",
"      tube feeding with more than 10 percent weight loss, or serum albumin &lt;2.5",
"      <span class=\"nowrap\">",
"       g/dL)",
"      </span>",
"      during the past 180 days",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    When these criteria were applied to 606 patients with advanced dementia, the specificity was 0.89 and the sensitivity was 0.20 for predicting death within six months [",
"    <a class=\"abstract\" href=\"UTD.htm?4/28/4552/abstract/35\">",
"     35",
"    </a>",
"    ], suggesting that better tools are needed for more patients with dementia to benefit.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     SUPPORT FOR CAREGIVERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Caregivers of patients with dementia can suffer significant stress, particularly as cognitive function declines or behavioral symptoms worsen. Respite care and support groups may be of benefit [",
"    <a class=\"abstract\" href=\"UTD.htm?4/28/4552/abstract/36\">",
"     36",
"    </a>",
"    ] and are available in most areas, often through the local agency on aging. Nationally, information can be obtained from the Alzheimer's Association at 1-800-272-3900, or on the internet at",
"    <a class=\"external\" href=\"file://www.alz.org/\">",
"     www.alz.org",
"    </a>",
"    . Specific interventions are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/48/27402?source=see_link&amp;anchor=H25#H25\">",
"     \"Treatment of behavioral symptoms related to dementia\", section on 'Support for caregivers'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?31/14/31970?source=see_link\">",
"       \"Patient information: Dementia (including Alzheimer disease) (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?31/22/32098?source=see_link\">",
"       \"Patient information: Tips for caregivers of people with Alzheimer disease (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?14/37/14934?source=see_link\">",
"       \"Patient information: Dementia (including Alzheimer disease) (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Safety issues are important aspects of the care of patients with dementia. Addressing these issues proactively can prevent serious incidents.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Driving becomes progressively less safe as cognition deteriorates. An American Academy of Neurology practice parameter outlines recommendations for counseling patients and families regarding driving safety based upon the Clinical Dementia Rating. Patients with a CDR &ge;2 are considered unsafe to drive. Patients with a CDR = 0.5 or 1 should undergo further risk assessment, based upon identified risk factors",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      an on-road driving evaluation. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Driving'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Impaired financial capacity can be the presenting clinical deficit in a patient with early dementia and can have serious adverse consequences. This impairment should be addressed with patients and families early on after diagnosis. (See",
"      <a class=\"local\" href=\"#H18644325\">",
"       'Financial capacity'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Some patients with dementia wander and may become lost, with an attendant risk of personal harm and even death. This can occur when a patient lives at home and when residing in a professional care center. Supervision, identification tags, and registration with Safe Return or similar programs may ameliorate risk. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Wandering and becoming lost'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Falls eventually become a problem in all dementias, but can be a problem early on in the dementias that are associated with parkinsonism (eg, dementia with Lewy bodies, Parkinson disease dementia). Patients and families should be asked about falling, which may be an indication for providing increased supervision. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Falls'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Aggressive behavior may present a risk to the caregiver as well as to the patient. Caregivers may be embarrassed to volunteer this problem; and this history should be solicited. The treatment of aggressive behavior is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/48/27402?source=see_link\">",
"       \"Treatment of behavioral symptoms related to dementia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Living alone presents risks for people with cognitive impairment and dementia, as self neglect, disorientation, and poor judgment present potential for harm and injury. Family members are useful allies in assessing when this situation becomes unsafe. In the absence of family or other caregivers, home safety evaluations through a professional nursing service may be helpful. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Living alone'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Palliative and hospice care can benefit patients with severe dementia at the end of their lives. However, the absence of reliable predictors for clinical decline and mortality limit patients&rsquo; access to this service (See",
"      <a class=\"local\" href=\"#H1136087\">",
"       'End of life issues'",
"      </a>",
"      above.).",
"     </li>",
"     <li>",
"      Caregivers of patients with dementia can suffer significant stress, particularly as cognitive function declines or behavioral symptoms worsen. Respite care and support groups are available in most areas, often through the local agency on aging. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/48/27402?source=see_link&amp;anchor=H25#H25\">",
"       \"Treatment of behavioral symptoms related to dementia\", section on 'Support for caregivers'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/28/4552/abstract/1\">",
"      Drachman DA, Swearer JM. Driving and Alzheimer's disease: the risk of crashes. Neurology 1993; 43:2448.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/28/4552/abstract/2\">",
"      Man-Son-Hing M, Marshall SC, Molnar FJ, Wilson KG. Systematic review of driving risk and the efficacy of compensatory strategies in persons with dementia. J Am Geriatr Soc 2007; 55:878.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/28/4552/abstract/3\">",
"      Ott BR, Heindel WC, Papandonatos GD, et al. A longitudinal study of drivers with Alzheimer disease. Neurology 2008; 70:1171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/28/4552/abstract/4\">",
"      Dawson JD, Anderson SW, Uc EY, et al. Predictors of driving safety in early Alzheimer disease. Neurology 2009; 72:521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/28/4552/abstract/5\">",
"      Ball KK, Roenker DL, Wadley VG, et al. Can high-risk older drivers be identified through performance-based measures in a Department of Motor Vehicles setting? J Am Geriatr Soc 2006; 54:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/28/4552/abstract/6\">",
"      Iverson DJ, Gronseth GS, Reger MA, et al. Practice parameter update: evaluation and management of driving risk in dementia: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2010; 74:1316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/28/4552/abstract/7\">",
"      Rapoport MJ, Herrmann N, Molnar FJ, et al. Sharing the responsibility for assessing the risk of the driver with dementia. CMAJ 2007; 177:599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/28/4552/abstract/8\">",
"      Hunt LA, Murphy CF, Carr D, et al. Reliability of the Washington University Road Test. A performance-based assessment for drivers with dementia of the Alzheimer type. Arch Neurol 1997; 54:707.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/28/4552/abstract/9\">",
"      Fitten LJ, Perryman KM, Wilkinson CJ, et al. Alzheimer and vascular dementias and driving. A prospective road and laboratory study. JAMA 1995; 273:1360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/28/4552/abstract/10\">",
"      Cushman LA, Stein K, Duffy CJ. Detecting navigational deficits in cognitive aging and Alzheimer disease using virtual reality. Neurology 2008; 71:888.",
"     </a>",
"    </li>",
"    <li>",
"     Marson DC, Hebert T. Financial Capacity. In: Encyclopedia of Psychiatry and the Law, Cutler BL (Ed), Sage, Thousand Oaks, CA 2008. Vol 1, p.313.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/28/4552/abstract/12\">",
"      Martin R, Griffith HR, Belue K, et al. Declining financial capacity in patients with mild Alzheimer disease: a one-year longitudinal study. Am J Geriatr Psychiatry 2008; 16:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/28/4552/abstract/13\">",
"      Triebel KL, Martin R, Griffith HR, et al. Declining financial capacity in mild cognitive impairment: A 1-year longitudinal study. Neurology 2009; 73:928.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/28/4552/abstract/14\">",
"      Griffith HR, Belue K, Sicola A, et al. Impaired financial abilities in mild cognitive impairment: a direct assessment approach. Neurology 2003; 60:449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/28/4552/abstract/15\">",
"      Okonkwo OC, Wadley VG, Griffith HR, et al. Cognitive correlates of financial abilities in mild cognitive impairment. J Am Geriatr Soc 2006; 54:1745.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/28/4552/abstract/16\">",
"      Widera E, Steenpass V, Marson D, Sudore R. Finances in the older patient with cognitive impairment: \"He didn't want me to take over\". JAMA 2011; 305:698.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/28/4552/abstract/17\">",
"      Rowe MA, Glover JC. Antecedents, descriptions and consequences of wandering in cognitively-impaired adults and the Safe Return (SR) program. Am J Alzheimers Dis Other Demen 2001; 16:344.",
"     </a>",
"    </li>",
"    <li>",
"     Koester RJ. The lost Alzheimer's and related disorders search subject: new research and perspectives. In: Response 98 NASAR Proceedings, Chantilly, Virginia, National Association of Search and Rescue, 1998. p.161.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/28/4552/abstract/19\">",
"      Rowe MA, Bennett V. A look at deaths occurring in persons with dementia lost in the community. Am J Alzheimers Dis Other Demen 2003; 18:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/28/4552/abstract/20\">",
"      Rowe MA. People with dementia who become lost. Am J Nurs 2003; 103:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/28/4552/abstract/21\">",
"      Rowe MA, Feinglass NG, Wiss ME. Persons with dementia who become lost in the community: a case study, current research, and recommendations. Mayo Clin Proc 2004; 79:1417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/28/4552/abstract/22\">",
"      Guo Z, Wills P, Viitanen M, et al. Cognitive impairment, drug use, and the risk of hip fracture in persons over 75 years old: a community-based prospective study. Am J Epidemiol 1998; 148:887.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/28/4552/abstract/23\">",
"      Cooper C, Selwood A, Blanchard M, Livingston G. Abusive behaviour experienced by family carers from people with dementia: the CARD (caring for relatives with dementia) study. J Neurol Neurosurg Psychiatry 2010; 81:592.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/28/4552/abstract/24\">",
"      Soniat BA. Dementia patients who live alone: research and clinical challenges. J Am Geriatr Soc 2004; 52:1576.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/28/4552/abstract/25\">",
"      Tierney MC, Charles J, Naglie G, et al. Risk factors for harm in cognitively impaired seniors who live alone: a prospective study. J Am Geriatr Soc 2004; 52:1435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/28/4552/abstract/26\">",
"      Karlawish JH, Bonnie RJ, Appelbaum PS, et al. Addressing the ethical, legal, and social issues raised by voting by persons with dementia. JAMA 2004; 292:1345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/28/4552/abstract/27\">",
"      Ott BR, Heindel WC, Papandonatos GD. A survey of voter participation by cognitively impaired elderly patients. Neurology 2003; 60:1546.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/28/4552/abstract/28\">",
"      Kiely DK, Givens JL, Shaffer ML, et al. Hospice use and outcomes in nursing home residents with advanced dementia. J Am Geriatr Soc 2010; 58:2284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/28/4552/abstract/29\">",
"      Shega JW, Hougham GW, Stocking CB, et al. Patients dying with dementia: experience at the end of life and impact of hospice care. J Pain Symptom Manage 2008; 35:499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/28/4552/abstract/30\">",
"      Torke AM, Holtz LR, Hui S, et al. Palliative care for patients with dementia: a national survey. J Am Geriatr Soc 2010; 58:2114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/28/4552/abstract/31\">",
"      Sachs GA, Shega JW, Cox-Hayley D. Barriers to excellent end-of-life care for patients with dementia. J Gen Intern Med 2004; 19:1057.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/28/4552/abstract/32\">",
"      Mitchell SL, Black BS, Ersek M, et al. Advanced dementia: state of the art and priorities for the next decade. Ann Intern Med 2012; 156:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/28/4552/abstract/33\">",
"      Medical guidelines for determining prognosis in selected non-cancer diseases. The National Hospice Organization. Hosp J 1996; 11:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/28/4552/abstract/34\">",
"      Sclan SG, Reisberg B. Functional assessment staging (FAST) in Alzheimer's disease: reliability, validity, and ordinality. Int Psychogeriatr 1992; 4 Suppl 1:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/28/4552/abstract/35\">",
"      Mitchell SL, Miller SC, Teno JM, et al. Prediction of 6-month survival of nursing home residents with advanced dementia using ADEPT vs hospice eligibility guidelines. JAMA 2010; 304:1929.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/28/4552/abstract/36\">",
"      Nichols LO, Martindale-Adams J, Burns R, et al. Translation of a dementia caregiver support program in a health care system--REACH VA. Arch Intern Med 2011; 171:353.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5080 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-122.72.80.101-C14A8A0C62-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_28_4552=[""].join("\n");
var outline_f4_28_4552=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H18\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18644508\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DRIVING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18644325\">",
"      FINANCIAL CAPACITY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      COOKING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      WANDERING AND BECOMING LOST",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Who is at risk",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Situations involving risk",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Risk of death",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Factors impeding the search",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Effective search strategies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Prevention",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Safe Return",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      FALLS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      AGGRESSIVE BEHAVIOR",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      LIVING ALONE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      VOTING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1136087\">",
"      END OF LIFE ISSUES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      SUPPORT FOR CAREGIVERS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEURO/5080\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/5080|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?0/0/2\" title=\"table 1\">",
"      Clinical dementia rating",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/19/3385?source=related_link\">",
"      Approach to the evaluation of older drivers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/25/28057?source=related_link\">",
"      Evaluation of cognitive impairment and dementia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/4/22602?source=related_link\">",
"      Falls in older persons: Risk factors and patient evaluation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/23/20855?source=related_link\">",
"      Palliative care: Issues specific to geriatric patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?14/37/14934?source=related_link\">",
"      Patient information: Dementia (including Alzheimer disease) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?31/14/31970?source=related_link\">",
"      Patient information: Dementia (including Alzheimer disease) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?31/22/32098?source=related_link\">",
"      Patient information: Tips for caregivers of people with Alzheimer disease (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/20/34120?source=related_link\">",
"      Pressure ulcers: Epidemiology, pathogenesis, clinical manifestations, and staging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/48/27402?source=related_link\">",
"      Treatment of behavioral symptoms related to dementia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/4/33865?source=related_link\">",
"      Treatment of dementia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_28_4553="Renal and patient outcomes after acute tubular necrosis";
var content_f4_28_4553=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Renal and patient outcomes after acute tubular necrosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/28/4553/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/28/4553/contributors\">",
"     Orfeas Liangos, MD, FASN",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/28/4553/contributors\">",
"     Bertrand L Jaber, MD, MS, FASN",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/28/4553/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/28/4553/contributors\">",
"     Paul M Palevsky, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/28/4553/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/28/4553/contributors\">",
"     Alice M Sheridan, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?4/28/4553/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 6, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients with acute tubular necrosis (ATN) spontaneously recover renal function. Recovery is usually heralded by an increase in urine output and a gradual return of the BUN and serum creatinine concentration to or very near the previous baseline level [",
"    <a class=\"abstract\" href=\"UTD.htm?4/28/4553/abstract/1-3\">",
"     1-3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Renal and patient outcomes following an episode of ATN will be reviewed here. The diagnosis, pathogenesis and possible treatment of this disorder and issues related to the definition of acute renal failure are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/60/35785?source=see_link\">",
"     \"Diagnostic approach to the patient with acute kidney injury (acute renal failure) or chronic kidney disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/54/12138?source=see_link\">",
"     \"Etiology and diagnosis of prerenal disease and acute tubular necrosis in acute kidney injury (acute renal failure)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/4/4170?source=see_link\">",
"     \"Pathogenesis and etiology of postischemic (ischemic) acute tubular necrosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/10/42154?source=see_link\">",
"     \"Possible prevention and therapy of postischemic (ischemic) acute tubular necrosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/49/42773?source=see_link\">",
"     \"Definition of acute kidney injury (acute renal failure)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence and prevalence of ATN is not well known, which is due in part to differences in definition and characteristics of assessed patients. The reported incidence ranges from approximately 150 to 600 per million population [",
"    <a class=\"abstract\" href=\"UTD.htm?4/28/4553/abstract/4-8\">",
"     4-8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The incidence of AKI, which is inclusive of ATN, appears to be increasing, at least in the United States. One study, for example, evaluated the incidence of acute kidney injury (AKI) using the 1988 to 2002 Nationwide Inpatient Sample, a United States based administrative database containing a representative sample of discharges from acute care, nonfederal hospitals [",
"    <a class=\"abstract\" href=\"UTD.htm?4/28/4553/abstract/8\">",
"     8",
"    </a>",
"    ]. The incidence of AKI rose from 61 per 100,000 population in 1988 to 288 per 100,000 population in 2002. For AKI requiring dialysis, the percentage of annual discharges increased from 0.03 percent in 1988 to 0.20 percent in 2002, translating to an increase in the incidence rate from 4 per 100,000 population in 1988 to 27 per 100,000 population in 2002. A more recent study, also using data from the Nationwide Inpatient Sample, reported an increase in the incidence rate of dialysis-requiring AKI, likely representing episodes of ATN, from 222 to 533 cases per million person-years, averaging a 10 percent increase per year [",
"    <a class=\"abstract\" href=\"UTD.htm?4/28/4553/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In an attempt to better assess the population-based incidence of ATN using laboratory data, several studies identified all patients with changes in serum creatinine concentrations in particular databases:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One report identified all patients with increased serum creatinine concentrations (150 and 130",
"      <span class=\"nowrap\">",
"       micromol/L",
"      </span>",
"      [1.7 and 1.5",
"      <span class=\"nowrap\">",
"       mg/dL]",
"      </span>",
"      for men and women, respectively) in a six month period in 2003 among a geographic population of 523,390 individuals [",
"      <a class=\"abstract\" href=\"UTD.htm?4/28/4553/abstract/10\">",
"       10",
"      </a>",
"      ]. The incidence of acute renal failure and acute chronic renal failure was 1811 and 336 per million population, respectively. Unlike other studies, this report included all patients from a defined geographic area, independent of the need for dialysis and independent of location of treatment. Inclusion of patients with milder forms of ATN or prerenal dysfunction and participation of all patient care facilities in one region may have resulted in the relatively higher annual incidence.",
"     </li>",
"     <li>",
"      A second study identified all patients with significant increases in serum creatinine values (defined in part by baseline renal function) who were enrolled in a large integrated healthcare system in the United States [",
"      <a class=\"abstract\" href=\"UTD.htm?4/28/4553/abstract/11\">",
"       11",
"      </a>",
"      ]. Between the years 1996 to 2003, there was an increased incidence of acute renal failure not requiring dialysis from 323 to 522 per 100,000 person-years and of acute renal failure requiring dialysis from 20 to 30 per 100,000 person-years [",
"      <a class=\"abstract\" href=\"UTD.htm?4/28/4553/abstract/11\">",
"       11",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The epidemiology of and risk factors for acute renal failure occurring after coronary artery bypass graft surgery are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/25/35226?source=see_link&amp;anchor=H22#H22\">",
"     \"Early noncardiac complications of coronary artery bypass graft surgery\", section on 'Acute kidney injury'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     RENAL OUTCOMES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Duration of ATN",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with ATN have a renal failure phase that typically lasts between 7 and 21 days [",
"    <a class=\"abstract\" href=\"UTD.htm?4/28/4553/abstract/1\">",
"     1",
"    </a>",
"    ]. However, the duration of ATN is variable, being dependent upon the length and severity of the initial ischemic episode, whether or not recurrent ischemia occurs or nephrotoxic therapy is continued, and perhaps whether the patient is oliguric or nonoliguric [",
"    <a class=\"abstract\" href=\"UTD.htm?4/28/4553/abstract/1\">",
"     1",
"    </a>",
"    ]. Some patients recover within days, while others require dialysis for many months. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/28/2501?source=see_link\">",
"     \"Nonoliguric versus oliguric acute tubular necrosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Rapid recovery",
"    </span>",
"    &nbsp;&mdash;&nbsp;A short duration of clinical ATN has been described in patients undergoing suprarenal aortic clamping for aortic aneurysm surgery, resulting in 20 to 80 minutes of total renal ischemia. Although clinical evidence of ATN is often present postoperatively (low glomerular filtration rate (GFR), elevated fractional excretion of sodium), renal function usually returns to baseline within one to three days since the duration of ischemia is short-lived (",
"    <a class=\"graphic graphic_figure graphicRef67443 \" href=\"UTD.htm?42/27/43453\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?4/28/4553/abstract/1,12\">",
"     1,12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although its pathophysiology differs from that of ischemic ATN, the limited duration of the insult may also explain in part the typical three to five day course of radiocontrast media-induced acute renal failure. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/13/10457?source=see_link\">",
"     \"Pathogenesis, clinical features, and diagnosis of contrast-induced nephropathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Two mechanisms have been proposed for the short duration of renal dysfunction: mild ATN or postischemic tubular dysfunction in which the tubular cells remain morphologically normal. This phenomenon, which is similar to postischemic dysfunction in the \"stunned\" myocardium, may be at least in part due to redistribution of membrane transport proteins.",
"   </p>",
"   <p>",
"    Tubular sodium reabsorption occurs via entry into the cells across the luminal membrane and then active transport out of the cells by the Na-K-ATPase pump in the basolateral membrane. Following renal ischemia in animal models, the actin cytoskeleton that anchors the Na-K-ATPase pump to the basolateral membrane becomes disrupted, resulting in partial redistribution of the pumps onto the luminal membrane, thereby interfering with normal ion transport by pumping sodium back into the tubular lumen [",
"    <a class=\"abstract\" href=\"UTD.htm?4/28/4553/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. Recovery of function is associated with recovery of normal polarity in which the Na-K-ATPase pumps are again limited to the basolateral membrane [",
"    <a class=\"abstract\" href=\"UTD.htm?4/28/4553/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Prolonged ATN",
"    </span>",
"    &nbsp;&mdash;&nbsp;Functional recovery may be markedly delayed in patients with persistent septic physiology and circulatory shock, or who have repeated episodes of renal ischemia",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    nephrotoxin administration [",
"    <a class=\"abstract\" href=\"UTD.htm?4/28/4553/abstract/1,15\">",
"     1,15",
"    </a>",
"    ]. In these settings, tubular cell apoptosis",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    necrosis have occurred and the regeneration of tubular cells that is required for the restoration of renal function may be delayed or completely abolished.",
"   </p>",
"   <p>",
"    Hemodynamic autoregulation in kidneys with ATN is altered, creating an environment that is particularly sensitive to diminished perfusion. Normal kidneys vasodilate in the presence of ischemia as part of the normal autoregulatory response to maintain renal blood flow near the baseline level. This response is impaired in ATN, perhaps because vascular endothelial injury reduces the release of vasodilating substances such as prostacyclin and nitric oxide (endothelium-derived relaxing factor) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/28/4553/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As a result, recurrent episodes of hypotension, as with sepsis or hemodialysis, are more likely to lead to renewed tubular injury. Hemodialysis may also delay recovery of renal function by a second mechanism: neutrophil activation induced by the interaction of blood with a bioincompatible hemodialysis membrane. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/37/4696?source=see_link&amp;anchor=H4#H4\">",
"     \"Renal replacement therapy (dialysis) in acute kidney injury (acute renal failure): Recovery of renal function and effect of hemodialysis membrane\", section on 'Can dialysis delay recovery of renal function?'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/51/21306?source=see_link\">",
"     \"Evaluation and management of severe sepsis and septic shock in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Nevertheless, even patients with prolonged disease who require dialysis for eight weeks or more will, if they survive and leave the hospital, usually recover sufficient function to allow dialysis to be discontinued [",
"    <a class=\"abstract\" href=\"UTD.htm?4/28/4553/abstract/15,17,18\">",
"     15,17,18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Degree of recovery",
"    </span>",
"    &nbsp;&mdash;&nbsp;The previously established perception that patients, particularly those with previous normal function, who recover from acute kidney injury (AKI), return to or near their baseline kidney function, has been increasingly called into question. Multiple studies have demonstrated an increase in the risk of chronic kidney disease (CKD) and end stage renal disease (ESRD) among patients who recover from AKI [",
"    <a class=\"abstract\" href=\"UTD.htm?4/28/4553/abstract/19-21\">",
"     19-21",
"    </a>",
"    ]. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An analysis of matched data obtained from US Medicare beneficiary claims and the US Renal Data System (USRDS) revealed that patients aged 67 years or older, who developed AKI were 6.7 times more likely to develop end stage renal disease by two years after discharge compared with those without renal injury [",
"      <a class=\"abstract\" href=\"UTD.htm?4/28/4553/abstract/21\">",
"       21",
"      </a>",
"      ]. Patients with a history of CKD who developed AKI had a 41-fold increase in the risk of ESRD.",
"     </li>",
"     <li>",
"      In a case control study of 343 patients with dialysis-requiring AKI who were compared with a matched control group of 3430 patients, and based on 562,779 members of a US health maintenance organization, dialysis-requiring AKI was independently associated with a 28-fold increase in the risk of developing stage 4 or 5 CKD and a greater than twofold increased risk of death, over an eight-year follow-up period (",
"      <a class=\"graphic graphic_figure graphicRef65211 \" href=\"UTD.htm?21/55/22397\">",
"       figure 2",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?4/28/4553/abstract/19\">",
"       19",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A population-based matched cohort study of 3769 patients with dialysis-requiring AKI who survived dialysis-free for at least 30 days after discharge showed a higher incidence of chronic dialysis (adjusted hazard ratio of 3.2 compared with matched control patients) [",
"      <a class=\"abstract\" href=\"UTD.htm?4/28/4553/abstract/20\">",
"       20",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A meta-analysis that included 13 cohort studies demonstrated a higher risk of developing CKD and ESRD among patients who developed AKI compared with patients who did not (pooled adjusted hazard ratios of 8.8 and 3.1) [",
"      <a class=\"abstract\" href=\"UTD.htm?4/28/4553/abstract/22\">",
"       22",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Acute kidney injury appears to be associated with a higher risk of CKD even among relatively low-risk patients. This was suggested by a cohort study of 1610 patients who developed in-hospital AKI [",
"    <a class=\"abstract\" href=\"UTD.htm?4/28/4553/abstract/23\">",
"     23",
"    </a>",
"    ]. Patients selected for the analysis had normal renal function prior to AKI and recovered to within 90 percent of pre-AKI estimated GFR within 90 days; 81 percent of patients recovered baseline renal function within four days. Patients who developed AKI were more likely to develop CKD by 3.3 years compared with matched control patients who did not develop AKI (hazard ratio 1.9). The same result was observed in a larger cohort study of 3809 patients with normal baseline renal function, in which AKI was associated with a higher risk of CKD at 2.5 years (hazard ratio (HR) by propensity score-stratified analysis, 3.82, 95% CI 2.81&ndash;5.19) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/28/4553/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, in a population-based cohort study, patients who developed reversible AKI, ie, who recovered to within 25 percent of baseline renal function, had better clinical outcomes compared to patients with irreversible AKI [",
"    <a class=\"abstract\" href=\"UTD.htm?4/28/4553/abstract/25\">",
"     25",
"    </a>",
"    ]. The latter group had an increased risk of death (adjusted HR 1.26, 95% CI 1.10&ndash;1.43) and of a composite renal outcome that included doubling of serum creatinine and ESRD (adjusted HR 4.13, 95% CI 3.38&ndash;5.04) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/28/4553/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An irreversible decline in renal function after recovery is more likely in patients over age 65, lower baseline GFR, hypoalbuminemia, and comorbidities including hypertension and heart failure [",
"    <a class=\"abstract\" href=\"UTD.htm?4/28/4553/abstract/23,26\">",
"     23,26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Preexisting chronic kidney disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;In studies of acute kidney injury (AKI) in hospitalized patients, the prevalence of preexisting CKD has been 30 to 35 percent in most studies [",
"    <a class=\"abstract\" href=\"UTD.htm?4/28/4553/abstract/27-32\">",
"     27-32",
"    </a>",
"    ] but as high as 75 percent in one large series [",
"    <a class=\"abstract\" href=\"UTD.htm?4/28/4553/abstract/33\">",
"     33",
"    </a>",
"    ]. Not surprisingly, these patients have a higher rate of requiring dialysis when they develop AKI [",
"    <a class=\"abstract\" href=\"UTD.htm?4/28/4553/abstract/27,29,33\">",
"     27,29,33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    When patients with CKD develop dialysis-requiring AKI, available data in critically ill patients suggest that renal recovery is less likely than in patients without CKD. This is illustrated by the following observations [",
"    <a class=\"abstract\" href=\"UTD.htm?4/28/4553/abstract/21,32,34\">",
"     21,32,34",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among 48 patients initiating dialysis for AKI, survivors with preexisting CKD were more likely to be dialysis-dependent at 90 days (50 versus 11 percent of those without preexisting CKD [3 versus 1 patients]) [",
"      <a class=\"abstract\" href=\"UTD.htm?4/28/4553/abstract/34\">",
"       34",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Similar findings were noted in a review of 299 intensive care unit patients with dialysis-requiring acute AKI, 102 of whom had underlying CKD [",
"      <a class=\"abstract\" href=\"UTD.htm?4/28/4553/abstract/32\">",
"       32",
"      </a>",
"      ]. Among survivors, the rate of being dialysis-dependent at discharge was higher in those with underlying CKD (34 versus 5 percent [20 versus 5 patients]) [",
"      <a class=\"abstract\" href=\"UTD.htm?4/28/4553/abstract/32\">",
"       32",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The baseline serum creatinine concentration was not given in these studies.",
"   </p>",
"   <p>",
"    Patients with CKD who develop AKI are also more likely to progress to end-stage renal disease compared to CKD patients who never have an episode of AKI. In a retrospective study of nearly 40,000 patients, acute or chronic renal failure was associated with a 30 percent increase in the long term risk for death or end-stage renal disease (HR 1.3, 95% CI 1.04-1.64) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/28/4553/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Dialysis modality",
"    </span>",
"    &nbsp;&mdash;&nbsp;The type of renal replacement therapy may impact the incidence of recovery of renal function in patients with ATN. This is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/58/25513?source=see_link\">",
"     \"Renal replacement therapy (dialysis) in acute kidney injury (acute renal failure) in adults: Indications, timing, and dialysis dose\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     PATIENT SURVIVAL",
"    </span>",
"    &nbsp;&mdash;&nbsp;The above findings apply to those patients who are able to leave the hospital after their acute illness. ATN during a hospitalization is associated with high in-hospital and long-term mortality.",
"   </p>",
"   <p>",
"    Among patients in the intensive care unit who develop ATN requiring dialysis, reported mortality rates range from 40 to over 60 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?4/28/4553/abstract/18,28,35-41\">",
"     18,28,35-41",
"    </a>",
"    ]. In-hospital mortality rates are lower among patients with ATN in the general hospital population or who have less severe ATN (15 to 30 percent versus 1 to &lt;10 percent among patients without ATN) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/28/4553/abstract/7,8,42-45\">",
"     7,8,42-45",
"    </a>",
"    ]. A modest degree of renal insufficiency due to ATN may also increase in-hospital mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?4/28/4553/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Post-hospitalization mortality is also increased [",
"    <a class=\"abstract\" href=\"UTD.htm?4/28/4553/abstract/22,23,43,45,47,48\">",
"     22,23,43,45,47,48",
"    </a>",
"    ]. The following observations illustrate the range of findings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a study of over five million hospital discharges, death within 90 days after hospital discharge was 35 and 13 percent among patients with and without AKI [",
"      <a class=\"abstract\" href=\"UTD.htm?4/28/4553/abstract/45\">",
"       45",
"      </a>",
"      ]. The major causes of in-hospital mortality in patients with ATN are infection and the underlying disease (such as hypotension following open heart surgery), not necessarily renal failure itself. Patients at risk are generally very ill with evidence of multiple organ dysfunction.",
"     </li>",
"     <li>",
"      Longer term mortality may also be increased as demonstrated in a study of 843 patients who underwent cardiac surgery [",
"      <a class=\"abstract\" href=\"UTD.htm?4/28/4553/abstract/43\">",
"       43",
"      </a>",
"      ]. Eight years after hospital discharge, mortality was significantly higher in patients with postoperative acute renal failure (defined as at least a 25 percent elevation in serum creatinine in the first postoperative week) compared with those who did not have a deterioration in kidney function (36 versus 22 percent, adjusted hazard ratio of 1.63, 95% CI 1.15-2.32). The increase in risk was independent of whether or not renal function had recovered at the time of hospital discharge. However, the increase in late mortality did not begin until more than four to five years after surgery, raising a question about the relationship to postoperative acute tubular necrosis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/25/35226?source=see_link&amp;anchor=H22#H22\">",
"       \"Early noncardiac complications of coronary artery bypass graft surgery\", section on 'Acute kidney injury'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In a systematic review of 47,017 patients that examined the long-term morbidity and mortality risk among survivors of AKI, the incidence rate of mortality was 8.9 deaths per 100 person-years in survivors of AKI and 4.3 deaths per 100 patient-years in survivors without AKI (rate ratio of 2.59, 95% CI 1.97-3.42) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/28/4553/abstract/49\">",
"     49",
"    </a>",
"    ]. AKI was also associated with development of myocardial infarction. The incidence rate of CKD after an episode of AKI was 7.8 events per 100 patient-years, and the rate of end-stage renal disease was 4.9 events per 100 patient-years. Unfortunately, the relative risk of development of CKD after episodes of AKI was not determined because of lack of follow-up of control subjects who did not have AKI. The majority of patients who sustain an episode of AKI are not followed by nephrologists after discharge from the hospital [",
"    <a class=\"abstract\" href=\"UTD.htm?4/28/4553/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Factors influencing mortality",
"    </span>",
"    &nbsp;&mdash;&nbsp;An understanding of the clinical characteristics that appear to most strongly affect mortality among patients with ATN may help direct supportive care to those most likely to benefit. A variety of factors have been associated with increased mortality, including male gender, race, older age, oliguria, cardiovascular and cerebrovascular events, overall severity of illness and quality of life after recovery from AKI [",
"    <a class=\"abstract\" href=\"UTD.htm?4/28/4553/abstract/51-58\">",
"     51-58",
"    </a>",
"    ]. A multicenter, prospective cohort study evaluating the natural history and predictors of mortality in 618 critically ill patients with ATN, 64 percent of whom required dialysis [",
"    <a class=\"abstract\" href=\"UTD.htm?4/28/4553/abstract/57\">",
"     57",
"    </a>",
"    ]. Multivariable logistic regression analysis revealed that the following characteristics were predictive of mortality at 60 days:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Age (odds ratio [OR] 1.13 per decade)",
"     </li>",
"     <li>",
"      Sepsis (OR 1.50)",
"     </li>",
"     <li>",
"      Adult respiratory distress syndrome (OR 1.79)",
"     </li>",
"     <li>",
"      Liver failure (OR 1.62)",
"     </li>",
"     <li>",
"      Thrombocytopenia (OR 1.66)",
"     </li>",
"     <li>",
"      Blood urea nitrogen (OR 1.09 per 10",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      [3.6",
"      <span class=\"nowrap\">",
"       mmol/L])",
"      </span>",
"     </li>",
"     <li>",
"      Creatinine &lt;2.0",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (177",
"      <span class=\"nowrap\">",
"       micromol/L)",
"      </span>",
"      (OR 1.99)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The underlying importance of the overall severity of illness in determining survival among patients with AKI was supported by the findings of a multicenter prospective controlled trial of 153 patients with AKI requiring dialysis [",
"    <a class=\"abstract\" href=\"UTD.htm?4/28/4553/abstract/59\">",
"     59",
"    </a>",
"    ]. Illness severity within 24 hours of the initiation of dialysis as determined by the APACHE II scoring system predicted survival and recovery of renal function. Other observational studies also showed an association of the APACHE II and other severity of illness scores with hospital mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?4/28/4553/abstract/30,60\">",
"     30,60",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/56/27527?source=see_link\">",
"     \"Predictive scoring systems in the intensive care unit\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Acute pancreatitis represents a good example of the relation between multiple organ dysfunction and patient survival in ATN. A report of 267 patients with acute pancreatitis noted a 16 percent incidence of ATN [",
"    <a class=\"abstract\" href=\"UTD.htm?4/28/4553/abstract/61\">",
"     61",
"    </a>",
"    ]. Renal failure tended to occur relatively late in the course, usually in the setting of multiple organ failure. The mortality rate in these patients was 81 percent. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/5/20569?source=see_link\">",
"     \"Clinical manifestations and diagnosis of acute pancreatitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In contrast, the prognosis is usually excellent in patients who are otherwise healthy, as with ATN following a transfusion reaction, the administration of a nephrotoxic drug, or ischemia in which perfusion has been restored. This was illustrated by the results among patients enrolled in the placebo-arm of a multicenter randomized trial, the mortality rate was 10 versus 30 percent among patients with nephrotoxic versus ischemic ATN [",
"    <a class=\"abstract\" href=\"UTD.htm?4/28/4553/abstract/62\">",
"     62",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Preexisting poor nutritional status may enhance mortality in those with ATN. In a prospective study of 309 patients with AKI, a significantly higher proportion of patients with severe malnutrition died compared with those with a normal nutritional status (62 versus 13 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/28/4553/abstract/63\">",
"     63",
"    </a>",
"    ]. Similar findings were noted in a second series in which both hypoalbuminemia and hypocholesterolemia, each assumed to reflect poor nutritional status, were associated with a significantly increased risk of death among patients with AKI [",
"    <a class=\"abstract\" href=\"UTD.htm?4/28/4553/abstract/64\">",
"     64",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Race may also influence the effect of ATN on in-hospital mortality. One study of approximately 400,000 patients with AKI found a significantly lower in-house mortality among black patients compared to white patients [",
"    <a class=\"abstract\" href=\"UTD.htm?4/28/4553/abstract/52\">",
"     52",
"    </a>",
"    ]. This was observed for almost all diagnoses or procedures. As an example, a significantly lower mortality rate was noted among black patients with AKI post-coronary artery bypass surgery (an odds ratio of 0.73, 95% CI 0.62-0.87). The reasons underlying this observation are not clear.",
"   </p>",
"   <p>",
"    Health-related quality of life may predict mortality among survivors of AKI. This was suggested by a multivariate analysis of 429 AKI survivors who were identified from a randomized multicenter study [",
"    <a class=\"abstract\" href=\"UTD.htm?4/28/4553/abstract/58\">",
"     58",
"    </a>",
"    ]. A low health-related quality of life, assessed at day 60 using the Health Utilities Index Mark 3 (HUI3), was associated with a higher mortality at one year compared with higher scores. Four prespecified HUI3 attributes including higher ambulation, emotion, cognition, and subscale pain scores were associated with better survival. Other variables that were associated with an increased risk of death in this study included older age, comorbid disease, and a longer length of initial hospital stay. Dialysis dependence at day 60 was not associated with increased mortality on the multivariate analysis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Dialysis factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dialysis with a biocompatible membrane, as compared with a bioincompatible membrane, was considered to be associated with enhanced patient survival and renal recovery [",
"    <a class=\"abstract\" href=\"UTD.htm?4/28/4553/abstract/65,66\">",
"     65,66",
"    </a>",
"    ]. However, a meta-analysis of nine studies with a total of 1062 patients with AKI requiring intermittent hemodialysis, showed no significant difference between use of biocompatible and bioincompatible membranes for survival or recovery of renal function [",
"    <a class=\"abstract\" href=\"UTD.htm?4/28/4553/abstract/67\">",
"     67",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A related issue is whether the particular dialysis modality that is utilized affects mortality. There are conflicting data, for example, concerning the effect on mortality of CRRT versus intermittent hemodialysis, with some studies showing improved survival with continuous therapies and others reporting increased mortality. These issues are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/37/4696?source=see_link\">",
"     \"Renal replacement therapy (dialysis) in acute kidney injury (acute renal failure): Recovery of renal function and effect of hemodialysis membrane\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/40/28295?source=see_link&amp;anchor=H6#H6\">",
"     \"Continuous renal replacement therapy in acute kidney injury (acute renal failure)\", section on 'Effect on mortality'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Does renal failure itself affect prognosis?",
"    </span>",
"    &nbsp;&mdash;&nbsp;A separate question is whether the development of ATN itself directly contributes to mortality. Possible mechanisms for such an effect are decreased ability to fight infection and altered platelet function with kidney failure, changes that could predispose to sepsis and bleeding.",
"   </p>",
"   <p>",
"    The possible independent association of ATN with increased mortality in acutely ill hospitalized patients is illustrated by the following studies [",
"    <a class=\"abstract\" href=\"UTD.htm?4/28/4553/abstract/41,43,44,68-71\">",
"     41,43,44,68-71",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one report, 183 ICU patients were divided into four groups: at risk for renal failure (60 patients), kidney injury (56 patients), kidney failure (43 patients), and control (24 patients) [",
"      <a class=\"abstract\" href=\"UTD.htm?4/28/4553/abstract/70\">",
"       70",
"      </a>",
"      ]. The kidney failure group, compared with all other groups, had significantly increased mortality at one and six months (74 and 86 percent, respectively).",
"     </li>",
"     <li>",
"      Among 843 cardiac surgery patients, death was much more common in the 145 patients who developed postoperative ATN (14.5 versus 1.1 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?4/28/4553/abstract/43\">",
"       43",
"      </a>",
"      ]. Multivariate analysis revealed that in-hospital mortality was significantly associated with kidney failure (hazard ratio of 7.8, 95% CI 3.1-20.0).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The impact of ATN on in-hospital mortality may be proportional to the degree of elevation in the serum creatinine independent of dialysis [",
"    <a class=\"abstract\" href=\"UTD.htm?4/28/4553/abstract/72-75\">",
"     72-75",
"    </a>",
"    ]. This issue was addressed in a single center survey of 9210 hospitalized adults who had two or more serum creatinine concentrations measured [",
"    <a class=\"abstract\" href=\"UTD.htm?4/28/4553/abstract/72\">",
"     72",
"    </a>",
"    ]. An increase in the serum creatinine concentration of &ge;0.5, &ge;1.0, and &ge;2",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (44, 88, and 177",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    was associated with an incrementally increased risk of in-hospital mortality (adjusted odds ratio 6.5, 11, and 50, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/28/4553/abstract/72\">",
"     72",
"    </a>",
"    ]. In addition, even milder forms of ATN adversely affect long term mortality. In a large retrospective study of 864,933 US veteran patients with a mean follow-up time of 2.3 years, hospitalized patients surviving an episode of AKI for more than 90 days after discharge from the hospital and not requiring dialysis experienced an adjusted long-term mortality risk of 1.41 (95% CI, 1.39-1.43) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/28/4553/abstract/76\">",
"     76",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The possibility that nonoliguric ATN is associated with a more favorable prognosis relative to oliguric ATN is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/28/2501?source=see_link\">",
"     \"Nonoliguric versus oliguric acute tubular necrosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H450663\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with acute tubular necrosis (ATN) have a kidney failure phase that typically lasts between 7 and 21 days, although the duration is variable. The duration is dependent upon the length and severity of the initial ischemic episode, whether or not recurrent ischemia occurs or nephrotoxic therapy is continued, and perhaps whether the patient is oliguric or nonoliguric. Whereas some patients recover within days, others require dialysis for weeks to months. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H4\">",
"       'Duration of ATN'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients who recover from ATN may not return to their baseline kidney function. An irreversible decline in kidney function after recovery is more likely in patients over age 65, those who have atheroembolic disease, and those with underlying chronic kidney disease (CKD). Patients with CKD who develop acute kidney injury (AKI) are more likely to progress to end-stage renal disease compared with patients with CKD who do not experience an episode of AKI. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Degree of recovery'",
"      </a>",
"      above.)",
"      <br/>",
"     </li>",
"     <li>",
"      ATN during hospitalization is associated with high in-hospital and long-term mortality. A variety of factors have been associated with increased mortality, including male gender, race, older age, oliguria, sepsis, respiratory or liver failure, and cerebrovascular events, and in particular, overall severity of illness. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Patient survival'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/28/4553/abstract/1\">",
"      Myers BD, Moran SM. Hemodynamically mediated acute renal failure. N Engl J Med 1986; 314:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/28/4553/abstract/2\">",
"      Lewers DT, Mathew TH, Maher JF, Schreiner GE. Long-term follow-up of renal function and histology after acute tubular necrosis. Ann Intern Med 1970; 73:523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/28/4553/abstract/3\">",
"      Georgaki-Angelaki HN, Steed DB, Chantler C, Haycock GB. Renal function following acute renal failure in childhood: a long term follow-up study. Kidney Int 1989; 35:84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/28/4553/abstract/4\">",
"      Khan IH, Catto GR, Edward N, Macleod AM. Acute renal failure: factors influencing nephrology referral and outcome. QJM 1997; 90:781.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/28/4553/abstract/5\">",
"      Stevens PE, Tamimi NA, Al-Hasani MK, et al. Non-specialist management of acute renal failure. QJM 2001; 94:533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/28/4553/abstract/6\">",
"      Feest TG, Round A, Hamad S. Incidence of severe acute renal failure in adults: results of a community based study. BMJ 1993; 306:481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/28/4553/abstract/7\">",
"      Lia&ntilde;o F, Pascual J. Epidemiology of acute renal failure: a prospective, multicenter, community-based study. Madrid Acute Renal Failure Study Group. Kidney Int 1996; 50:811.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/28/4553/abstract/8\">",
"      Waikar SS, Curhan GC, Wald R, et al. Declining mortality in patients with acute renal failure, 1988 to 2002. J Am Soc Nephrol 2006; 17:1143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/28/4553/abstract/9\">",
"      Hsu RK, McCulloch CE, Dudley RA, et al. Temporal changes in incidence of dialysis-requiring AKI. J Am Soc Nephrol 2013; 24:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/28/4553/abstract/10\">",
"      Ali T, Khan I, Simpson W, et al. Incidence and outcomes in acute kidney injury: a comprehensive population-based study. J Am Soc Nephrol 2007; 18:1292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/28/4553/abstract/11\">",
"      Hsu CY, McCulloch CE, Fan D, et al. Community-based incidence of acute renal failure. Kidney Int 2007; 72:208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/28/4553/abstract/12\">",
"      Myers BD, Miller DC, Mehigan JT, et al. Nature of the renal injury following total renal ischemia in man. J Clin Invest 1984; 73:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/28/4553/abstract/13\">",
"      Molitoris BA, Dahl R, Geerdes A. Cytoskeleton disruption and apical redistribution of proximal tubule Na(+)-K(+)-ATPase during ischemia. Am J Physiol 1992; 263:F488.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/28/4553/abstract/14\">",
"      Fish EM, Molitoris BA. Alterations in epithelial polarity and the pathogenesis of disease states. N Engl J Med 1994; 330:1580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/28/4553/abstract/15\">",
"      Spurney RF, Fulkerson WJ, Schwab SJ. Acute renal failure in critically ill patients: prognosis for recovery of kidney function after prolonged dialysis support. Crit Care Med 1991; 19:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/28/4553/abstract/16\">",
"      Conger JD, Robinette JB, Schrier RW. Smooth muscle calcium and endothelium-derived relaxing factor in the abnormal vascular responses of acute renal failure. J Clin Invest 1988; 82:532.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/28/4553/abstract/17\">",
"      Morgera S, Kraft AK, Siebert G, et al. Long-term outcomes in acute renal failure patients treated with continuous renal replacement therapies. Am J Kidney Dis 2002; 40:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/28/4553/abstract/18\">",
"      Schiffl H. Renal recovery from acute tubular necrosis requiring renal replacement therapy: a prospective study in critically ill patients. Nephrol Dial Transplant 2006; 21:1248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/28/4553/abstract/19\">",
"      Lo LJ, Go AS, Chertow GM, et al. Dialysis-requiring acute renal failure increases the risk of progressive chronic kidney disease. Kidney Int 2009; 76:893.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/28/4553/abstract/20\">",
"      Wald R, Quinn RR, Luo J, et al. Chronic dialysis and death among survivors of acute kidney injury requiring dialysis. JAMA 2009; 302:1179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/28/4553/abstract/21\">",
"      Ishani A, Xue JL, Himmelfarb J, et al. Acute kidney injury increases risk of ESRD among elderly. J Am Soc Nephrol 2009; 20:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/28/4553/abstract/22\">",
"      Coca SG, Singanamala S, Parikh CR. Chronic kidney disease after acute kidney injury: a systematic review and meta-analysis. Kidney Int 2012; 81:442.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/28/4553/abstract/23\">",
"      Bucaloiu ID, Kirchner HL, Norfolk ER, et al. Increased risk of death and de novo chronic kidney disease following reversible acute kidney injury. Kidney Int 2012; 81:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/28/4553/abstract/24\">",
"      Jones J, Holmen J, De Graauw J, et al. Association of complete recovery from acute kidney injury with incident CKD stage 3 and all-cause mortality. Am J Kidney Dis 2012; 60:402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/28/4553/abstract/25\">",
"      Pannu N, James M, Hemmelgarn B, et al. Association between AKI, recovery of renal function, and long-term outcomes after hospital discharge. Clin J Am Soc Nephrol 2013; 8:194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/28/4553/abstract/26\">",
"      Schmitt R, Coca S, Kanbay M, et al. Recovery of kidney function after acute kidney injury in the elderly: a systematic review and meta-analysis. Am J Kidney Dis 2008; 52:262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/28/4553/abstract/27\">",
"      Hsu CY, Chertow GM, McCulloch CE, et al. Nonrecovery of kidney function and death after acute on chronic renal failure. Clin J Am Soc Nephrol 2009; 4:891.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/28/4553/abstract/28\">",
"      Uchino S, Kellum JA, Bellomo R, et al. Acute renal failure in critically ill patients: a multinational, multicenter study. JAMA 2005; 294:813.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/28/4553/abstract/29\">",
"      Thakar CV, Arrigain S, Worley S, et al. A clinical score to predict acute renal failure after cardiac surgery. J Am Soc Nephrol 2005; 16:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/28/4553/abstract/30\">",
"      Mehta RL, Pascual MT, Soroko S, et al. Spectrum of acute renal failure in the intensive care unit: the PICARD experience. Kidney Int 2004; 66:1613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/28/4553/abstract/31\">",
"      Zhang L, Wang M, Wang H. Acute renal failure in chronic kidney disease--clinical and pathological analysis of 104 cases. Clin Nephrol 2005; 63:346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/28/4553/abstract/32\">",
"      Silvester W, Bellomo R, Cole L. Epidemiology, management, and outcome of severe acute renal failure of critical illness in Australia. Crit Care Med 2001; 29:1910.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/28/4553/abstract/33\">",
"      Hsu CY, Ordo&ntilde;ez JD, Chertow GM, et al. The risk of acute renal failure in patients with chronic kidney disease. Kidney Int 2008; 74:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/28/4553/abstract/34\">",
"      Metcalfe W, Simpson M, Khan IH, et al. Acute renal failure requiring renal replacement therapy: incidence and outcome. QJM 2002; 95:579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/28/4553/abstract/35\">",
"      Turney JH, Marshall DH, Brownjohn AM, et al. The evolution of acute renal failure, 1956-1988. Q J Med 1990; 74:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/28/4553/abstract/36\">",
"      Barton IK, Hilton PJ, Taub NA, et al. Acute renal failure treated by haemofiltration: factors affecting outcome. Q J Med 1993; 86:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/28/4553/abstract/37\">",
"      McCarthy JT. Prognosis of patients with acute renal failure in the intensive-care unit: a tale of two eras. Mayo Clin Proc 1996; 71:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/28/4553/abstract/38\">",
"      Schrier RW, Wang W. Acute renal failure and sepsis. N Engl J Med 2004; 351:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/28/4553/abstract/39\">",
"      Bagshaw SM, Laupland KB, Doig CJ, et al. Prognosis for long-term survival and renal recovery in critically ill patients with severe acute renal failure: a population-based study. Crit Care 2005; 9:R700.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/28/4553/abstract/40\">",
"      de Mendon&ccedil;a A, Vincent JL, Suter PM, et al. Acute renal failure in the ICU: risk factors and outcome evaluated by the SOFA score. Intensive Care Med 2000; 26:915.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/28/4553/abstract/41\">",
"      Metnitz PG, Krenn CG, Steltzer H, et al. Effect of acute renal failure requiring renal replacement therapy on outcome in critically ill patients. Crit Care Med 2002; 30:2051.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/28/4553/abstract/42\">",
"      Hou SH, Bushinsky DA, Wish JB, et al. Hospital-acquired renal insufficiency: a prospective study. Am J Med 1983; 74:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/28/4553/abstract/43\">",
"      Loef BG, Epema AH, Smilde TD, et al. Immediate postoperative renal function deterioration in cardiac surgical patients predicts in-hospital mortality and long-term survival. J Am Soc Nephrol 2005; 16:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/28/4553/abstract/44\">",
"      Liangos O, Wald R, O'Bell JW, et al. Epidemiology and outcomes of acute renal failure in hospitalized patients: a national survey. Clin J Am Soc Nephrol 2006; 1:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/28/4553/abstract/45\">",
"      Xue JL, Daniels F, Star RA, et al. Incidence and mortality of acute renal failure in Medicare beneficiaries, 1992 to 2001. J Am Soc Nephrol 2006; 17:1135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/28/4553/abstract/46\">",
"      Coca SG, Peixoto AJ, Garg AX, et al. The prognostic importance of a small acute decrement in kidney function in hospitalized patients: a systematic review and meta-analysis. Am J Kidney Dis 2007; 50:712.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/28/4553/abstract/47\">",
"      Welten GM, Schouten O, Chonchol M, et al. Temporary worsening of renal function after aortic surgery is associated with higher long-term mortality. Am J Kidney Dis 2007; 50:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/28/4553/abstract/48\">",
"      Newsome BB, Warnock DG, McClellan WM, et al. Long-term risk of mortality and end-stage renal disease among the elderly after small increases in serum creatinine level during hospitalization for acute myocardial infarction. Arch Intern Med 2008; 168:609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/28/4553/abstract/49\">",
"      Coca SG, Yusuf B, Shlipak MG, et al. Long-term risk of mortality and other adverse outcomes after acute kidney injury: a systematic review and meta-analysis. Am J Kidney Dis 2009; 53:961.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/28/4553/abstract/50\">",
"      Siew ED, Peterson JF, Eden SK, et al. Outpatient nephrology referral rates after acute kidney injury. J Am Soc Nephrol 2012; 23:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/28/4553/abstract/51\">",
"      Lia&ntilde;o F, Felipe C, Tenorio MT, et al. Long-term outcome of acute tubular necrosis: a contribution to its natural history. Kidney Int 2007; 71:679.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/28/4553/abstract/52\">",
"      Waikar SS, Curhan GC, Ayanian JZ, Chertow GM. Race and mortality after acute renal failure. J Am Soc Nephrol 2007; 18:2740.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/28/4553/abstract/53\">",
"      El-Shahawy MA, Agbing LU, Badillo E. Severity of illness scores and the outcome of acute tubular necrosis. Int Urol Nephrol 2000; 32:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/28/4553/abstract/54\">",
"      Lia&ntilde;o F, Gallego A, Pascual J, et al. Prognosis of acute tubular necrosis: an extended prospectively contrasted study. Nephron 1993; 63:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/28/4553/abstract/55\">",
"      Cantarovich F, Verho MT. A simple prognostic index for patients with acute renal failure requiring dialysis. French Multicentric Prospective Study on Furosemide in Acute Renal Failure Requiring Dialysis. Ren Fail 1996; 18:585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/28/4553/abstract/56\">",
"      Chertow GM, Lazarus JM, Paganini EP, et al. Predictors of mortality and the provision of dialysis in patients with acute tubular necrosis. The Auriculin Anaritide Acute Renal Failure Study Group. J Am Soc Nephrol 1998; 9:692.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/28/4553/abstract/57\">",
"      Chertow GM, Soroko SH, Paganini EP, et al. Mortality after acute renal failure: models for prognostic stratification and risk adjustment. Kidney Int 2006; 70:1120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/28/4553/abstract/58\">",
"      Joyce VR, Smith MW, Johansen KL, et al. Health-related quality of life as a predictor of mortality among survivors of AKI. Clin J Am Soc Nephrol 2012; 7:1063.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/28/4553/abstract/59\">",
"      Parker RA, Himmelfarb J, Tolkoff-Rubin N, et al. Prognosis of patients with acute renal failure requiring dialysis: results of a multicenter study. Am J Kidney Dis 1998; 32:432.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/28/4553/abstract/60\">",
"      Mehta RL, Pascual MT, Gruta CG, et al. Refining predictive models in critically ill patients with acute renal failure. J Am Soc Nephrol 2002; 13:1350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/28/4553/abstract/61\">",
"      Tran DD, Oe PL, de Fijter CW, et al. Acute renal failure in patients with acute pancreatitis: prevalence, risk factors, and outcome. Nephrol Dial Transplant 1993; 8:1079.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/28/4553/abstract/62\">",
"      Weisberg LS, Allgren RL, Genter FC, Kurnik BR. Cause of acute tubular necrosis affects its prognosis. The Auriculin Anaritide Acute Renal Failure Study Group. Arch Intern Med 1997; 157:1833.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/28/4553/abstract/63\">",
"      Fiaccadori E, Lombardi M, Leonardi S, et al. Prevalence and clinical outcome associated with preexisting malnutrition in acute renal failure: a prospective cohort study. J Am Soc Nephrol 1999; 10:581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/28/4553/abstract/64\">",
"      Obialo CI, Okonofua EC, Nzerue MC, et al. Role of hypoalbuminemia and hypocholesterolemia as copredictors of mortality in acute renal failure. Kidney Int 1999; 56:1058.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/28/4553/abstract/65\">",
"      Schiffl H, Lang SM, K&ouml;nig A, et al. Biocompatible membranes in acute renal failure: prospective case-controlled study. Lancet 1994; 344:570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/28/4553/abstract/66\">",
"      Himmelfarb J, Tolkoff Rubin N, Chandran P, et al. A multicenter comparison of dialysis membranes in the treatment of acute renal failure requiring dialysis. J Am Soc Nephrol 1998; 9:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/28/4553/abstract/67\">",
"      Alonso A, Lau J, Jaber BL. Biocompatible hemodialysis membranes for acute renal failure. Cochrane Database Syst Rev 2005; :CD005283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/28/4553/abstract/68\">",
"      Levy EM, Viscoli CM, Horwitz RI. The effect of acute renal failure on mortality. A cohort analysis. JAMA 1996; 275:1489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/28/4553/abstract/69\">",
"      Clermont G, Acker CG, Angus DC, et al. Renal failure in the ICU: comparison of the impact of acute renal failure and end-stage renal disease on ICU outcomes. Kidney Int 2002; 62:986.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/28/4553/abstract/70\">",
"      Abosaif NY, Tolba YA, Heap M, et al. The outcome of acute renal failure in the intensive care unit according to RIFLE: model application, sensitivity, and predictability. Am J Kidney Dis 2005; 46:1038.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/28/4553/abstract/71\">",
"      Bagshaw SM, Mortis G, Doig CJ, et al. One-year mortality in critically ill patients by severity of kidney dysfunction: a population-based assessment. Am J Kidney Dis 2006; 48:402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/28/4553/abstract/72\">",
"      Chertow GM, Burdick E, Honour M, et al. Acute kidney injury, mortality, length of stay, and costs in hospitalized patients. J Am Soc Nephrol 2005; 16:3365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/28/4553/abstract/73\">",
"      Lassnigg A, Schmidlin D, Mouhieddine M, et al. Minimal changes of serum creatinine predict prognosis in patients after cardiothoracic surgery: a prospective cohort study. J Am Soc Nephrol 2004; 15:1597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/28/4553/abstract/74\">",
"      Uchino S, Bellomo R, Goldsmith D, et al. An assessment of the RIFLE criteria for acute renal failure in hospitalized patients. Crit Care Med 2006; 34:1913.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/28/4553/abstract/75\">",
"      Kuitunen A, Vento A, Suojaranta-Ylinen R, Pettil&auml; V. Acute renal failure after cardiac surgery: evaluation of the RIFLE classification. Ann Thorac Surg 2006; 81:542.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/28/4553/abstract/76\">",
"      Lafrance JP, Miller DR. Acute kidney injury associates with increased long-term mortality. J Am Soc Nephrol 2010; 21:345.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7225 Version 14.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-61.234.146.186-D40D2B0C78-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_28_4553=[""].join("\n");
var outline_f4_28_4553=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H450663\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      RENAL OUTCOMES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Duration of ATN",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Rapid recovery",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Prolonged ATN",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Degree of recovery",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Preexisting chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Dialysis modality",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      PATIENT SURVIVAL",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Factors influencing mortality",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Dialysis factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Does renal failure itself affect prognosis?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H450663\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/7225\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/7225|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?42/27/43453\" title=\"figure 1\">",
"      Transient ATN post AAA repair",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?21/55/22397\" title=\"figure 2\">",
"      Risk of progressive CKD",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/5/20569?source=related_link\">",
"      Clinical manifestations and diagnosis of acute pancreatitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/40/28295?source=related_link\">",
"      Continuous renal replacement therapy in acute kidney injury (acute renal failure)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/49/42773?source=related_link\">",
"      Definition of acute kidney injury (acute renal failure)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/60/35785?source=related_link\">",
"      Diagnostic approach to the patient with acute kidney injury (acute renal failure) or chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/25/35226?source=related_link\">",
"      Early noncardiac complications of coronary artery bypass graft surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/54/12138?source=related_link\">",
"      Etiology and diagnosis of prerenal disease and acute tubular necrosis in acute kidney injury (acute renal failure)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/51/21306?source=related_link\">",
"      Evaluation and management of severe sepsis and septic shock in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/28/2501?source=related_link\">",
"      Nonoliguric versus oliguric acute tubular necrosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/4/4170?source=related_link\">",
"      Pathogenesis and etiology of postischemic (ischemic) acute tubular necrosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/13/10457?source=related_link\">",
"      Pathogenesis, clinical features, and diagnosis of contrast-induced nephropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/10/42154?source=related_link\">",
"      Possible prevention and therapy of postischemic (ischemic) acute tubular necrosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/56/27527?source=related_link\">",
"      Predictive scoring systems in the intensive care unit",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/58/25513?source=related_link\">",
"      Renal replacement therapy (dialysis) in acute kidney injury (acute renal failure) in adults: Indications, timing, and dialysis dose",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/37/4696?source=related_link\">",
"      Renal replacement therapy (dialysis) in acute kidney injury (acute renal failure): Recovery of renal function and effect of hemodialysis membrane",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_28_4554="Cannabis use disorders: Treatment, prognosis, and long-term medical effects";
var content_f4_28_4554=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Cannabis use disorders: Treatment, prognosis, and long-term medical effects",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/28/4554/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/28/4554/contributors\">",
"     Scott A Teitelbaum, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/28/4554/contributors\">",
"     Robert L DuPont, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/28/4554/contributors\">",
"     John A Bailey, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/28/4554/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/28/4554/contributors\">",
"     Andrew J Saxon, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/28/4554/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/28/4554/contributors\">",
"     Richard Hermann, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?4/28/4554/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 13, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION AND DEFINITIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cannabis use can lead to three DSM-IV disorders: cannabis intoxication, abuse, and dependence [",
"    <a class=\"abstract\" href=\"UTD.htm?4/28/4554/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Intoxication develops after ingestion of a substance and is characterized by a reversible syndrome of maladaptive behavioral or psychological changes, such as mood lability, cognitive impairment, or poor judgment.",
"     </li>",
"     <li>",
"      Abuse is a problematic pattern of substance use that results in poor role functioning, interpersonal difficulties, recurrent substance use in physically hazardous situations, or repeated legal difficulties.",
"     </li>",
"     <li>",
"      Dependence is a maladaptive pattern of substance use manifested by such symptoms as repeated substance ingestion despite physical or psychological problems caused by the substance, ingesting larger amounts of the substance over longer periods of time, unsuccessful efforts to limit substance use, tolerance to the substance's effects, and physiologic withdrawal.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The psychoactive properties of cannabis are primarily due to delta-9-tetrahydrocannabinol (THC) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/28/4554/abstract/2\">",
"     2",
"    </a>",
"    ]. The THC content of marijuana has increased significantly since the late 1960s from approximately 1 to 5 percent to as much as 10 to 15 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?4/28/4554/abstract/1\">",
"     1",
"    </a>",
"    ]. Increased potency may have contributed to increased rates of dependence observed in recent years.",
"   </p>",
"   <p>",
"    The treatment and prognosis of cannabis use disorders, and the long-term medical effects of cannabis use will be reviewed here. Other issues related to cannabis use, abuse, or dependence are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/3/1079?source=see_link\">",
"     \"Cannabis use disorders: Epidemiology, comorbidity, and pathogenesis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/17/21783?source=see_link\">",
"     \"Cannabis use disorders: Clinical features and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     TREATMENT PRINCIPLES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment for cannabis use disorders usually occurs on an outpatient basis, but residential treatment may be required for patients who cannot remain abstinent in an ambulatory setting or those with multiple concurrent substance use disorders. Treatment may occur in a partial hospital or inpatient setting if the patient is psychotic, suicidal, or agitated, or has been hospitalized for another psychiatric disorder.",
"   </p>",
"   <p>",
"    The patient's family should be involved in treatment, in order to provide additional history, learn about the disorder, and help monitor the patient's progress.",
"   </p>",
"   <p>",
"    Patients should generally aim to achieve sustained abstinence from cannabis rather than a controlled level of use that does not impair functioning. It may be necessary to accept moderation as an initial goal in order to engage some patients in the treatment process. Patients may develop a series of goals along the way to abstinence, such as abstaining from cannabis but not nicotine, reducing the frequency or amount of cannabis used, or limiting cannabis use to low risk situations, for example, not driving while intoxicated. Other goals for treatment include improved psychological, social, and occupational functioning [",
"    <a class=\"abstract\" href=\"UTD.htm?4/28/4554/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Drug testing is useful for monitoring progress and early detection of relapse. A review found that intensive monitoring of substance use may increase recovery rates [",
"    <a class=\"abstract\" href=\"UTD.htm?4/28/4554/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/17/21783?source=see_link\">",
"     \"Cannabis use disorders: Clinical features and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Abstinence from marijuana for one or more consecutive days prior to the day of the intake assessment for treatment is associated with better treatment outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?4/28/4554/abstract/4\">",
"     4",
"    </a>",
"    ]. A study found that a significantly higher proportion of patients who abstained prior to treatment submitted one or more marijuana negative urine tests during treatment, compared to patients who did not abstain prior to treatment (60 versus 38 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     TREATMENT OF INTOXICATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute intoxication with marijuana alone rarely requires medical treatment, although dysphoria may result in distress that causes the user to seek help (",
"    <a class=\"graphic graphic_table graphicRef73321 \" href=\"UTD.htm?19/29/19931\">",
"     table 1",
"    </a>",
"    ). First-time users, older persons, users of high-potency marijuana, or those predisposed to psychiatric illness are at higher risk of experiencing unpleasant effects during intoxication.",
"   </p>",
"   <p>",
"    Problematic effects of acute intoxication, such as anxiety, mild paranoia, or palpitations, are generally managed with supportive treatment. Placing the distraught user in a quiet environment and maintaining gentle contact is often sufficient until the acute effects subside. More severe paranoia or psychosis may require close observation and a low dose of a benzodiazepine (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/8/8329?source=see_link\">",
"     lorazepam",
"    </a>",
"    0.5 to 1 mg) or antipsychotic (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/56/20361?source=see_link\">",
"     quetiapine",
"    </a>",
"    50 mg) for sedation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     TREATMENT OF ABUSE AND DEPENDENCE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Prevention",
"    </span>",
"    &nbsp;&mdash;&nbsp;Preventive treatment is partly based on the gateway theory of drug abuse, which hypothesizes that there is a sequential progression of drug involvement from adolescence into adulthood, starting with tobacco, alcohol, and marijuana, which then leads to the use of other illicit substances [",
"    <a class=\"abstract\" href=\"UTD.htm?4/28/4554/abstract/5\">",
"     5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/3/1079?source=see_link&amp;anchor=H6#H6\">",
"     \"Cannabis use disorders: Epidemiology, comorbidity, and pathogenesis\", section on 'Comorbid substance use disorders'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A meta-analysis of four studies, involving sixth and seventh grade students, compared a school-based social skills program against the usual curriculum [",
"    <a class=\"abstract\" href=\"UTD.htm?4/28/4554/abstract/6\">",
"     6",
"    </a>",
"    ]. The active intervention significantly reduced the use of marijuana at follow-up assessments that occurred one, two, five, or six years after the intervention, depending upon the study (relative risk 0.82, 95% CI 0.73-0.92).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Psychosocial interventions",
"    </span>",
"    &nbsp;&mdash;&nbsp;The standard treatment for cannabis abuse (",
"    <a class=\"graphic graphic_table graphicRef53923 \" href=\"UTD.htm?24/5/24667\">",
"     table 2",
"    </a>",
"    ) and dependence (",
"    <a class=\"graphic graphic_table graphicRef64590 \" href=\"UTD.htm?31/34/32299\">",
"     table 3",
"    </a>",
"    ) is psychotherapy, based upon positive results from controlled clinical trials and the lack of efficacy for pharmacotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?4/28/4554/abstract/3,7,8\">",
"     3,7,8",
"    </a>",
"    ]. Nevertheless, many patients do not complete treatment, do not achieve abstinence, or they resume cannabis use soon after completing psychotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?4/28/4554/abstract/3,9,10\">",
"     3,9,10",
"    </a>",
"    ]. A systematic review of randomized controlled trials concluded that psychotherapy more often results in reduced cannabis use than continuous abstinence [",
"    <a class=\"abstract\" href=\"UTD.htm?4/28/4554/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The many different psychotherapies available for treating cannabis use disorders all attempt to stop compulsive use by one or more of the following strategies [",
"    <a class=\"abstract\" href=\"UTD.htm?4/28/4554/abstract/3\">",
"     3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Enhance motivation to reduce or end cannabis use",
"     </li>",
"     <li>",
"      Improve social skills",
"     </li>",
"     <li>",
"      Improve social support and interpersonal functioning",
"     </li>",
"     <li>",
"      Change reinforcement contingencies",
"     </li>",
"     <li>",
"      Manage painful feelings",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A review from 2007 concluded that no therapy is better than another, with the exception of adding vouchers to a regimen combining motivational enhancement plus cognitive behavioral treatment (see below) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/28/4554/abstract/8\">",
"     8",
"    </a>",
"    ]. The review also concluded that longer therapies do not consistently lead to better outcomes than shorter therapies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Cognitive behavioral therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;This psychotherapy attempts to change maladaptive cognitions (thoughts) about one self and others, and to improve social skills and interpersonal relationships. Behavioral strategies to help patients cope with events that trigger cannabis use are based upon a functional analysis of cannabis use. This analysis helps patients recognize the antecedents and consequences of cannabis use (ABC: Antecedents, cannabis use Behavior, Consequences). Treatment sessions last approximately an hour and occur once per week.",
"   </p>",
"   <p>",
"    A systematic review from 2008 evaluated randomized psychotherapy trials administered to adult outpatients in the US and Australia [",
"    <a class=\"abstract\" href=\"UTD.htm?4/28/4554/abstract/10\">",
"     10",
"    </a>",
"    ]. Cognitive behavioral therapy, ranging from 6 to 14 weeks in duration, resulted in higher rates of abstinence compared to control treatments (10 to 37 versus 4 to 9 percent).",
"   </p>",
"   <p>",
"    A similar systematic review from 2006 concluded that group or individual cognitive behavioral therapy efficaciously treated cannabis dependence and associated problems [",
"    <a class=\"abstract\" href=\"UTD.htm?4/28/4554/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Motivational interviewing",
"    </span>",
"    &nbsp;&mdash;&nbsp;This psychotherapy, also called motivational enhancement therapy, attempts to increase the patient's motivation to stop addictive behaviors by eliciting the patient's reasons for changing as well as ambivalence towards change. The therapy takes a less directive approach and includes such techniques as expression of empathy, reflection, summarization, and exploration of the pros and cons of cannabis use [",
"    <a class=\"abstract\" href=\"UTD.htm?4/28/4554/abstract/11\">",
"     11",
"    </a>",
"    ]. This therapy was specifically developed for treatment of substance use disorders and may be especially effective for increasing retention within treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?4/28/4554/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Systematic reviews from 2006 and 2008 concluded motivational interviewing was efficacious in reducing cannabis use [",
"    <a class=\"abstract\" href=\"UTD.htm?4/28/4554/abstract/7,12\">",
"     7,12",
"    </a>",
"    ]. As an example, one study found the percentage of days that patients smoked marijuana was significantly less in the group assigned motivational enhancement compared to the control group (56 versus 76 percent of days smoking) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/28/4554/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A review found that motivational interviewing may be especially efficient for treating cannabis dependence. Similar rates of abstinence occurred in patients receiving either three hours of motivational interviewing or 28 hours of cognitive behavioral therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?4/28/4554/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Voucher based incentives",
"    </span>",
"    &nbsp;&mdash;&nbsp;This psychotherapy is a form of contingency management (behavioral therapy) that provides the patient with a tangible reward contingent upon a therapeutically desired behavior, such as attending a treatment session or maintaining marijuana abstinence as documented through a negative urine test. These incentives are used in conjunction with psychotherapy, such as cognitive behavioral therapy or motivational enhancement therapy.",
"   </p>",
"   <p>",
"    The reward is typically a voucher with monetary value that escalates with each session attended or negative drug test [",
"    <a class=\"abstract\" href=\"UTD.htm?4/28/4554/abstract/11\">",
"     11",
"    </a>",
"    ]. Patients exchange vouchers for items or services such as sporting goods or classes.",
"   </p>",
"   <p>",
"    A systematic review from 2006 concluded that voucher based incentives increase the efficacy of outpatient cognitive behavioral therapy or motivational enhancement therapy for adults [",
"    <a class=\"abstract\" href=\"UTD.htm?4/28/4554/abstract/7\">",
"     7",
"    </a>",
"    ]. As an example, a US study found the proportion of patients who completed a four week treatment program was significantly higher for the group assigned to motivational enhancement plus vouchers, compared to those assigned to motivational enhancement alone (64 versus 39 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/28/4554/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Family therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;This psychotherapy theorizes that the patient's cannabis use disorder occurs within a larger system, and that specific processes within the family system need to be addressed, such as conflicts, communication, and affective issues. There are many types of family therapy, including one termed multidimensional family therapy, which was adapted for a study of adolescents with cannabis dependence [",
"    <a class=\"abstract\" href=\"UTD.htm?4/28/4554/abstract/14\">",
"     14",
"    </a>",
"    ]. Twelve to 15 family therapy sessions (typically six with the cannabis dependent adolescent, three with the parents, and six with the whole family) resulted in considerable reductions in cannabis use and negative consequences sustained through the 12 month follow-up. Adolescents assigned to family therapy, compared to adolescents assigned to treatment combining motivational enhancement therapy plus cognitive behavioral therapy, demonstrated similar improvements with regard to the proportion who recovered from cannabis dependence (19 versus 23 percent of adolescents), and total days abstinent over 12 months (257 versus 251 days).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Pharmacotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no medications for cannabis abuse or dependence of established effectiveness. Small trials of N-",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/1/20504?source=see_link\">",
"     acetylcysteine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/19/19768?source=see_link\">",
"     gabapentin",
"    </a>",
"    show promise but require confirmation in larger randomized trials.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H324028646\">",
"    <span class=\"h3\">",
"     Acetylcysteine",
"    </span>",
"    &nbsp;&mdash;&nbsp;The antioxidant",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/1/20504?source=see_link\">",
"     acetylcysteine",
"    </a>",
"    , an",
"    <em>",
"     N",
"    </em>",
"    -acetyl prodrug of the naturally occurring amino acid cysteine available over-the-counter as a dietary supplement and as a prescribed medication in the US and other countries. Acetylcysteine (NAC) was tested to treat cannabis dependence based on findings from preclinical studies suggesting glutamate modulation in the nucleus accumbens.",
"   </p>",
"   <p>",
"    Results from a single trial suggest the efficacy of NAC. In an eight week trial, 116 adolescents (15 to 21 years old) with cannabis dependence were randomized to receive orally administered NAC capsules 1200 mg or placebo twice daily [",
"    <a class=\"abstract\" href=\"UTD.htm?4/28/4554/abstract/15\">",
"     15",
"    </a>",
"    ]. Both groups additionally received a contingency management intervention and brief (&lt;10 minutes) weekly cessation counseling. Compared to those receiving placebo, participants receiving NAC had more than twice the odds of having negative urine cannabinoid test results during treatment, the primary outcome (odds ratio 2.4, 95% CI 1.1 to 5.2). Forty-one percent of urine tests in the NAC group were negative compared to 27 percent in the placebo group. An analysis of the treatment effect over time was negative. NAC was well tolerated with minimal adverse events.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Antidepressants",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple randomized controlled trials with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/29/26073?source=see_link\">",
"     bupropion",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/0/2057?source=see_link\">",
"     nefazodone",
"    </a>",
"    have demonstrated that neither is efficacious in reducing weekly cannabis use, decreasing the severity of cannabis dependence symptoms, or ameliorating cannabis withdrawal symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?4/28/4554/abstract/3,16,17\">",
"     3,16,17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Anticonvulsants",
"    </span>",
"    &nbsp;&mdash;&nbsp;A 12-week, randomized trial compared",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/19/19768?source=see_link\">",
"     gabapentin",
"    </a>",
"    <span class=\"nowrap\">",
"     (1200&thinsp;mg/day)",
"    </span>",
"    to placebo in 50 adult outpatients with cannabis dependence [",
"    <a class=\"abstract\" href=\"UTD.htm?4/28/4554/abstract/18\">",
"     18",
"    </a>",
"    ]. All participants received manual-guided, abstinence-oriented individual counseling weekly. Gabapentin reduced cannabis use by self-report and urine toxicology, and led to decreased withdrawal symptoms. Study limitations included a high dropout out rate.",
"   </p>",
"   <p>",
"    Two trials found minimal evidence to support divalproex in marijuana dependence. A randomized, placebo-controlled trial showed that divalproex at a dose of 750 mg twice per day decreases marijuana craving but worsens other withdrawal symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?4/28/4554/abstract/19\">",
"     19",
"    </a>",
"    ]. A second controlled trial found no significant differences between divalproex and placebo with regard to abstinence [",
"    <a class=\"abstract\" href=\"UTD.htm?4/28/4554/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Cannabinoid agonists",
"    </span>",
"    &nbsp;&mdash;&nbsp;These agents show promise in reducing symptoms of cannabis withdrawal and therefore may also prevent relapse, but further study is needed.",
"   </p>",
"   <p>",
"    Oral delta-9-tetrahydrocannabinol (THC) is the best candidate for a medication to treat cannabis withdrawal symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?4/28/4554/abstract/19,21\">",
"     19,21",
"    </a>",
"    ]. A double blind, placebo controlled trial showed that THC (10 mg taken five times per day) decreased withdrawal symptoms and craving during marijuana abstinence while producing no intoxication [",
"    <a class=\"abstract\" href=\"UTD.htm?4/28/4554/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A small cross-over study found that the combination of THC and lofexidine (an alpha-2 adrenergic agonist that is not currently available in the US) was superior to other treatments in preventing withdrawal and relapse [",
"    <a class=\"abstract\" href=\"UTD.htm?4/28/4554/abstract/22\">",
"     22",
"    </a>",
"    ]. Compared to placebo, THC (20 mg three times per day) alone significantly decreased only a small subset of withdrawal symptoms and did not decrease cannabis relapse while lofexidine (0.6 mg per four times per day) alone did not attenuate withdrawal symptoms but significantly decreased relapse. The combination of THC and lofexidine significantly decreased withdrawal symptoms including craving and significantly decreased relapse.",
"   </p>",
"   <p>",
"    THC is currently available for prescription in Canada as a spray that combines THC and another plant cannabinoid called cannabidiol. The spray is indicated for treatment of neuropathic pain due to multiple sclerosis or cancer. The spray is not available in the US.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/49/30485?source=see_link\">",
"     Dronabinol",
"    </a>",
"    is a cannabinoid used to treat anorexia associated with the acquired immunodeficiency syndrome, and nausea and vomiting associated with chemotherapy. A review found that dronabinol was superior to placebo in reducing withdrawal symptoms for heavy marijuana users in doses ranging from 10 mg three times per day to 30 mg three times per day [",
"    <a class=\"abstract\" href=\"UTD.htm?4/28/4554/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     COURSE OF ILLNESS AND PROGNOSIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Cannabis use, abuse, and dependence",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Adolescents and young adults",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cannabis use disorders vary considerably over time. A German epidemiologic study prospectively followed a sample aged 14 to 24 years at baseline, including 311 subjects who had used cannabis one to four times in their lifetime prior to baseline [",
"    <a class=\"abstract\" href=\"UTD.htm?4/28/4554/abstract/24\">",
"     24",
"    </a>",
"    ]. During the following 10 years, 69 percent stopped using cannabis, 17 percent used cannabis one to four times, 11 percent used cannabis five or more times, 2 percent developed cannabis abuse, and 1 percent developed cannabis dependence. These results are consistent with other studies showing that about 60 percent of cannabis users stop between the ages of 23 to 30 [",
"    <a class=\"abstract\" href=\"UTD.htm?4/28/4554/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Predictors of continued cannabis use among adolescents and young adults include [",
"    <a class=\"abstract\" href=\"UTD.htm?4/28/4554/abstract/26\">",
"     26",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Early onset of use",
"     </li>",
"     <li>",
"      Frequent use",
"     </li>",
"     <li>",
"      Male sex",
"     </li>",
"     <li>",
"      Using cannabis to enhance positive feelings and reduce negative feelings",
"     </li>",
"     <li>",
"      Using other illegal substances",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Over 50 percent of adolescents and young adults with abuse or dependence spontaneously improve. A German epidemiologic study prospectively followed a sample aged 14 to 24 years at baseline for up to four years [",
"    <a class=\"abstract\" href=\"UTD.htm?4/28/4554/abstract/25\">",
"     25",
"    </a>",
"    ]. Among those who at any point during follow up met criteria for cannabis abuse, over the following 12 months, 57 percent improved and no longer met abuse criteria, 41 percent remained abusers, and 2 percent developed dependence.",
"   </p>",
"   <p>",
"    Among those 14 to 24 years old who at any point during four years of follow up ever met criteria for cannabis dependence, over the following 12 months, 60 percent improved and no longer met criteria for dependence or abuse, 21 percent improved to the point where they met only abuse criteria, and 19 percent remained dependent [",
"    <a class=\"abstract\" href=\"UTD.htm?4/28/4554/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Adults age 17 years and older",
"    </span>",
"    &nbsp;&mdash;&nbsp;An observational study followed 162 Australian adults who used cannabis at least weekly for a minimum of three years [",
"    <a class=\"abstract\" href=\"UTD.htm?4/28/4554/abstract/26\">",
"     26",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One year after baseline, the same level of use persisted in 66 percent, and criteria for cannabis dependence were met by approximately 70 percent. Cannabis use declined to less than weekly or not at all in 19 percent.",
"     </li>",
"     <li>",
"      The only predictor of quantity of cannabis used at follow up one year later, after adjusting for various confounders, was quantity used at baseline.",
"     </li>",
"     <li>",
"      Use of other substances in the past year was common, including alcohol (in 97 percent), tobacco (79 percent), hallucinogens (44 percent), amphetamines (34 percent), cocaine (27 percent), and benzodiazepines (24 percent).",
"     </li>",
"     <li>",
"      Only 5 percent of the cohort obtained treatment, whereas 92 percent of those who decreased or stopped using cannabis did so without professional help.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Persistent withdrawal symptoms often contribute to relapse of cannabis use [",
"    <a class=\"abstract\" href=\"UTD.htm?4/28/4554/abstract/9,16\">",
"     9,16",
"    </a>",
"    ]. A study of 739 cannabis users found that 42 percent reported craving cannabis as one of the symptoms of withdrawal [",
"    <a class=\"abstract\" href=\"UTD.htm?4/28/4554/abstract/27\">",
"     27",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/17/21783?source=see_link&amp;anchor=H9#H9\">",
"     \"Cannabis use disorders: Clinical features and diagnosis\", section on 'Withdrawal'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Maintaining abstinence is difficult for adults who chronically use marijuana in large doses. A study evaluated adult cannabis dependent patients who regularly used marijuana for a mean of 15 years, and four times per day in the month prior to initiating a 14 week outpatient psychotherapy program [",
"    <a class=\"abstract\" href=\"UTD.htm?4/28/4554/abstract/28\">",
"     28",
"    </a>",
"    ]. Of the 82 patients who achieved at least two weeks of abstinence (confirmed by a negative urine screen), 71 percent subsequently resumed use at least once during the following six months. The mean time to use was 74 days. Relapse with at least four days of use within any seven day period occurred in 50 percent of the patients, with a mean of 83 days until relapse.",
"   </p>",
"   <p>",
"    Patients appear to move in and out of dependence, achieving abstinence and then relapsing. It is not clear how often this occurs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Psychosocial functioning and health",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Short-term outcomes",
"    </span>",
"    &nbsp;&mdash;&nbsp;A review found that cannabis use is associated with a number of adverse psychosocial problems in the short term, including school dropout, using other illicit drugs, crime, and unemployment [",
"    <a class=\"abstract\" href=\"UTD.htm?4/28/4554/abstract/29\">",
"     29",
"    </a>",
"    ]. Many of the associations remain significant after controlling for various confounders.",
"   </p>",
"   <p>",
"    A longitudinal study followed a New Zealand birth cohort of 1265 children until age 21 and found a direct and significant relationship between frequency of cannabis use and the number of crimes committed, controlling for numerous known confounders [",
"    <a class=\"abstract\" href=\"UTD.htm?4/28/4554/abstract/29\">",
"     29",
"    </a>",
"    ]. As an example, individuals aged 14 to 15 years who used cannabis less than monthly committed 1.6 times more crimes compared to those who never used cannabis, while those who used who used at least weekly committed 3.7 times more crimes. These relationships declined with age but remained significant.",
"   </p>",
"   <p>",
"    An observational study of 162 Australian adults who used cannabis at least weekly for a minimum of three years found that one year after baseline, problems related to cannabis in the past year were reported by 44 percent of the cohort, including problems with family, friends, study, work, and the law [",
"    <a class=\"abstract\" href=\"UTD.htm?4/28/4554/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Long-term outcomes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adverse consequences of cannabis use may diminish or disappear with sustained abstinence or reductions in use. As an example, a study found that previous heavy marijuana use was not associated with adverse effects on physical and mental health, quality of life, and sociodemographic measures [",
"    <a class=\"abstract\" href=\"UTD.htm?4/28/4554/abstract/30\">",
"     30",
"    </a>",
"    ]. These findings came from a study of 56 monozygotic male twins discordant for cannabis use, in which the cannabis using twins consumed cannabis for a mean of 1085 days, and had last used cannabis a mean of 20 years earlier. The control co-twins used cannabis for a maximum of five days in their lifetime. The twins reported no other significant illicit drug use. The study design controlled for many confounders because the twins had the same genes and shared many of the same environmental experiences during childhood. There were no significant differences between the former marijuana using twins and their siblings for:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Current level of education and household income",
"     </li>",
"     <li>",
"      Proportion who were married and employed",
"     </li>",
"     <li>",
"      Current level of health related quality of life",
"     </li>",
"     <li>",
"      Lifetime nicotine abuse or dependence",
"     </li>",
"     <li>",
"      Lifetime alcohol abuse or dependence",
"     </li>",
"     <li>",
"      Lifetime risk of various mood or anxiety disorders",
"     </li>",
"     <li>",
"      Medication use for medical problems in the past five years",
"     </li>",
"     <li>",
"      Number of outpatient or emergency room visits in the past five years",
"     </li>",
"     <li>",
"      Number of hospitalizations in the past five years",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     LONG TERM MEDICAL EFFECTS OF CANNABIS USE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Pulmonary",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cannabis smoke contains many of the same combusted particles found in tobacco smoke [",
"    <a class=\"abstract\" href=\"UTD.htm?4/28/4554/abstract/31\">",
"     31",
"    </a>",
"    ], sometimes in larger quantities. As an example, marijuana smoke contains approximately three times the amount of tar found in tobacco smoke and 50 percent more carcinogens [",
"    <a class=\"abstract\" href=\"UTD.htm?4/28/4554/abstract/32\">",
"     32",
"    </a>",
"    ]. In addition, hand rolled marijuana cigarettes are not filtered and the smoke is inhaled deeply [",
"    <a class=\"abstract\" href=\"UTD.htm?4/28/4554/abstract/33\">",
"     33",
"    </a>",
"    ]. However, individuals typically smoke far less cannabis than tobacco.",
"   </p>",
"   <p>",
"    Cannabis smoke irritates the airways and is associated with cough, sputum production, wheezing, bronchodilatation, and bronchitis, as well as dyspnea, pharyngitis, exacerbation of asthma, and exacerbation of cystic fibrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?4/28/4554/abstract/31\">",
"     31",
"    </a>",
"    ]. An epidemiologic survey of a nationally representative US sample found that marijuana smokers have significantly higher rates of chronic inflammatory changes compared to those who do not smoke, after controlling for sex, age, current asthma, and tobacco use [",
"    <a class=\"abstract\" href=\"UTD.htm?4/28/4554/abstract/34\">",
"     34",
"    </a>",
"    ]. Longer-term use is associated with increased respiratory symptoms suggestive of obstructive lung disease [",
"    <a class=\"abstract\" href=\"UTD.htm?4/28/4554/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A systematic review of marijuana smoking and its effects on pulmonary function found no association between long-term marijuana smoking and measures of pulmonary function and airflow obstruction [",
"    <a class=\"abstract\" href=\"UTD.htm?4/28/4554/abstract/31\">",
"     31",
"    </a>",
"    ]. As an example, a longitudinal study of 5,115 people over a 20 year period found that occasional and low, cumulative marijuana use was not associated with reduced pulmonary function (forced expiratory volume and forced vital capacity) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/28/4554/abstract/35\">",
"     35",
"    </a>",
"    ]. Although the study lacked a sufficient number of heavy users, the results suggested that heavy, longterm use may be associated with reduced pulmonary function.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;Molecular, cellular, and histopathological evidence all indicate that marijuana smoking may cause cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?4/28/4554/abstract/36,37\">",
"     36,37",
"    </a>",
"    ]. However, a 2005 review of epidemiologic studies concluded that sufficient studies are not available to adequately evaluate the effect of marijuana on cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?4/28/4554/abstract/36\">",
"     36",
"    </a>",
"    ]. Many methodologic problems of the existing studies, such as inadequate sample sizes and not accounting for important confounding factors, especially cigarette smoking, limit the ability to detect an association that probably exists.",
"   </p>",
"   <p>",
"    There is evidence that cannabis smoking is associated with an increased risk for lung cancer. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/0/12298?source=see_link&amp;anchor=H13#H13\">",
"     \"Cigarette smoking and other risk factors for lung cancer\", section on 'Marijuana'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A pooled analysis of five case control studies did not find an association between marijuana use and cancer of the head and neck [",
"    <a class=\"abstract\" href=\"UTD.htm?4/28/4554/abstract/38\">",
"     38",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/6/20583?source=see_link&amp;anchor=H4#H4\">",
"     \"Epidemiology and risk factors for head and neck cancer\", section on 'Smoking'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A case control study found that patients with transitional cell carcinoma of the bladder were significantly more likely to be habitual marijuana users, compared to the controls without transitional cell carcinoma (89 versus 69 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/28/4554/abstract/39\">",
"     39",
"    </a>",
"    ]. However, the clinical significance of this finding is unclear, especially in light of the fact that tobacco use was a potential confounding variable. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/61/26586?source=see_link\">",
"     \"Epidemiology and etiology of urothelial (transitional cell) carcinoma of the bladder\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Central nervous system",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h3\">",
"     Neuropsychological effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Evidence of an association between cannabis use and long-term residual neurocognitive deficits is mixed.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A 2003 meta-analysis including more than 600 cannabis users found no evidence that marijuana causes significant long term effects on neurocognitive processes [",
"      <a class=\"abstract\" href=\"UTD.htm?4/28/4554/abstract/40\">",
"       40",
"      </a>",
"      ]. These results were consistent with an epidemiologic study [",
"      <a class=\"abstract\" href=\"UTD.htm?4/28/4554/abstract/41\">",
"       41",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In studies completed after the metaanalysis:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      A comprehensive neuropsychological test battery was administered to monozygotic twin pairs discordant for regular marijuana use, in which neither twin used any other illicit substance regularly [",
"      <a class=\"abstract\" href=\"UTD.htm?4/28/4554/abstract/42\">",
"       42",
"      </a>",
"      ]. Testing was completed a minimum of one year after marijuana had last been used, with a mean of almost 20 years since last regular use. A total of 56 tests assessed the domains of general intelligence, attention, memory, executive functioning, and motor skills. Marijuana users performed significantly worse on only one of the tests compared with those who did not use marijuana.",
"     </li>",
"     <li>",
"      In a prospective study of 1,037 individuals in New Zealand followed from birth to age 38 years, persistent cannabis use was associated with neuropsychological decline, across domains of functioning, controlling for education and other factors [",
"      <a class=\"abstract\" href=\"UTD.htm?4/28/4554/abstract/43\">",
"       43",
"      </a>",
"      ]. Impairment was seen principally among adolescent-onset cannabis users, with more persistent use associated with greater decline. Participants received serial neuropsychological testing beginning at age 13 years, prior to initiation of cannabis use, and at age 38 years",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    While other studies have found evidence of deficits in attention, memory, executive functioning, and psychomotor speed related to dose and cumulative exposure to cannabis, these studies have involved smaller patient groups as well as potential confounding by ongoing or recent cannabis use and other factors [",
"    <a class=\"abstract\" href=\"UTD.htm?4/28/4554/abstract/44-46\">",
"     44-46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Neuroimaging studies have attempted to correlate structural and neurophysiologic changes with long-term cannabis use. In one study, magnetic resonance imaging showed that long term, heavy use is associated with significantly reduced volumes in the hippocampus and amygdala (two regions of the brain rich in cannabinoid receptors) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/28/4554/abstract/47\">",
"     47",
"    </a>",
"    ]. In addition, a greater cumulative cannabis exposure is associated with more severe volume reductions. Other investigations using positron emission tomography, transcranial Doppler sonography, and EEG, have all suggested neurophysiologic changes in chronic cannabis users [",
"    <a class=\"abstract\" href=\"UTD.htm?4/28/4554/abstract/48-50\">",
"     48-50",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h3\">",
"     Psychotic disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;Substantial evidence indicates that cannabis use causes psychosis beyond transient intoxication:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A meta-analysis of 83 observational studies found that onset of psychosis (schizophrenia-related illness) occurred significantly earlier (2.7 years) in patients who used cannabis, compared with patients who did not [",
"      <a class=\"abstract\" href=\"UTD.htm?4/28/4554/abstract/51\">",
"       51",
"      </a>",
"      ]. By contrast, alcohol use was not associated with a significantly earlier age of onset of psychosis.",
"     </li>",
"     <li>",
"      A systematic review of 35 longitudinal studies found a significantly increased risk of psychosis for those who ever used cannabis compared to those who did not (adjusted OR 1.41, 95% CI 1.20-1.65) [",
"      <a class=\"abstract\" href=\"UTD.htm?4/28/4554/abstract/52\">",
"       52",
"      </a>",
"      ]. The review also found a dose response relationship, with a two-fold increase in risk of psychosis for people who used cannabis most frequently (OR 2.09, 1.54-2.84). The outcome of psychosis ranged from self reported symptoms to clinical diagnoses of schizophrenia, and the study adjusted for confounding factors and excluded cohorts with identified mental illness or substance use problems.",
"     </li>",
"     <li>",
"      A review of neurochemical studies suggested cannabis use may cause psychosis through its effects on dopamine release [",
"      <a class=\"abstract\" href=\"UTD.htm?4/28/4554/abstract/53\">",
"       53",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      There is evidence that genetic factors may influence the risk of psychosis in adults who used cannabis as adolescents [",
"      <a class=\"abstract\" href=\"UTD.htm?4/28/4554/abstract/54,55\">",
"       54,55",
"      </a>",
"      ]. This may help explain why the vast majority of cannabis users do not develop psychosis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, the nature of these studies is such that their results can be explained by the possibility that the presence of psychosis or a psychotic disorder leads to use of cannabis.",
"   </p>",
"   <p>",
"    A related question is whether cannabis use exacerbates symptoms in patients with established psychotic illnesses such as schizophrenia. A systematic review of longitudinal studies found cannabis use was consistently associated with increased relapse of psychosis, rehospitalization, and poor compliance with treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?4/28/4554/abstract/56\">",
"     56",
"    </a>",
"    ]. However, the review concluded that it is far from settled that cannabis caused these worse outcomes, because the studies did not adjust for confounding factors such as baseline illness severity, use of alcohol and other drugs, personality traits, and sociodemographic characteristics. In addition, some studies reported better outcomes in patients using cannabis, for example, an association between cannabis dependence and reduced negative symptoms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h3\">",
"     Depression",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cannabis use does not appear to cause depression.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A systematic review of longitudinal studies did not find a significantly increased risk of depression for those who ever used cannabis compared to those who did not [",
"      <a class=\"abstract\" href=\"UTD.htm?4/28/4554/abstract/52\">",
"       52",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A twin study concluded that comorbidity of cannabis dependence and major depressive disorder is probably due to genetic and environmental factors that predispose to both outcomes [",
"      <a class=\"abstract\" href=\"UTD.htm?4/28/4554/abstract/57\">",
"       57",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h3\">",
"     Amotivational syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;A state of chronic complacency, passivity, aimless drifting, introversion, apathy, and lack of motivation and productivity has been attributed to the long-term use of marijuana and termed the \"amotivational syndrome\" [",
"    <a class=\"abstract\" href=\"UTD.htm?4/28/4554/abstract/58\">",
"     58",
"    </a>",
"    ]. One case-control study found that individuals who smoked cannabis a mean of 18,000 times and a minimum of 5000 times were significantly less likely to graduate college compared to controls (44 versus 78 percent), and significantly less likely to earn 30,000 US dollars or more per year (49 versus 74 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/28/4554/abstract/59\">",
"     59",
"    </a>",
"    ]. However, other conditions such as depression or limited career aspirations can produce similar symptoms and outcomes. In addition, a study that compared individuals who used cannabis seven days per week versus those who had never used cannabis found no difference in level of motivation as measured by scores on the Apathy Evaluation Scale [",
"    <a class=\"abstract\" href=\"UTD.htm?4/28/4554/abstract/60\">",
"     60",
"    </a>",
"    ]. Furthermore, other studies report that the adverse consequences of cannabis use may diminish or disappear with sustained abstinence or reduction in use. (See",
"    <a class=\"local\" href=\"#H24\">",
"     'Long-term outcomes'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Cardiovascular",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cannabis intoxication usually causes an increase in sympathetic activity and a decrease in parasympathetic activity, resulting in tachycardia and an increase in cardiac output with little or no increase in blood pressure [",
"    <a class=\"abstract\" href=\"UTD.htm?4/28/4554/abstract/61\">",
"     61",
"    </a>",
"    ]. High doses of marijuana inhibit sympathetic activity and increase parasympathetic activity, leading to bradycardia and hypotension. There have been reports of reversible EKG abnormalities affecting the P and T waves and the ST segment, and an increase in supraventricular and ventricular ectopic activity.",
"   </p>",
"   <p>",
"    Marijuana smoking may pose a risk of cardiovascular events for older people with coronary artery or cerebrovascular disease, because of increased catecholamines, increased carboxyhemoglobin levels, increased cardiac work, and possible episodes of intense postural hypotension [",
"    <a class=\"abstract\" href=\"UTD.htm?4/28/4554/abstract/62\">",
"     62",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A large study of myocardial infarction found that smoking cannabis rarely triggered this event. &nbsp;Among the cannabis users who did sustain an acute myocardial infarction, the risk was nearly five times higher within the first hour after smoking compared to periods of nonuse (relative risk 4.8, 95% CI 2.9-9.5) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/28/4554/abstract/63\">",
"     63",
"    </a>",
"    ]. The elevated risk rapidly declined thereafter.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h2\">",
"     Immune system",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cannabis use appears to suppress aspects of immunological function, but it is not clear whether this causes increased rates of infection or other problems [",
"    <a class=\"abstract\" href=\"UTD.htm?4/28/4554/abstract/50,64\">",
"     50,64",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7270550\">",
"    <span class=\"h2\">",
"     Cannabinoid hyperemesis syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic heavy cannabis use can cause recurrent episodes of severe nausea, intractable vomiting, and abdominal pain, which resolves when cannabis use is stopped [",
"    <a class=\"abstract\" href=\"UTD.htm?4/28/4554/abstract/65\">",
"     65",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h2\">",
"     Reproductive",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cannabis use suppresses secretion of testosterone in men [",
"    <a class=\"abstract\" href=\"UTD.htm?4/28/4554/abstract/66\">",
"     66",
"    </a>",
"    ], which may decrease libido and lead to impotence and gynecomastia. Cannabis use also causes decreased sperm count and motility. Changes in semen characteristics seen with heavy marijuana smoking may cause increased infertility [",
"    <a class=\"abstract\" href=\"UTD.htm?4/28/4554/abstract/67\">",
"     67",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Chronic cannabis use increases prolactin levels in women [",
"    <a class=\"abstract\" href=\"UTD.htm?4/28/4554/abstract/68\">",
"     68",
"    </a>",
"    ], which may cause galactorrhea.",
"   </p>",
"   <p>",
"    The impact of prenatal marijuana use on the infant is not clear. Perinatal outcome and marijuana use are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/12/6346?source=see_link&amp;anchor=H16#H16\">",
"     \"Overview of illicit drug use in pregnant women\", section on 'Marijuana'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h2\">",
"     Dental",
"    </span>",
"    &nbsp;&mdash;&nbsp;Marijuana smoking may be associated with increased periodontal disease. In a prospective cohort study of 903 subjects, marijuana use was associated with a significantly higher incidence of periodontitis at age 32 years after controlling for tobacco smoking and a number of other potential confounders related to dental hygiene and regular dental care (OR 2.2, 95% CI 1.2-3.9) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/28/4554/abstract/69\">",
"     69",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h2\">",
"     Ophthalmologic effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Smoking marijuana causes corneal vasodilation (red eyes) and reduction of intraocular pressure [",
"    <a class=\"abstract\" href=\"UTD.htm?4/28/4554/abstract/70\">",
"     70",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?17/54/18274?source=see_link\">",
"       \"Patient information: Marijuana use and addiction (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Relatively few patients with cannabis use disorders pursue treatment despite the availability of efficacious treatments. Typically, 10 years elapse between onset of cannabis use and contact with treatment services. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Treatment principles'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Treatment should generally aim to provide sustained abstinence from cannabis. It may be necessary to accept moderation as an initial goal in order to engage some patients in the treatment process. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Treatment principles'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest psychotherapy for patients seeking treatment for cannabis abuse or dependence (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Efficacious therapies include cognitive behavioral therapy, motivational enhancement therapy, voucher based incentives, and family therapy. No one of these therapies is clearly better than another; combined treatments may work better, but this approach may not be feasible. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Psychosocial interventions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with cannabis dependence who did not adequately respond to a psychosocial intervention, we suggest augmentation of one of the psychosocial interventions above with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/1/20504?source=see_link\">",
"       acetylcysteine",
"      </a>",
"      (NAC) (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Acetylcysteine 1200 mg is taken orally twice daily. (See",
"      <a class=\"local\" href=\"#H324028646\">",
"       'Acetylcysteine'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Many patients treated for cannabis dependence do not complete treatment, do not achieve abstinence, or they relapse soon after completion. Reduced use is more common than continuous abstinence. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Psychosocial interventions'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      While awaiting better evidence on the need for treatment and its effectiveness, we suggest not treating symptoms of withdrawal from cannabis dependence (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Cannabinoid agonists'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most adolescents or young adults using cannabis or suffering from abuse or dependence spontaneously improve over time. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Adolescents and young adults'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Cannabis dependence in adults is fairly stable over the short term. Maintaining abstinence is difficult for adults who chronically use marijuana in large doses. Discontinuation of cannabis can lead to a withdrawal syndrome that can contribute to relapse of cannabis use. Drug testing is useful for monitoring progress and early detection of relapse, and can increase recovery rates. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Adults age 17 years and older'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/17/21783?source=see_link\">",
"       \"Cannabis use disorders: Clinical features and diagnosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Cannabis use is associated with a number of adverse psychosocial problems in the short term, including school dropout, using other illicit drugs, interpersonal problems with family and friends, crime, unemployment. These adverse consequences diminish or disappear with sustained abstinence or reductions in cannabis use. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Psychosocial functioning and health'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Cannabis affects multiple organ systems, but it is not clear whether continuous use causes long-term medical consequences. (See",
"      <a class=\"local\" href=\"#H25\">",
"       'Long term medical effects of cannabis use'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th ed, American Psychiatric Association, Washington, DC 2000.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/28/4554/abstract/2\">",
"      Ashton CH. Pharmacology and effects of cannabis: a brief review. Br J Psychiatry 2001; 178:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/28/4554/abstract/3\">",
"      American Psychiatric Association. Practice guideline for the treatment of patients with substance use disorders, second edition. Am J Psychiatry 2007; 164(Suppl):1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/28/4554/abstract/4\">",
"      Moore BA, Budney AJ. Abstinence at intake for marijuana dependence treatment predicts response. Drug Alcohol Depend 2002; 67:249.",
"     </a>",
"    </li>",
"    <li>",
"     Kaminer, Y. Adolescent substance abuse. In: The American Psychiatric Publishing Textbook of Substance Abuse Treatment, 4th ed, Galanter, M, Kleber HD (Ed), American Psychiatric Publishing, Washington, DC 2008. p.527.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/28/4554/abstract/6\">",
"      Faggiano F, Vigna-Taglianti FD, Versino E, et al. School-based prevention for illicit drugs' use. Cochrane Database Syst Rev 2005; :CD003020.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/28/4554/abstract/7\">",
"      Denis C, Lavie E, Fats&eacute;as M, Auriacombe M. Psychotherapeutic interventions for cannabis abuse and/or dependence in outpatient settings. Cochrane Database Syst Rev 2006; :CD005336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/28/4554/abstract/8\">",
"      Nordstrom BR, Levin FR. Treatment of cannabis use disorders: a review of the literature. Am J Addict 2007; 16:331.",
"     </a>",
"    </li>",
"    <li>",
"     Cooper, ZD. Cannabis reinforcement and dependence: role of the cannabinoid CB1 receptor. Addict Biology 2008: 13:188.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/28/4554/abstract/10\">",
"      Dutra L, Stathopoulou G, Basden SL, et al. A meta-analytic review of psychosocial interventions for substance use disorders. Am J Psychiatry 2008; 165:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/28/4554/abstract/11\">",
"      Elkashef A, Vocci F, Huestis M, et al. Marijuana neurobiology and treatment. Subst Abus 2008; 29:17.",
"     </a>",
"    </li>",
"    <li>",
"     DiClemente, Garay, M, Gemmell, L. Motivational enhancement. In: The American Psychiatric Publishing Textbook of Substance Abuse Treatment, 4th ed, Galanter, M, Kleber HD (Ed), American Psychiatric Publishing, Washington, DC 2008. p.366.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/28/4554/abstract/13\">",
"      Marijuana Treatment Project Research Group. Brief treatments for cannabis dependence: findings from a randomized multisite trial. J Consult Clin Psychol 2004; 72:455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/28/4554/abstract/14\">",
"      Dennis M, Godley SH, Diamond G, et al. The Cannabis Youth Treatment (CYT) Study: main findings from two randomized trials. J Subst Abuse Treat 2004; 27:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/28/4554/abstract/15\">",
"      Gray KM, Carpenter MJ, Baker NL, et al. A double-blind randomized controlled trial of N-acetylcysteine in cannabis-dependent adolescents. Am J Psychiatry 2012; 169:805.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/28/4554/abstract/16\">",
"      Lichtman AH, Martin BR. Cannabinoid tolerance and dependence. Handb Exp Pharmacol 2005; :691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/28/4554/abstract/17\">",
"      Carpenter KM, McDowell D, Brooks DJ, et al. A preliminary trial: double-blind comparison of nefazodone, bupropion-SR, and placebo in the treatment of cannabis dependence. Am J Addict 2009; 18:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/28/4554/abstract/18\">",
"      Mason BJ, Crean R, Goodell V, et al. A proof-of-concept randomized controlled study of gabapentin: effects on cannabis use, withdrawal and executive function deficits in cannabis-dependent adults. Neuropsychopharmacology 2012; 37:1689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/28/4554/abstract/19\">",
"      Haney M, Hart CL, Vosburg SK, et al. Marijuana withdrawal in humans: effects of oral THC or divalproex. Neuropsychopharmacology 2004; 29:158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/28/4554/abstract/20\">",
"      Levin FR, McDowell D, Evans SM, et al. Pharmacotherapy for marijuana dependence: a double-blind, placebo-controlled pilot study of divalproex sodium. Am J Addict 2004; 13:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/28/4554/abstract/21\">",
"      Budney AJ, Vandrey RG, Hughes JR, et al. Oral delta-9-tetrahydrocannabinol suppresses cannabis withdrawal symptoms. Drug Alcohol Depend 2007; 86:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/28/4554/abstract/22\">",
"      Haney M, Hart CL, Vosburg SK, et al. Effects of THC and lofexidine in a human laboratory model of marijuana withdrawal and relapse. Psychopharmacology (Berl) 2008; 197:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/28/4554/abstract/23\">",
"      Levin FR, Kleber HD. Use of dronabinol for cannabis dependence: two case reports and review. Am J Addict 2008; 17:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/28/4554/abstract/24\">",
"      Perkonigg A, Goodwin RD, Fiedler A, et al. The natural course of cannabis use, abuse and dependence during the first decades of life. Addiction 2008; 103:439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/28/4554/abstract/25\">",
"      von Sydow K, Lieb R, Pfister H, et al. The natural course of cannabis use, abuse and dependence over four years: a longitudinal community study of adolescents and young adults. Drug Alcohol Depend 2001; 64:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/28/4554/abstract/26\">",
"      Swift W, Hall W, Copeland J. One year follow-up of cannabis dependence among long-term users in Sydney, Australia. Drug Alcohol Depend 2000; 59:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/28/4554/abstract/27\">",
"      Mennes CE, Ben Abdallah A, Cottler LB. The reliability of self-reported cannabis abuse, dependence and withdrawal symptoms: multisite study of differences between general population and treatment groups. Addict Behav 2009; 34:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/28/4554/abstract/28\">",
"      Moore BA, Budney AJ. Relapse in outpatient treatment for marijuana dependence. J Subst Abuse Treat 2003; 25:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/28/4554/abstract/29\">",
"      Fergusson DM, Horwood LJ, Swain-Campbell N. Cannabis use and psychosocial adjustment in adolescence and young adulthood. Addiction 2002; 97:1123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/28/4554/abstract/30\">",
"      Eisen SA, Chantarujikapong S, Xian H, et al. Does marijuana use have residual adverse effects on self-reported health measures, socio-demographics and quality of life? A monozygotic co-twin control study in men. Addiction 2002; 97:1137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/28/4554/abstract/31\">",
"      Tetrault JM, Crothers K, Moore BA, et al. Effects of marijuana smoking on pulmonary function and respiratory complications: a systematic review. Arch Intern Med 2007; 167:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/28/4554/abstract/32\">",
"      Wu TC, Tashkin DP, Djahed B, Rose JE. Pulmonary hazards of smoking marijuana as compared with tobacco. N Engl J Med 1988; 318:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/28/4554/abstract/33\">",
"      Leggett T, United Nations Office on Drugs and Crime. A review of the world cannabis situation. Bull Narc 2006; 58:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/28/4554/abstract/34\">",
"      Moore BA, Augustson EM, Moser RP, Budney AJ. Respiratory effects of marijuana and tobacco use in a U.S. sample. J Gen Intern Med 2005; 20:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/28/4554/abstract/35\">",
"      Pletcher MJ, Vittinghoff E, Kalhan R, et al. Association between marijuana exposure and pulmonary function over 20 years. JAMA 2012; 307:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/28/4554/abstract/36\">",
"      Hashibe M, Straif K, Tashkin DP, et al. Epidemiologic review of marijuana use and cancer risk. Alcohol 2005; 35:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/28/4554/abstract/37\">",
"      Mehra R, Moore BA, Crothers K, et al. The association between marijuana smoking and lung cancer: a systematic review. Arch Intern Med 2006; 166:1359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/28/4554/abstract/38\">",
"      Berthiller J, Lee YC, Boffetta P, et al. Marijuana smoking and the risk of head and neck cancer: pooled analysis in the INHANCE consortium. Cancer Epidemiol Biomarkers Prev 2009; 18:1544.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/28/4554/abstract/39\">",
"      Chacko JA, Heiner JG, Siu W, et al. Association between marijuana use and transitional cell carcinoma. Urology 2006; 67:100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/28/4554/abstract/40\">",
"      Grant I, Gonzalez R, Carey CL, et al. Non-acute (residual) neurocognitive effects of cannabis use: a meta-analytic study. J Int Neuropsychol Soc 2003; 9:679.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/28/4554/abstract/41\">",
"      Lyketsos CG, Garrett E, Liang KY, Anthony JC. Cannabis use and cognitive decline in persons under 65 years of age. Am J Epidemiol 1999; 149:794.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/28/4554/abstract/42\">",
"      Lyons MJ, Bar JL, Panizzon MS, et al. Neuropsychological consequences of regular marijuana use: a twin study. Psychol Med 2004; 34:1239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/28/4554/abstract/43\">",
"      Meier MH, Caspi A, Ambler A, et al. Persistent cannabis users show neuropsychological decline from childhood to midlife. Proc Natl Acad Sci U S A 2012; 109:E2657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/28/4554/abstract/44\">",
"      Solowij N, Stephens RS, Roffman RA, et al. Cognitive functioning of long-term heavy cannabis users seeking treatment. JAMA 2002; 287:1123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/28/4554/abstract/45\">",
"      Bolla KI, Brown K, Eldreth D, et al. Dose-related neurocognitive effects of marijuana use. Neurology 2002; 59:1337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/28/4554/abstract/46\">",
"      Pope HG Jr, Gruber AJ, Hudson JI, et al. Early-onset cannabis use and cognitive deficits: what is the nature of the association? Drug Alcohol Depend 2003; 69:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/28/4554/abstract/47\">",
"      Yap MB, Whittle S, Y&uuml;cel M, et al. Interaction of parenting experiences and brain structure in the prediction of depressive symptoms in adolescents. Arch Gen Psychiatry 2008; 65:1377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/28/4554/abstract/48\">",
"      Bolla KI, Eldreth DA, Matochik JA, Cadet JL. Neural substrates of faulty decision-making in abstinent marijuana users. Neuroimage 2005; 26:480.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/28/4554/abstract/49\">",
"      Herning RI, Better WE, Tate K, Cadet JL. Cerebrovascular perfusion in marijuana users during a month of monitored abstinence. Neurology 2005; 64:488.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/28/4554/abstract/50\">",
"      Adams IB, Martin BR. Cannabis: pharmacology and toxicology in animals and humans. Addiction 1996; 91:1585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/28/4554/abstract/51\">",
"      Large M, Sharma S, Compton MT, et al. Cannabis use and earlier onset of psychosis: a systematic meta-analysis. Arch Gen Psychiatry 2011; 68:555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/28/4554/abstract/52\">",
"      Moore TH, Zammit S, Lingford-Hughes A, et al. Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. Lancet 2007; 370:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/28/4554/abstract/53\">",
"      Fergusson DM, Poulton R, Smith PF, Boden JM. Cannabis and psychosis. BMJ 2006; 332:172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/28/4554/abstract/54\">",
"      Caspi A, Moffitt TE, Cannon M, et al. Moderation of the effect of adolescent-onset cannabis use on adult psychosis by a functional polymorphism in the catechol-O-methyltransferase gene: longitudinal evidence of a gene X environment interaction. Biol Psychiatry 2005; 57:1117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/28/4554/abstract/55\">",
"      Henquet C, Rosa A, Delespaul P, et al. COMT ValMet moderation of cannabis-induced psychosis: a momentary assessment study of 'switching on' hallucinations in the flow of daily life. Acta Psychiatr Scand 2009; 119:156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/28/4554/abstract/56\">",
"      Zammit S, Moore TH, Lingford-Hughes A, et al. Effects of cannabis use on outcomes of psychotic disorders: systematic review. Br J Psychiatry 2008; 193:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/28/4554/abstract/57\">",
"      Lynskey MT, Glowinski AL, Todorov AA, et al. Major depressive disorder, suicidal ideation, and suicide attempt in twins discordant for cannabis dependence and early-onset cannabis use. Arch Gen Psychiatry 2004; 61:1026.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/28/4554/abstract/58\">",
"      McGlothlin WH, West LJ. The marihuana problem: an overview. Am J Psychiatry 1968; 125:126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/28/4554/abstract/59\">",
"      Gruber AJ, Pope HG, Hudson JI, Yurgelun-Todd D. Attributes of long-term heavy cannabis users: a case-control study. Psychol Med 2003; 33:1415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/28/4554/abstract/60\">",
"      Barnwell SS, Earleywine M, Wilcox R. Cannabis, motivation, and life satisfaction in an internet sample. Subst Abuse Treat Prev Policy 2006; 1:2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/28/4554/abstract/61\">",
"      Ghuran A, Nolan J. Recreational drug misuse: issues for the cardiologist. Heart 2000; 83:627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/28/4554/abstract/62\">",
"      Jones RT. Cardiovascular system effects of marijuana. J Clin Pharmacol 2002; 42:58S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/28/4554/abstract/63\">",
"      Mittleman MA, Lewis RA, Maclure M, et al. Triggering myocardial infarction by marijuana. Circulation 2001; 103:2805.",
"     </a>",
"    </li>",
"    <li>",
"     American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th ed, text revision, American Psychiatric Association, Washington, DC, 2000.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/28/4554/abstract/65\">",
"      Sullivan S. Cannabinoid hyperemesis. Can J Gastroenterol 2010; 24:284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/28/4554/abstract/66\">",
"      Kolodny RC, Masters WH, Kolodner RM, Toro G. Depression of plasma testosterone levels after chronic intensive marihuana use. N Engl J Med 1974; 290:872.",
"     </a>",
"    </li>",
"    <li>",
"     Hembree, WC, Nahas, GG, Zeidenberg, P, et al. Changes in human spermatozoa associated with high-dose marijuana smoking. In: Nahas, GG (ed) Marijuana and Medicine, Humana Press, Totowa, NJ, 2001.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/28/4554/abstract/68\">",
"      Cohen, S. Marijuana and reproductive functions. Drug Abuse and Alcoholism News 1985; 13:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/28/4554/abstract/69\">",
"      Thomson WM, Poulton R, Broadbent JM, et al. Cannabis smoking and periodontal disease among young adults. JAMA 2008; 299:525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/28/4554/abstract/70\">",
"      Yazulla S. Endocannabinoids in the retina: from marijuana to neuroprotection. Prog Retin Eye Res 2008; 27:501.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7796 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-61.55.141.10-A7B94B43F3-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_28_4554=[""].join("\n");
var outline_f4_28_4554=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H38\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION AND DEFINITIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      TREATMENT PRINCIPLES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      TREATMENT OF INTOXICATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      TREATMENT OF ABUSE AND DEPENDENCE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Prevention",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Psychosocial interventions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Cognitive behavioral therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Motivational interviewing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Voucher based incentives",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Family therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Pharmacotherapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H324028646\">",
"      - Acetylcysteine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Antidepressants",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Anticonvulsants",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Cannabinoid agonists",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      COURSE OF ILLNESS AND PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Cannabis use, abuse, and dependence",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Adolescents and young adults",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Adults age 17 years and older",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Psychosocial functioning and health",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Short-term outcomes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Long-term outcomes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      LONG TERM MEDICAL EFFECTS OF CANNABIS USE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Pulmonary",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Central nervous system",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      - Neuropsychological effects",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      - Psychotic disorders",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      - Depression",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      - Amotivational syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Cardiovascular",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      Immune system",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7270550\">",
"      Cannabinoid hyperemesis syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      Reproductive",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      Dental",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      Ophthalmologic effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PSYCH/7796\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PSYCH/7796|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?19/29/19931\" title=\"table 1\">",
"      DSM-IV-TR diagnostic criteria for cannabis intoxication",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?24/5/24667\" title=\"table 2\">",
"      DSM-IV-TR diagnostic criteria for cannabis abuse",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?31/34/32299\" title=\"table 3\">",
"      DSM-IV-TR diagnostic criteria for cannabis dependence",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/17/21783?source=related_link\">",
"      Cannabis use disorders: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/3/1079?source=related_link\">",
"      Cannabis use disorders: Epidemiology, comorbidity, and pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/0/12298?source=related_link\">",
"      Cigarette smoking and other risk factors for lung cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/61/26586?source=related_link\">",
"      Epidemiology and etiology of urothelial (transitional cell) carcinoma of the bladder",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/6/20583?source=related_link\">",
"      Epidemiology and risk factors for head and neck cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/12/6346?source=related_link\">",
"      Overview of illicit drug use in pregnant women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?17/54/18274?source=related_link\">",
"      Patient information: Marijuana use and addiction (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_28_4555="Contraindications to thrombolytic therapy";
var content_f4_28_4555=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F71568&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F71568&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Contraindications to thrombolytic therapy",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        History of hemorrhagic stroke",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Active intracranial neoplasm",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Recent (&lt;2 months) intracranial surgery or trauma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Active or recent internal bleeding in prior 6 months",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bleeding diathesis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Uncontrolled severe hypertension (systolic BP &gt;200 mmHg or diastolic BP &gt;110 mmHg)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nonhemorrhagic stroke within prior 2 months",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Surgery within the previous 10 days",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Thrombocytopenia (&lt;100,000 platelets per mm",
"        <sup>",
"         3",
"        </sup>",
"        )",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_28_4555=[""].join("\n");
var outline_f4_28_4555=null;
var title_f4_28_4556="GI peptide modes of action";
var content_f4_28_4556=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F64495&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F64495&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Classification of gastrointestinal peptides based upon mode of action",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Hormone",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Gastrin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cholecystokinin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Secretin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Gastric inhibitory peptide*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pancreatic polypeptide",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Motilin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Insulin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Glucagon",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Enteroglucagon",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Peptide YY",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Somatostatin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Paracrine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Somatostatin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Peptide YY",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Neurocrine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cholecystokinin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Secretin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Gastrin releasing peptide",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Neuropeptide Y",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Peptide YY",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Vasoactive intestinal peptide",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Neurotensin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Peptide histidine-isoleucine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Substance P",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Substance K",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Enkephalin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dynorphin",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Also called glucose-dependent insulinotropic polypeptide.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_28_4556=[""].join("\n");
var outline_f4_28_4556=null;
var title_f4_28_4557="Drugs implicated in serum sickness and serum sickness-like reactions";
var content_f4_28_4557=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F73703&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F73703&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Drugs and serum sickness",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <tbody>",
"      <tr>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Commonly implicated drugs",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Cefaclor",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Penicillins",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Trimethoprim-sulfamethoxazole",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Uncommonly implicated drugs",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Aspirin/salicylates",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Barbiturates",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Bupropion",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Captopril",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Carbamazepine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Cefatrizine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Cholecystographic dyes",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Ciprofloxacin",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Clarithromycin",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Fluoxetine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Furazolidone",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Hair straightener",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Heparin",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Indomethacin",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Insulin (in type 1 diabetes)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Iron-dextran",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Itraconazole",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Uncommonly implicated drugs (cont.)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            6-mercaptopurine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Methimazole",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Metronidazole",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Minocycline",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            N-acetyl cysteine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Naproxen",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Novobiocin",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Penicillamine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Phenylbutazone",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Phenytoin",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Propranolol",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Propylthiouracil",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Rifampin",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Streptomycin",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Sulfasalazine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Sulfonamides",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Tinidazole",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Verapamil",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_28_4557=[""].join("\n");
var outline_f4_28_4557=null;
var title_f4_28_4558="Incidence of diabetes in youth by age group";
var content_f4_28_4558=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F88297&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F88297&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 474px\">",
"   <div class=\"ttl\">",
"    Incidence of diabetes mellitus in youth by age group",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 454px; height: 318px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Incidence of type 1 and type 2 diabetes mellitus in youth in the United States, from the SEARCH for Diabetes in Youth Study Group, 2002-2003.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Writing Group for the SEARCH for Diabetes in Youth Study Group, Dabelea D, Bell RA, et al. Incidence of diabetes in youth in the United States. JAMA 2007; 297:2716.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_28_4558=[""].join("\n");
var outline_f4_28_4558=null;
var title_f4_28_4559="Colds symptom profile";
var content_f4_28_4559=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F65898&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F65898&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 605px\">",
"   <div class=\"ttl\">",
"    Symptom profile of the common cold in children",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 585px; height: 376px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Symptom profile in 81 colds in healthy school children. Symptoms include congestion, runny nose, cough, sneezing, and feverish.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted with permission from: Pappas DE, Hendley JO, Hayden FG, Winther B. Symptom profile of common colds in school-aged children. Pediatr Infect Dis J 2008; 27:8. Copyright &copy; 2008 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_28_4559=[""].join("\n");
var outline_f4_28_4559=null;
